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The adrenal gland is a highly dynamic organ with the ability to respond to changes in its 
environment with rapid changes in hormone production, and dramatic remodelling of its 
structure. Our understanding of the role of the melanocortin peptides in this process has 
been mostly restricted to the anterior pituitary hormone ACTH, via the melanocortin 2 
receptor MC2R. The presence of additional melanocortin receptors and their antagonists 
has been demonstrated in rat and bovine adrenals, but the role of these in humans has 
not been well explored. 
 
An intensive clinical and biochemical work-up of a single patient with ACTH-independent 
Cushing’s syndrome and a gastrointestinal stromal tumour (GIST) was performed. The 
data presented are consistent with the possibility that her disease was caused by release 
of some bioactive molecule released from the GIST. We propose that alpha-MSH is a 
possible candidate for this molecule, on the basis that the GIST immuno-stained for alpha-
MSH but not ACTH, that alpha-MSH but not ACTH was present in supernatant from a 
primary culture, and that alpha-MSH has the potential to stimulate cortisol production 
from adrenal cells. The precise mechanism for alpha-MSH secretion from the tumour is 
not fully elucidated, and further work is required to corroborate this hypothesis. 
 
The patient had both pigmented skin and pigmented adrenal nodules, and we further 
demonstrated the presence of the alpha-MSH receptor MC1R was demonstrated with her 
excised adrenal gland. The pigment was identified as melanin, and we went on to show 
that same pattern in primary pigmented nodular adrenal disease, and to demonstrate that 
the zona reticularis in normal adrenal gland contains melanin, and has additional features 
in common with melanocytic tissues elsewhere in the body. 
 
The role of alpha-MSH in normal adrenal function, and the possibility that melanin is also 
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Chapter 1 Introduction 
1.1 The Adrenal Gland 
The adrenal gland is a vital mediator of an organism’s response to stress, and a regulator 
of immune function, blood pressure and energy homeostasis. It focuses multiple 
endocrine systems within a single organ: the hypothalamic-pituitary adrenal (HPA), the 
renin-angiotensin-aldosterone system (RAS), and the sympathoadrenal. This close 
anatomical proximity is no coincidence, and in recent times we have come to understand 
more about the communication between these systems (Haase et al., 2011; Schinner & 
Bornstein, 2005). The adrenal gland has a remarkable capacity for regeneration and 
remodelling (Bland et al., 2003; Brennan et al., 2008), and recent insights into its 
developmental origins (Wood & Hammer, G. D., 2011) have aided our understanding of 
the functioning of the gland in normal physiology and disease. 
 
I will describe the anatomy of the gland, and how that structure relates to its function as 
an endocrine organ both at a macroscopic and microscopic level. I will explore molecular 
mechanisms underpinning its embryology and post-natal growth and remodelling, and 
the biochemistry of hormone production. I will discuss the manifold internal and external 
stimuli that are employed to control these processes, with a focus on glucocorticoid 
production. 
1.1.1 History 
The adrenal gland was described in antiquity by Galen, but only recognised as a discrete 
organ by Eustachi in 1563 (Eustachi, 1564). 19th century advances in lens technology 
allowed Von Kolliker to define its microscopic anatomy (Kölliker & Huxley, 1854), and in 
1855 the clinical consequences of failure of “the supra-renal capsules” was described by 
Thomas Addison (Addison, 1855). Charles Brown-Sequard postulated the existence of 
hormones fifty years before Bayliss and Starling identified secretin, and in 1856 
performed adrenalectomies on several different species of animal which resulted in their 







In 1886 Felix Frankel was the first to describe a phaeochromocytoma, a tumour derived 
from the catecholamine secreting cells of the adrenal medulla (Fraenkel, 1886). The 
pressor effects of adrenal extract were shown ten years later by Oliver and Schafer (Oliver 
& Schäfer, 1895) before adrenaline was purified by John Abel in 1899 (Abel, 1901). 
Harvey Cushing described the consequences of severe glucocorticoid excess in 1910 
(Cushing, 1912), but it was not until the 1930s that the hormones of the adrenal cortex 
were identified by Edward Kendall, Tadeus Reichstein and Philip Hench, winning them 
the Nobel Prize for physiology in 1950 (Hench & Kendall, 1949). 
 
The existence of adrenal steroids with pure mineralocorticoid activity was a source of 
controversy until it was formally determined that electrocortin was secreted from the zona 
glomerulosa under provocation from a low salt diet or potassium loading (Deane et al., 
1948). Simpson and Tait isolated electrocortin from bovine adrenals, and the structure of 
the hormone - now renamed aldosterone - was reported in 1953 (Grundy et al., 1952; 
Simpson, S. A. et al., 1953). 
 
1.2 The Anatomy of the Adrenal Gland 
 
 
Figure 1.1 Anatomy and structure of the adrenal gland 
(A) The adrenal glands are located at the upper poles of the kidneys. (B) Zonation differs between 
species. The human gland has three recognisable cortical zones, the ZG, ZF and ZR, surrounding 






this takes the form of an undifferentiated ZU between ZG and ZG. The X zone in the mouse forms 
around the time of birth, and remains until puberty in males or first pregnancy in females. From 
Yates et al (Yates et al., 2013). 
1.2.1 Macroscopic Anatomy 
The human adrenal gland (Figure 1.1) is located anterior and superior to the upper part 
of the kidney, within its own compartment of renal fascia (Gray et al., 2005). The adult 
human glands weigh approximately 8-10g and are approximately 90% cortex. The right 
gland is pyramidal in shape, and the left more crescentic. A thick, collagenous capsule 
composed of fibroblasts and myofibroblasts extends trabeculae deep into the cortex, and 
the latter completely encloses the medulla, except at the hilum. Veins and lymphatic 
vessels leave at the hila, but arteries and nerves enter the gland at multiple sites. 
1.2.2 Adrenal Histology 
Underneath the capsule, the cortex is subdivided into three main zones, first described 
and named by Arnold in 1852 on the basis of morphological appearance (Arnold, 1886) 
 
The zona glomerulosa (ZG) is composed of small, narrow, polyhedral cells in rounded 
clusters, with deep staining nuclei and basophilic cytoplasm, and a few lipid droplets. 
They contain abundant smooth ER, typical of steroidogenic cells, and their mitochondria 
are characterised by lamelliform (shelf-like) cristae (Belloni et al., 1987). The ZG makes 
up around 15% of the cortex depending on the prevailing sodium intake of the animal. 
The main hormone produced is the mineralocorticoid aldosterone. 
 
The zona fasciculata (ZF) cells are larger than the ZG and due to their paler staining 
properties are known as clear cells (Wheater et al., 2013). They are laid out in columns 
two cells wide, parallel to fenestrated sinusoids, and contain abundant lipid and smooth 
ER. In humans some of these columns reach past the ZG clusters to the capsule 
(Boulkroun et al., 2010). The cristae of ZF mitochondria are tubulovesicular in shape 
(Robba et al., 1980; Belloni et al., 1987). The ZF predominantly secretes glucocorticoid: 
cortisol in humans, corticosterone in rodents. 
 
The zona reticularis (ZR) are a branching network of smaller, compact cells with 
numerous smooth ER and multiple lysosomes containing brown lipofuscin pigment. In 






cells and they are said to become more compact-like in appearance(Hornsby, 2002). The 
ZR also produces glucocorticoid, and additionally in humans and higher primates secretes 
adrenal androgens - androstenedione and dehydroepiandrosterone (DHEA) and its 
sulphate DHEAS (Parker, L. N. & Odell, 1980).  
 
The inner mass of the gland is the medulla, with little connective tissue separating it from 
the cortex. This leaves the cells in direct contact, allowing crosstalk between the two 
adrenal departments (Schinner & Bornstein, 2005). The medulla is composed of groups 
and columns of chromaffin cells, although there are also smaller islands of these scattered 
throughout the cortex (Gallo-Payet et al., 1987). The cells are large, with large nuclei, 
and contain fine cytoplasmic granules which stain brown with chromium salts (and are 
therefore named phaeochromocytes) (Sjostrand & Wetztein, 1956; Bander, 1951). 
Catecholamine hormones are packaged within the granules and released in response to 
stimulation from sympathetic nerve terminals, which contact the cells on the opposite 
side to venous sinusoids (Bulbring & Burn, 1949). 80% of the medulla cells secrete 
adrenaline, and 20% noradrenaline, with a few dopaminergic cells (Wong, 2003). They 
are functionally equivalent to postganglionic sympathetic nerves. 
 
The most studied mammalian species are humans, mice and rats, and they demonstrate 
a few notable differences in adrenal zonation (Figure 1.1). The ZG is a continuous zone 
beneath the capsules in rats, and is separated from the ZF by a sudanophobic zone three 
to 4 cells thick known variously as the zona intermedia or undifferentiated zone (ZU), 
with mitochondria similar to ZF (Cater & Lever, 1954; Mitani et al., 2003). The ZR in 
mice and rats is often difficult to identify histologically (Tanaka, S. & Matsuzawa, 1995), 
and does not express CYP17A1, so these species do not produce adrenal androgens: the 
ZR and ZF are therefore thought to be functionally equivalent (Endoh et al., 1996). In 
mice an additional inner X-zone adjacent to the medulla is present, but which involutes 
at puberty in the male or first pregnancy in the female. The function of this zone is 
obscure, and while it does not express 3β-hydroxysteroid dehydrogenase, it does express 
20α-hydroxysteroid dehydrogenase, enabling catabolism of progesterone and 11-
deoxycorticosterone (Hershkovitz et al., 2007). There is a wide variation in the 
appearance of the ZR between species, with some expressing little functional tissue at all 






1.2.3 Blood supply 
Arterial blood supply is abundant with arteries branching freely before up to 60 vessels 
penetrate the capsule - there are usually 6-8 superior adrenal arteries branching from the 
inferior phrenic artery, and sometimes a middle adrenal artery direct from the aorta, and 
an inferior adrenal artery from the renal artery (Dobbie & Symington, 1966).  On entering 
the gland these vessels form a subcapsular capillary plexus that gives rise to fenestrated 
sinusoids which pass through the gland before forming a further plexus in the zona 
reticularis. There are also direct branches to the medulla from the subcapsular plexus in 
all mammalian species (Coupland & Selby, 1976). This complex vascular arrangement 
ensures that most cells in the adrenal are only one to two cells away from a vascular 
endothelial cell, with efficient delivery of adrenal hormones to the blood stream(Vinson 
et al., 1985). The human adrenal vasculature is represented in figure 1.2.  
 
Venules pass between the chromaffin cells and enter the medullary veins between bundles 
of smooth muscle fibres, merging into a single adrenal vein at the hilum (Idelman, 1970). 
On the right this is usually directly to the inferior vena cava (IVC) with a longer vein on 
the left into the renal vein (Dobbie & Symington, 1966). There are lymphatic plexus deep 
to the capsule and in the medulla which drain through the hilum to para-aortic nodes 
(Merklin, 1966).  
 
Figure 1.2 Blood supply of the human adrenal gland 
Vessels entering the gland form a subcapsular capillary plexus that gives rise to fenestrated 






gland are only one to two cells away from a vascular endothelial cell, allowing for efficient delivery 
of hormones to the blood stream. 
 
1.2.4 Nerve Supply 
Relative to its size, the adrenal gland has a more substantial autonomic nerve supply than 
any other organ (Parker, T. L. et al., 1993). Myelinated preganglionic sympathetic fibres 
from splanchnic nerves originating from the interomediolateral cell column or lateral 
horn of T10-11 synapse directly on medullary chromaffin cells (Idelman, 1970).  
 
Early descriptions of adrenal microanatomy suggested that there was no direct 
innervation to the cortex (Elliott, 1913; Hollinshead, 1936), but this was challenged by 
Alpert (Alpert, 1931) and confirmed by Unsicker’s observations in the early 1970s of 
nerve fibres synapsing directly on to cortical cells in the pig and rat adrenal glands 
(Unsicker, 1971). There is also post-ganglionic sympathetic supply to blood vessels within 
the cortex, which is thought to have an element of ACTH control attached (Holzwarth et 
al., 1987), and is thought to be largely mediated by neuropeptides as we will discuss 
(Breslow et al., 1987). 
1.3 Adrenocortical physiology 
1.3.1 Functional zonation of the adrenal cortex 
The main hormonal products of the adrenal gland are corticosteroids, and medullary 
catecholamines. Functional zonation of the adrenal cortex allows mineralocorticoid, 
glucocorticoid and adrenal androgen secretion to be regulated independently of each 
other. This is achieved in part through the differential expression of steroidogenic 
enzymes and cofactors in the different zones, and distinct cell surface receptors (Miller & 
Auchus, 2011).  
 
In all cortical cells steroid production begins with cholesterol uptake, there is initial 
trafficking to the inner mitochondrial membrane (IMM), then conversion to pregnenolone 
by the cytochrome p450 enzyme p450scc (side chain cleavage). The main source of 
cholesterol is plasma low density lipoprotein (LDL) with a lesser contribution from 






from HDL using a SR-B1 selective pathway (Valacchi et al., 2011). In a zone dependent 
manner ACTH, angiotensin II (AII) and increasing potassium ion (K+) concentrations all 
increase cholesterol availability by increasing expression and activity of LDL receptors, 
stimulating HMG CoA reductase and hormone sensitive lipase (Kraemer, 2007). The 
steroidogenic acute regulatory protein (StAR) controls trafficking of cholesterol to the 
IMM, and this is also up-regulated and phosphorylated following ACTH and AII/K+ 
stimulation (Mathieu et al., 2002; Murcia et al., 2006). In this way steroid hormone 
secretion can be induced within minutes. Cholesterol trafficking is favoured by the 
tubulovesicular mitochondria, as in the ZF and ZR.  
 
The steroidogenic enzyme pathway is illustrated in figure 1.3. The enzymes employed 
belong to the cytochrome p450 and hydroxy-steroid dehydrogenase (HSD) classes. 
Cytochrome p450 enzymes use electrons derived from NADPH to facilitate their catalytic 
actions (Gonzalez, 1988). HSD reactions convert hydroxysteroids to ketosteroids using 
nicotinamide cofactors without intermediary proteins, but unlike the p450 enzymes, 
different isoforms may catalyse the reverse reaction (Agarwal & Auchus, 2005). The 
intermediate products of these enzymes shuttle back and forth between smooth 
endoplasmic reticulum and inner mitochondrial membrane. 
 






1.3.2 Cytochrome p450 enzymes  
Cytochrome p450 enzymes comprise the mitochondrial type I and the microsomal type II 
enzymes. They use different cofactors as discussed below. 
 
Ferredoxin (Fdx) and ferredoxin reductase (FdR) are a complex of enzymes on the IMM 
which transfer electrons from NADPH to p450scc, with a pair being required for each of 
the three sequential reactions catalysed by this enzyme (Miller, 2005) . Fdx forms a 
complex with FdR, then dissociates to form a similar complex with p450scc. Regulation 
of FdX/FdR expression does not seem to be a point of hormonal regulation of 
steroidogenesis(Ziegler et al., 1999). FdX/FdR are also the electron donors for p450c11β 
and p450c11AS. 
 
The type II enzymes (CYP17A1 and CYP21A1) receive their electrons from NADPH via 
P450 oxidoreductase (POR). POR always donates the first electron, but the second may 
be provided by cytochrome b5 (Storbeck et al., 2013). The availability of electrons from 
POR is a rate-limiting step. 
  
p450scc (protein), CYP11A1 (gene): The rate limiting step in steroidogenesis, present in 
all 3 zones; this catalyses three reactions – hydroxylation at C-20, C-22, and cleavage of 
the amine side chain(Koritz & Kumar, 1970). The pregnenolone generated is trafficked 
back out of the mitochondria. 
 
p450c17 (CYP17A1): This enzyme catalyses two reactions - 17 alpha-hydroxylation, and 
17,20 lyase - which were originally thought to be the actions of two separate enzymes. 
The two activities can be controlled separately to a degree by availability of cofactors. The 
17,20 lyase activity is favoured in the ZR by increased expression of POR and cytochrome 
b5 , with increased androgen secretion as a consequence (Endoh et al., 1996). The activity 
of CYP17A1 is also influenced by phosphorylation, which seems to favour the 17,20 lyase 
activity (Miller, 2005). CYP17A1 is not expressed in adult rats and mice, so the ZR of 
these animals does not synthesise adrenal androgens, but the fetal zone of the developing 
adrenal in these species does express the enzyme, and therefore is able to produce large 
amounts of DHEA. This is thought to be the precursor for placental oestrogen production 







p450c21 (CYP21A1): The 21 alpha hydroxylase enzyme that generates 11-
deoxycorticosterone (DOC) from progesterone, and 11-deoxycortisol from 17α-
hydroxyprogesterone (17OHP). The CYP21 gene locus is highly complex, with both a 
functional CYP21A1 gene and CYP21A1P pseudogene within the HLA locus on 
chromosome 6. The HLA locus is highly recombinogenic, and exchange of DNA between 
the gene and pseudogene during cell division is common (Nebert et al., 2013). Gene 
conversion events can lead to some or all of the pseudogene replacing the corresponding 
area of CYP21A1, with decreased expression or reduced activity of the p450c21 protein. 
21-hydroxylase deficiency is therefore on of the most common autosomal recessive 
disorders affecting 1 in 20000 live births (Auchus, 2010). In the absence of enzyme 
activity, the inability to convert progesterone to DOC results in aldosterone deficiency, 
and the inability to convert 17OHP to 11-deoxycortisol results in cortisol deficiency. At 
its most severe this causes hypoglycaemia, hyponatraemia, hyperkalaemia and acidosis, 
with hypotension and cardiovascular collapse. The absence of cortisol delivery to the 
medulla results in lower adrenaline levels, compounding the hypotension and 
hypoglycaemia (Merke et al., 2000). Increased shuttling of intermediates to adrenal 
androgens causes variable amounts of virilisation depending on the specific abnormality.	
 
p450c11β (CYP11B1) and p450c11AS (CYP11B2): These closely related enzymes catalyse 
the final steps in the synthesis of glucocorticoids and mineralocorticoids, following 
trafficking of DOC or deoxycortisol back to the IMM (White, P. C. & Pascoe, 1992). 
p450c11β has a single 11-hydroxylation activity and is expressed in the ZF; p450c11AS 
can also catalyse 18-hydroxylation and 18 methyl-oxidation and its expression in the ZG 
restricts aldosterone production to this layer. An unequal crossing over of these genes can 
result in glucocorticoid-remediable hyperaldosteronism, when a hybrid gene allows 
aldosterone synthesis in the ZF, stimulated by ACTH (Salti et al., 1969; Lifton et al., 
1992). The condition is named because treatment with glucocorticoid will have a negative 
feedback on the pituitary and reduce the ACTH drive to the ZG. A lack of CYP17A1 
expression in rats and mice means that DOC is the substrate for both p450c11β as well as 
p450c11AS and therefore the main glucocorticoid produced in these species is 






1.3.3 Hydroxy-steroid dehydrogenase enzymes 
3βHSD is common to all of the steroidogenic cells(Mason et al., 1997). It converts the C-
3 hydroxyl to a keto group, and isomerises the double bond from the B to the A ring. The 
type 2 isoform is predominant in the adrenal gland and gonad. Low levels in the ZR impair 
conversion of DHEA to androstenedione, ensuring that DHEA is the most abundant 
adrenal androgen (Rainey et al., 2002). DHEA can be sulphated by sulphotransferase 
SULT2A1 to the inactive DHEA-S (Arlt et al., 1999). 
 
17βHSD: Isoforms of this are important in the gonad and the periphery in generating 
testosterone and interconverting oestrogens. Small amounts of testosterone in the ZR are 
probably a result of local production of 17βHSD5 (Nakamura et al., 2009).  
 
11βHSD1 and 11βHSD2: Although not expressed in the adrenal, the ability of the two 
isoforms of this enzyme to interconvert cortisol and its inactive metabolite cortisone is 
vital to regulating the actions of both cortisol and aldosterone. 11βHSD2 prevents cortisol 
from activating the mineralocorticoid receptor in the kidney (Funder et al., 1988), while 
11βHSD1 allows amplification of the cortisol signal in liver, muscle and nervous tissue 
(Seckl, 2004) 
1.3.4 Mineralocorticoids 
The principal mineralocorticoid is aldosterone, secreted in amounts 3 orders of magnitude 
less than cortisol. DOC has mineralocorticoid activity but this is not physiologically 
significant (Vinson & Coghlan, 2010). ZG cells are distinguished by expression of the type 
I angiotensin II receptor (AT1), aldosterone synthase, low levels of p450c17, and no 
expression of p450c11β. ZG cells do express receptors for ACTH but the main regulators 
of secretion are angiotensin II (Ang II) (Ganong et al., 1962) and small increases in the 
extracellular potassium concentration (Bing & Schulster, 1977). Angiotensin II levels 
increase because of volume depletion causing renin release in the kidney, but sodium 
depletion does not seem to cause aldosterone release through this mechanism (Okubo et 
al., 1997). Aldosterone release is inhibited by somatostatin, heparin, atrial natriuretic 
peptide and dopamine (Boscaro et al., 1982; Chartier et al., 1984). Additional control 







Binding of Ang II to the G-protein coupled AT1 receptor activates multiple downstream 
signalling pathways (Bird et al., 1993). Phospholipase C is the best characterised second 
messenger, causing an increase in intracellular calcium (Wojcikiewicz & Nahorski, 1993). 
The ZG cell membrane is depolarised by increasing extracellular concentrations of 
potassium, leading to calcium influx. In the short term StAR activity is increased (minutes 
to hours), while in the longer term (hours to days) CYP11B2 is upregulated (Pezzi et al., 
1997; Nogueira et al., 2009).  ZG cell proliferation is upregulated by Ang II mediated up-
regulation of the mitogen-activated protein kinase pathway (McNeill et al., 1998). 
 
The classical effects of aldosterone are mediated by binding to the mineralocorticoid 
receptor (MR) in the cytosol (Funder et al., 1972). The MR is distributed widely across a 
range of tissues, including the kidney, cardiomyocytes and vascular endothelium (Cat & 
Jaisser, 2012). It is a member of a steroid receptor superfamily that includes the 
glucocorticoid receptor and the androgen receptor (Arriza et al., 1987). Ligand binding 
induces dimerisation and dissociation from chaperone proteins, including hsp 90. The 
bound receptor translocates to the nucleus and is recruited to target genes by direct DNA 
binding or by associating with other DNA-bound transcription factors. There are 
aldosterone-induced effects on the vascular system which take place over a time course 
which is too rapid to be accounted for by transcriptional mechanisms alone. For instance, 
aldosterone injection in healthy human subjects was associated with an increase in 
vascular resistance within the first 10 minutes (Briet & Schiffrin, 2013). The 7-
transmembrane spanning, G-protein coupled receptor GPR30 has been suggested as one 
receptor involved in these non-genomic effects of aldosterone (Gros et al., 2011). Some 
of these rapid effects are abrogated by the MR antagonist eplerenone, and may be 
mediated by the MR binding additional receptors itself (Funder, 2010). 
 
The MR binds cortisol and aldosterone with equal affinity, and it is widely held that 
cortisol, present in 100-fold excess of aldosterone, is inactivated by the action of 11βHSD-
2 in the kidney. However, even in tissues with a plentiful supply of this enzyme, clearance 
of active cortisol is rarely complete, remaining at 10 times the level of aldosterone  
(Funder, 1996). The mechanism by which MR occupied by cortisol is held inactive is yet 
to be fully elucidated, but may be a consequence of the prevailing preponderance of 







Aldosterone induces renal retention of sodium, by upregulating epithelial sodium 
channels (ENaC) in the distal tubules(Bastl & Hayslett, 1992; Bubien, 2010). Although 
widely held to be the mechanism by which hyperaldosteronism increases blood pressure, 
this is not the sole mechanism -  direct aldosterone actions on the vasculature and the 
CNS are also important (Moura & Worcel, 1984). Oxidative stress upregulates the 
expression of the MR in cardiac cells, where it induces cardiac remodelling and fibrosis 
(Favre et al., 2011). Aldosterone itself can promote inflammation and oxidative stress, 
and contribute to impaired insulin signalling (Luther et al., 2011), while it induces 
swelling and stiffening of vascular epithelial cells and counteracts their ability to trigger 
vasodilatation (Oberleithner et al., 2004). This pro-inflammatory role is in contrast to the 
anti-inflammatory effects of glucocorticoid signalling. 
1.3.5 Glucocorticoids 
Glucocorticoid production is under the control of the hypothalamic-pituitary adrenal 
(HPA) axis. Upon activation, parvocellular neurons of the hypothalamic paraventricular 
nucleus synthesise and secrete corticotrophin-releasing hormone (CRH) and arginine 
vasopressin (AVP) into the hypophyseal portal circulation (Chrousos, 1995; Sapolsky et 
al., 2000). CRH binding to the CRH receptor on the corticotroph cell surface leads to 
ACTH release into the systemic circulation (Carrasco & Van de Kar, 2003). AVP has a 
synergistic role but does not stimulate ACTH release alone (Chrousos, 1995). CRH 
neurons projecting directly on to pro-opiomelanocortin (POMC) containing neurons in 
the hypothalamic arcuate nucleus can also stimulate local ACTH production, by inducing 
POMC cleavage (Pritchard & White, 2007). Cortisol levels are increased in line with the 
circadian rhythm of ACTH secretion, and in response to physical stresses such as 
hypotension, hypoglycaemia and fever which activate the HPA axis (Engeland et al., 
1977).  
 
ACTH binds to the melanocortin-2 receptor (MC2R), a 7-transmembrane G-protein 
coupled receptor (GPCR) which is expressed primarily in the ZF and activates cAMP-
mediated downstream signalling pathways (Chida et al., 2007). The immediate effects 
are mediated through the activation of cAMP-dependent protein kinase A (PKA) 
phosphorylating and activating cholesteryl ester hydrolases and StAR, and bring about 
rapid changes in cholesterol trafficking. Chronic ACTH stimulation (hours to days) leads 






et al., 2007; Waterman & Bischof, 1996). Adrenal blood flow increases (Vinson et al., 
1985), and the ZF layer hypertrophies, although the specific role of ACTH in this process 
is questioned as we shall see. ACTH fails to induce high levels of DHEA secretion from the 
ZF due to the low levels of cytochrome b5 in this zone. Additional factors modulating 
steroid output including locally produced cytokines, neuropeptides, and autonomic 
innervation of the gland will be considered later (Mikhaylova et al., 2007; Tkachenko et 
al., 2011). 
   
The glucocorticoid receptor is found in almost all cell types, and ligand binding is 
essentially identical to MR binding (Arriza et al., 1987). Receptor activation generally 
results in an inhibition of DNA synthesis (Santos et al., 2011). The effects of cortisol excess 
are well characterised, but the actual physiological role for the hormone is less clear cut, 
being predominantly a permissive one at basal levels. Glucocorticoids are named for their 
effect in modifying glucose metabolism - they stimulate gluconeogenesis and antagonise 
insulin - but whether this is an important homeostatic mechanism in the day to day life 
of normal individuals is debated (Vinson, 2009). The importance of cortisol production 
in response to starvation-induced stress in providing substrates for gluconeogenesis from 
muscle breakdown, for instance, is likely to have been more important from an 
evolutionary perspective (Nakamura et al., 2016). 
 
In the cardiovascular system cortisol increases the transcription of receptors for 
angiotensin II, epinephrine and norepinephrine, supporting a role in maintaining blood 
pressure (Sakaue & Hoffman, 1991). A role for inhibiting inflammation through 
negatively regulating signalling pathways controlled by NFκB and AP-1 transacting 
factors, and by down-regulating anti-inflammatory cytokine gene expression (IL-1-6, IL-
12, IFN-γ, TNF-α), is hypothesised to be more significant (Franchimont, 2004). The pro-
inflammatory effects of MR activation, which can be stimulated by cortisol, would appear 
to support this contention. The CNS effects of increasing appetite and paranoia under 
stress have a theoretical evolutionary benefit, and are commonly observed in cortisol 
excess (Bertagna et al., 2009). 
1.3.6 Adrenal Androgens 
Adrenal androgens are the most abundant steroids secreted from the adrenal gland (>20 






(A4) and very small amounts of testosterone. Maturation of the zona reticularis occurs at 
adrenarche in humans, gorillas and chimpanzees, usually at aged 8-10 in the human (Hui 
et al., 2009). ACTH has a permissive role, and a cortical androgen stimulating factor 
(CASH) has long been sought, but the stimulus for ZR maturation is thought likely to be 
adrenal in origin (Hornsby, 2002). Roles for the GH/IGF1 axis, or oestrogens produced 
by aromatase in the medulla, may be important (Belgorosky et al., 2008). The physical 
consequences of ZR maturation at adrenarche are the development of pubic hair, with a 
possible CNS role for DHEA in fine-tuning of the GnRH pulse generator to signal puberty. 
Pubertal development per se is not affected, nor is the individual’s final height, but 
premature adrenarche is associated with later metabolic disease and polycystic ovarian 
syndrome (Idkowiak et al., 2011). 
 
The key feature of the ZR is low levels of expression of 3β-HSD (Sasano et al., 1990; Gell 
et al., 1996) The enzymes p450c17, POR and cytochrome b5 are up-regulated at 
adrenarche, favouring the 17,20 lyase activity and therefore androgen production (Miller 
et al., 1997). The mass of the ZR increases, and 3βHSD1 levels decrease, so more DHEA 
is produced than A4. The MC2R is expressed in the ZR, but cortisol production is restricted 
by low levels of p450c21 and p450c11β1. As DHEA accumulates, there is conversion to 
A4, and to testosterone in very small amounts. SULT2A1, the sulphotransferase which 
produces DHEAS, is up-regulated at adrenarche, but whether DHEAS is an active 
endocrine hormone is not clear (Suzuki, T. et al., 2000). The affinity of DHEA for the 
androgen receptor is low until peripheral conversion to testosterone and 
dihydrotestosterone (Chen, F., 2005). As mentioned previously, the lack of CYP17 
expression in rat and mouse means that adrenal androgens are not produced in these 
animals. 
1.3.7 Catecholamines 
Catecholamines are packaged with chromogranins and a variety of neuropeptides within 
the dense granules of chromaffin cells. The chromogranins have a role in processing, 
storage and release of the contents of the granules (Louthan, 2011). 
 
Tyrosine is converted to dopamine by the successive actions of tyrosine hydroxylase and 
dopa-decarboxylase (Fukami et al., 1990). Dopamine β-hydroxylase converts this to 






phenylethanolamine N-methyltransferase (PNMT) in adrenergic chromaffin cells, before 
being taken up into another storage vesicle. Catecholamine half-life in the circulation is 
only 10-100 seconds, before being recovered by sympathetic nerves and chromaffin cells 
and metabolised to metanephrines by the action of catechol-O-methyltransferase (COMT) 
(De Diego et al., 2007). In 20% of chromaffin cells in humans PNMT is not expressed, 
and these cells therefore secrete noradrenaline (Wong, 2003). 
 
Catecholamine release is stimulated by acetylcholine release from the preganglionic 
sympathetic nerves, but there is a basal secretion even without neural input (De Diego et 
al., 2007). The pathways inducing adrenaline and noradrenaline release are different, 
with preferential noradrenaline release in response to haemorrhage, and adrenaline in 
response to hypoglycaemia (De Diego et al., 2007). The “fight or flight” response to severe 
stress, originally described by W B Cannon (Cannon, W. B., 1915), is due to a 60-fold 
increase in catecholamine secretion and is associated with increases in heart rate, 
metabolic rate and BP, glucose mobilised from liver and muscle, and dilatation of 
bronchioles and pupils. 
 
The commonly held view of the adrenal gland as containing two anatomically and 
functionally distinct zones of cortex and medulla has been increasingly challenged, with 
it becoming clear that there is a great deal of cross-talk between the two. (Haase et al., 
2011; Ehrhart-Bornstein & Bornstein, 2008). The close contact between cortex and 
medulla without an intervening connective tissue layer provide the morphological pre-
requisite (Schinner & Bornstein, 2005), and as described previously, the structure of the 
adrenal blood supply ensures that the medulla is exposed to high levels of cortisol. This 
has been shown to be  a requirement for the expression of PNMT and biosynthesis of 
adrenaline in medullary chromaffin cells (Wurtman & Axelrod, 1965). Conversely, 
deletion of the tyrosine hydroxylase gene in mice leading to catecholamine deficiency also 
results reduced steroid production from the adrenal cortex (Bornstein et al., 2000). 
Furthermore, as will be outlined in section 1.8.4, the role of medullary neuropeptides in 
regulating corticosteroid production is also becoming well established. An understanding 
of the development of the gland and the control mechanisms regulating growth and 






1.4 Adrenal Development 
The adrenal cortex develops from a thickening of coelomic epithelium - the 
adrenogonadal primordium (AGP) between the urogenital ridge and the dorsal mesentery 
which in humans can be identified from 4 weeks post conception (dpc), and in mice 9.5-
10dpc (Figure 1.4) (Else & Hammer, G. D., 2005; Hatano et al., 1996). This 
adrenogonadal primordium is characterised by expression of the transcription factor SF-
1. As it grows its cells delaminate and invade the underlying mesenchyme, splitting into 
the distinct adrenal and gonadal primordia, the former with the higher SF-1 expression 
(33dpc human, 10.5dpc mouse) (Luo et al., 1994). At 41-44 dpc the human adrenal is 
expressing CYP17 and becoming vascularised, with two distinct zones detectable by 52 
dpc.  
 
The inner fetal zone (FZ) histologically resembles the zona reticularis, while the 
subcapsular definitive zone (DZ) comes to resemble the zona glomerulosa early in the 
third trimester. By the ninth week of gestation a mesenchymal capsule has formed around 
the gland, and by the 14th week a third cortical zone - the transitional zone (TZ) - has 
developed between FZ and DZ (Sucheston & Cannon, M. S., 1968). By late gestation the 
DZ and TZ have come to resemble the ZG and ZF respectively (Coulter et al., 1996). In 
addition to the morphological similarities, the localisation of steroidogenic enzymes and 
cofactors supports the concept that the DZ develops to form ZG, the TZ is analogous to 
the ZF, and the ZR emerges from the FZ (Ishimoto & Jaffe, 2011) 
 
The adrenal medulla is derived by invasion of the fetal cortex by cells derived from the 
neural crest. These sympathogonia migrate in nerves from the sympathetic chain and 
along blood vessels penetrating the cortex at its cranial aspect from 6 weeks post 
conception (wpc) (Yamamoto et al., 2004).  At least some of these cells retain the 
potential to become neuronal ganglion cells or chromaffin cells (Ernsberger et al., 2005). 
The chromaffin cells are scattered within the cortex initially and mostly noradrenergic; it 
is thought that cortisol production from the transitional zone induces PNMT expression 
and directs the majority to become adrenergic (Jozan et al., 2007; Wurtman & Axelrod, 
1965; Finotto et al., 1999). Islands of medullary tissue coalesce into the adult medulla 
only in the second year of postnatal life (Wilburn et al., 1986), but as discussed there 







The cortex of the fetal adrenal is itself an active endocrine organ - the fetal zone produces 
large amounts of adrenal androgens which are aromatised by the placenta for oestrogen 
synthesis (Carr & Simpson, E. R., 1981), 1981], while cortisol production is thought to 
assist in the maturation of the developing fetus, and theorised to have a role in the 
induction of parturition (Jaffe et al., 1998). There is transient 3βHSD expression in the 
FZ in the first trimester, then again in the third trimester in DZ and TZ, with this early 
expression thought to be part of the mechanism for avoiding virilisation, as the cortisol 
suppresses ACTH production from the fetal pituitary and excess androgen production at 
this time (Goto et al., 2006). 
 
The neonatal human adrenal gland is relatively large compared to the adult (3-5g at 
term), but the FZ rapidly involutes and remodels with attendant fall in adrenal androgen 
secretion shortly after birth (Jirásek, 1980), and the weight of the gland falls by 50% 
within two weeks. The DZ and TZ become the ZG and ZF respectively, but it is several 
years before ZR cells are seen, with a continuous ZR only seen following adrenarche 
(Belgorosky et al., 2008). 
 
An additional X zone adjacent to the medulla in the mouse appears in the second week 
of life, and occupies a third of the cortex by the time of weaning (Jones, I. C., 1948). It 
degenerates at puberty in males or first pregnancy in females, and may derive from fetal 








Figure 1.4 Development of the mouse adrenal gland 
The adrenogonadal primordium (AGP) develops as a thickening of the coelomic epithelium (CE) 
adjacent to the hindgut dorsal mesentery [A]. Expression of steroidogenic factor 1 (SF1) is the key 
step in adrenal development.  Wt1 and Cited2 together drive high levels of SF-1 required for AGP 
development. The more medial cell population with the highest SF-1 expression delaminates into 
the mesenchyme to form the adrenal primordium (AP)[C], while the cells adjacent to the 
mesonephros expressing lower levels of SF-1 are invaded by primordial germ cells and delaminate 
to form the gonadal primordium (GP)[H]. Cited2 is upregulated and Wt1 downregulated in the 
AP [D]; Cited2 is downregulated in the GP [H]. Migrating neural crest cells arrive at the urogenital 
region at around day 11.5 [D], entering the AP at approximately day 13 (Val et al., 2007) [D] and 
subsequently coalescing to form the adrenal medulla by around day 14.5 (Lumb & Schwarz, 2015) 
[E]. Surrounding mesenchymal cells form a capsule from day 13.5-16.5 (Bandiera et al., 2013), 
associated with the expression of the transcription factors FoxD1 and FoxD2 (Itäranta et al., 2009; 
Kume et al., 2000)[E]. The role of an adrenal gland specific enhancer of SF-1 (FAdE) is thought 
to be key in fetal adrenal development and zonation (Zubair et al., 2006; Zubair et al., 2008). This 






15.5dpc only in the inner cortex around the medulla, and persisting in the X zone of the adult 
mouse until its regression. The FAdE contains binding sites for Pbx1 and SF-1 itself (Gardiner et 
al., 2012). Pbx1 is thought to be required for initiation of SF-1 transcription, with prolonged 
expression requiring SF-1 to act in a feedforward mechanism. Differential FAdE activation is one 
proposed mechanism for initial zonation into a fetal zone and a definitive zone (Morohashi & 
Zubair, 2011). Upregulation of SF-1 by β-catenin and downregulation by Dax1 is described in more 
detail in the text. 
1.4.1 Growth and zonation 
The adrenal cortex is a dynamic organ, with the ability to adapt rapidly to changes in the 
prevailing hormone milieu both in terms of structure and function, and a remarkable 
regenerative capacity in the face of surgical injury. The centripetal migration hypothesis 
describes a model whereby there is a continual production of new cortical cells at the 
periphery of the gland, which then migrate to the centre of the gland before they die at 
the inner corticomedullary boundary (King, P. et al., 2009). The majority of mitoses in 
rat and mouse adrenals occur at the ZG/ZF boundary, while most cell death occurs at the 
ZR/medulla boundary (Rebuffat et al., 1992). Surgical enucleation of the ZF and medulla 
from the rat adrenal reveals that the adrenal cortex can completely regenerate within 4 
weeks, while a similar regeneration also occurs in human adrenals (Baker & Baillif, 1939). 
Lineage tracing studies following the fate of subcutaneously injected trypan blue revealed 
that it was taken up initially by capsule and ZG cells, before being observed in the ZF and 
eventually the ZR (Salmon & Zwemer, 1941). Mosaic transgenic studies provide more 
contemporary evidence for this theory - columns of β-galactosidase expressing cells under 
the control of the CYP21 promoter traverse the cortex from capsule to medulla boundary 
(Iannaccone et al., 2003), and recent genetic lineage tracing experiments have provided 
direct evidence for centripetal migration in the rat (Huang et al., 2010; King, P. et al., 
2009). Chang et al demonstrated that centripetal migration also occurs within the mouse 
adrenal, in a series of 5-bromo-2’-deoxyuridine (BrDU) labelling experiments (Chang et 
al., 2013). Labelled cells were initially present in the outer cortex, but were detected in 
the inner cortex after 1 week. In addition, there was evidence for bidirectional movement, 
with some cells in the outer cortex moving towards the capsule. 
 
Many authors have concluded from these experiments that the progenitor cells come from 
the capsule, but there is also evidence that they lie within the ZG (Kim et al., 2009). The 
DZ cells possess characteristics of proliferating rather than steroidogenic cells - expression 
of proliferating cell nuclear antigen (PCNA) and their relatively lipid-free state (McNutt 






adrenal cortex at the periphery of the gland between the ZG and ZF(Bertholet, 1980). 
Mitani et al have demonstrated that the majority of the proliferating cells are located 
around the ZU, and suggest that it is a stem cell zone in the rat adrenal(Mitani et al., 
2003). 
 
1.5 Molecular biology of adrenal development 
Identification of genes involved in adrenal development has come largely from knock out 
mouse models and genetic analysis of human adrenal insufficiency.  
1.5.1 Urogenital ridge development 
The transcription factor Odd skipped related 1 (Odd1) is involved in embryonic 
patterning in the mouse, with intermediate mesodermal expression at 8.5dpc (So & 
Danielian, 1999). Odd1 null mice die in utero with impaired urogenital ridge formation; 
those surviving to 15.5dpc show complete absence of adrenals, gonads and kidneys 
(Wang, Q. et al., 2005). 
 
Germline mutations in Wilms Tumour gene WT1 cause gonadal and renal defects in 
humans(Baird et al., 1992; Haber & Housman, 1992), and Wt1 null mice die at 13.5 dpc 
without significant urogenital ridge formation(Kreidberg et al., 1993). A WT1 transgene 
will allow them to survive to birth but with impaired adrenal development (Moore et al., 
1999). Wt1 expression is turned off prior to separation of adrenal and gonadal primordia 
(Nachtigal et al., 1998; Val et al., 2007). 
 
Sall1 is a transcription factor expressed in murine intermediate mesoderm at 10.5dpc and 
metanephric mesenchyme at 11.5dpc (Nishinakamura et al., 2001), and in human 
adrenal FZ (Ma et al., 2002). Sall1 null mice have severe kidney dysgenesis and 
hypoplastic adrenals at birth, while heterozygous mutations in the gene cause the renal 
and genital abnormalities of the Townes Brocks syndrome in humans (Kohlhase et al., 
1998). 
 
Without the Pbx1 transcription factor mice die at 15-16 dpc with multiple organ aplasia 






in the urogenital ridge, then adrenogonadal primordium, and throughout the human fetal 
adrenal cortex by 10 weeks gestation (Ferraz-de-Souza et al., 2009). Heterozygous 
knockout mice have adrenals with a ZF containing hypertrophied cells in smaller numbers 
than normal, and fewer proliferative cells in the subcapsular region (Lichtenauer et al., 
2007). 
 
The Wnt family of secreted glycoproteins have crucial roles in cell growth and 
differentiation. Wnt4 is first expressed in the metanephric mesenchyme on the medial 
side of the ureteric bud (Nishinakamura et al., 2001) and the coelomic epithelium and 
mesenchyme of the genital ridge at 11.5dpc in mice, but by 14.5dpc it is localised only in 
the subcapsular region of the adrenal primordium (Heikkilä et al., 2002). A WNT4 
homozygous missense mutation in humans is associated with adrenal hypoplasia from 19 
weeks gestation (Mandel et al., 2008), while Wnt4 null mice have gonadal defects as well 
as adrenals with reduced CYP11B2 expression (Heikkilä et al., 2002). 
 
FoxD1/FoxD2 are members of the forkhead/winged helix family of transcription factors. 
Both are expressed in nephrogenic mesenchyme and in the adrenal capsule (Hatini et al., 
1996), and homozygous null mice have hypoplastic adrenals and urological defects at 
birth (Kume et al., 2000). 
1.5.2 Adrenogonadal primordium development 
SF-1 is an orphan nuclear receptor transcription factor that is a key regulator of adrenal 
and gonadal development, and of steroidogenesis itself. It is the earliest marker of the 
adrenogonadal primordium, with highest levels of expression at the rostral adrenal end 
(Hatano et al., 1996). SF-1 expression is maintained in all steroidogenic cells of the 
adrenal cortex when the primordia separate, and it remains high in the steroidogenic cells 
of the testis, although there is a temporary decline in expression in the ovary in 
midgestation (Ikeda et al., 2001). Forced expression of SF-1 will differentiate mouse 
embryonal stem cells and bone marrow cells into steroidogenic cells (Crawford et al., 
1997), and expression under the control of its fetal adrenal enhancer leads to the 
formation of larger adrenals and ectopic adrenal tissue, indicating that non-adrenal 







Homozygous deletion of the Sf-1 gene in mice causes loss of the adrenals and gonads by 
12.5dpc (Luo et al., 1994; Sadovsky et al., 1995): the coelomic epithelium thickens, but 
the cells apoptose. Offspring have XY sex reversal and die from neonatal hypoglycaemia. 
Sf1+/- mice are viable, but have small adrenals which are less responsive to stress (Babu 
et al., 2002; Bland et al., 2000). Only heterozygous loss of function mutations have been 
identified in humans, and they much more commonly affect sexual development than 
adrenal development (Ferraz-de-Souza et al., 2011). 
 
Dax1 (dosage sensitive sex reversal adrenal hypoplasia congenital (AHC) critical region 
on the X chromosome) is a nuclear receptor transcription factor with an atypical DNA 
binding domain. It negatively regulates transcription, expressed in the same tissues as SF-
1 and acting as its corepressor (Hanley et al., 2001). Mutations in DAX1 in humans cause 
a form of adrenal hypoplasia congenita (AHC) (Muscatelli et al., 1994; Zanaria et al., 
1994) in which patients present with adrenal insufficiency of both glucocorticoids and 
mineralocorticoids. The adrenal cortex has poorly developed adult zones but retention of 
cytomegalic FZ cells. Deletion of Dax1 exon 2 has the surprising effect in mice of 
enhancing steroid output (Yu et al., 1998) until the cortex starts to regress and 
cytomegalic cells appear as the animals age, suggesting that the mutation is hypermorphic 
in mice (Scheys et al., 2011). This may be a consequence of Dax1 repression of Oct3/4m, 
which when activated in embryonal stem cells can cause differentiation (Sun et al., 2009). 
Loss of Dax1 may cause uncontrolled differentiation of adrenal stem/progenitor cells,  
with their exhaustion taking longer in mice than humans resulting in a delayed regression 
of the cortex (Scheys et al., 2011). Levels of SF-1 are also reduced by mutations in the 
mouse polycomb protein CBX1, which leads to adrenal and gonadal hypoplasia. (Katoh-
Fukui et al., 1998). 
 
The insulin-like growth factors also have a role in adrenal development. The IGF1 
receptor (IGFR1) is expressed in human fetal FZ and DZ, IGF2 is expressed at high levels 
throughout the gland, and IGF1 in the capsule only (Shigematsu et al., 1989; Mesiano et 
al., 1997).  A constitutive deletion of the insulin receptor (Insr) and the IGFR1 in a mouse 
model results in reduced growth, gonadal dysplasia with male to female sex reversal and 
a range of severe adrenal developmental defects (Pitetti et al., 2013). There are 40% 
fewer SF-1 positive progenitor cells in the urogenital ridge and a decrease in total Sf-1 






through these receptors may upregulate SF-1 expression or phosphorylate and thereby 
enhance its transcriptional activity. 
 
1.5.3 Adrenal primordium development 
Cited2 (CBP/p300-interacting transactivator with ED-rich tail 2) is a transcriptional co-
factor that binds with high affinity to these eponymous transcriptional co-activators; it 
can both positively and negatively regulate transcription. Deletion of Cited2 in mice is 
embryonically lethal (Bamforth et al., 2001) with embryos exhibiting markedly reduced 
adrenal development by 12 dpc (Val et al., 2007) and adrenal agenesis by 17.5 dpc 
(Bamforth et al., 2001), as well as cardiac, neural tube and left-right patterning defects 
(Bamforth et al., 2004). 
 
β-catenin is a protein with two major functions: the majority regulates cytoskeletal 
binding to cadherin complexes, while a cytoplasmic pool is the defining feature of the 
canonical Wnt signalling pathway mentioned earlier. Wnt signalling allows nuclear 
accumulation of β-catenin and thus co-activation of the TCF/LEF family of transcription 
factors (Wakil & Lalli, 2011). Transcriptionally active β-catenin has been detected in the 
coelomic epithelium of the adrenogonadal primordium, and later localised to subcapsular 
cell clusters (Kim et al., 2008). Using an SF-1 cre driver system to delete β-catenin in 
murine steroidogenic cells only, results in a detectable adrenal primordial at 12.5dpc, but 
with fewer cells expressing SF-1, and less expression of CYP11A1 and 3βHSD.  
 
As discussed, SF-1 is the major driver of adrenal development and function, and it is 
through changes in SF-1 expression that many of the genetic defects described are 
thought to act. Deletion of both Odd1 and Sall1 causes reduced Wt1 expression; Wt1 and 
Cited 2 together drive the high levels of SF-1 expression required for adrenal primordium 
development (Val et al., 2007). SF-1 upregulates its own negative regulator, Dax1, 
perhaps as a mechanism for fine tuning expression during adrenal development, but Dax1 
can also function as an SF-1 coactivator at high levels. SF-1 and β-catenin co-operate to 
transcriptionally activate Dax1 expression (Mizusaki et al., 2003). Wnt4 expression is 






1.6 Signalling pathways involved in adrenal development 
1.6.1 Shh signalling 
Sonic hedgehog (Shh), along with Desert hedgehog (Dhh) and Indian hedgehog (Ihh), 
belongs to the vertebrate hedgehog family of secreted ligands which have a multitude of 
vital roles during embryonic development and in tissue maintenance, differentiation and 
regulation of stem cell populations in the adult (King, P. J. et al., 2008). Hh signal 
receiving cells express the transmembrane protein Patched-1 (Ptch1), which in the 
absence of ligand binding inhibits the actions of the G-protein coupled receptor 
Smoothened (Smo), and ensures that the downstream Zn-finger transcription factors Gli2 
and Gli3 are subjected to an inhibitory proteolytic processing (Pan et al., 2006). Hh 
binding to Ptch 1 allows Smo to prevent this processing, so Gli2 and Gli3 can operate as 
transcriptional activators. The pathway also upregulates Gli1, which is a useful marker 
for active Hh signalling (Vokes et al., 2007). 
 
Sonic hedgehog is expressed in the adrenal primordium in subcapsular cells, and remains 
restricted to this population throughout gestation and adulthood (Ching & Vilain, 2009; 
King, P. et al., 2009; Huang et al., 2010). Shh expression in rodents occurs in relatively 
undifferentiated but steroidogenic cells expressing neither CYP11B1 or B2, arranged in a 
continuous layer between ZF and inner ZU in rats(Guasti, Paul, Laufer & King, 2011a), 
while in humans and mice they are arranged in clusters between cells of the ZG (King, P. 
et al., 2009).  
 
Defects in adrenal development have been seen as a results of inactivation of the Hh 
pathway. Holoprosencephaly is often accompanied by adrenal hypoplasia with defects in 
SHH, PTCH1 and GLI2 genes (Nanni et al., 1999; Ming et al., 2002; Roessler et al., 2003), 
while adrenal agenesis is seen in Pallister Hall syndrome, the result of a GLI3 mutation. 
Homozygous deletion in mice is embryonically lethal, but prior to this the adrenal 
primordial is noted to be much smaller than wild type (Ching & Vilain, 2009). Deletion 
from only steroidogenic tissue results in animals whose adrenals are small, but with intact 
zonation and a normal sized medulla (King, P. et al., 2009). 
 
Shh expression has been detected in the developing mouse adrenal almost immediately 






a Shh cre driver shows expression as early as 11.5dpc, increasing to 13% of all SF-1 
positive cells by 12.5dpc but mainly subcapsular, then to 75% of SF-1 positive cells by 
13.5dpc, but spread throughout the cortex. All the cortical cells are labelled in these 
adrenal glands when harvested after birth. When similar experiments are performed with 
an inducible Shh cre-T2 driver, labelled cells were seen at the periphery of the gland 
following tamoxifen injection at 14.5dpc, and after 28 days’ columns of cells were 
observed spanning the cortex from capsule to medulla. Similar results were obtained in 
the adult after 7 or 13 days, with labelled cells co-expressing CYP11B1 or CYP11B2. These 
data identify the Shh-expressing cells as candidate stem/progenitor cells. 
 
The cell population that are responding to the secreted Shh signal are mesenchymal cells 
in the capsule and periphery of the cortex. They do not express SF-1 or CYP11A1 but do 
express Gli1, Ptch1 and FoxD2. Deletion of Smo from cortical cells using the SF-1 cre 
driver does not affect adrenal development, but the adrenal hypoplasia associated with 
Shh deletion is associated with a much thinner capsule whose proliferative capacity is 
greatly reduced (King, P. et al., 2009). This suggests that the effect of Shh deletion is 
mediated via the capsule. Using inducible Gli1 cre drivers in lineage tracing experiments 
demonstrates that following tamoxifen injection at 14.5dpc there is initial labelling of the 
Shh-responsive cells in capsule and subcapsular mesenchyme (SF-1 negative), but that 
clusters of labelled cells which do express steroidogenic markers are observed in the 
cortex and expand into columns with extended chases (King, P. et al., 2009; Huang et al., 
2010). Interestingly, a proportion of these cells are observed to express Shh itself. Similar 
columns of cells are seen following postnatal induction of the Gli1 cre driver.  
 
Taken in concert, these lineage-tracing studies provide a direct confirmation for the 
centripetal migration hypothesis, and the periphery of the gland as the location for the 
stem/progenitor population. The implication is that Shh signals to a mesenchymal 
population of cells that differentiate from a non-steroidogenic to a steroidogenic 
phenotype, at least in part via a Shh-expressing intermediate. The definitive cortex 
develops from the capsule, and is of both coelomic epithelium and mesenchymal origin. 
Wood and Hammer (Wood & Hammer, G. D., 2011) have proposed a model wherein cells 
in the newly separate adrenal primordium enter the developing adrenal capsule and have 
their SF-1 expression turned off before Shh expression in the cortex begins; SF-1 






factor Pod1 is a candidate for the factor which represses SF-1: loss of Pod1 in mice leads 
to increased differentiation of steroidogenic Leydig cells in the testis, and ectopic 
expression of the SF-1 and SF-1 target genes (Cui et al., 2004). Adrenal expression in the 
adult mouse is exclusively in the capsule, where Pod1 null mice also show ectopic SF-1 
expression (Kim & Hammer, G. D., 2007). However, other data are not in support of this 
hypothesis – an SF-1 BAC transgene does not label the capsule, and Pod1 expression is 
not detected in the capsule at 16.5dpc in the mouse when SF-1 is undetectable (King, P. 
et al., 2009). 
 
There is a reduction in PCNA staining in Shh mutant adrenals compared to wild type, but 
no apparent increase in apoptosis, suggesting that Shh signalling to the capsule is 
generating a proliferative rather than a survival signal to the cortex (Ching & Vilain, 
2009). Huang suggests that Shh acts as a mitogen for the capsule, hence the thin capsule 
is Shh mutant adrenals, but an alternative explanation is that Shh acts as a 
chemoattractant to promote the coalescence of surrounding mesenchyme to form the 
capsule itself. A further hypothesis has it that Shh regulates the differentiation of the 
capsule into the steroidogenic lineages, and the capsule depletes rapidly of these cells 
when it is absent. The precise nature of how the signal from capsule to cortex is 
transduced has yet to be determined, but possible candidates include the Wnt signalling 
pathway, and fibroblast growth factors. 
 
1.6.2 FGF signalling 
Fibroblast Growth Factor (FGF) signalling controls a number of early developmental 
processes: cell movement during gastrulation, mesoderm and neuroectoderm formation, 
anterior/posterior patterning and organogenesis (Ornitz & Itoh, 2001). 22 members of 
the FGF family have been identified, all characterised by a conserved core of 140 amino 
acids, and all except for the intracellular FGFs (iFGF, FGF11-14) signal through the 
FGFRs. These are receptor tyrosine kinases, binding to which most commonly activates 
Ras/MAPK pathways to control cell proliferation and differentiation, Akt to determine 
cell survival or protein kinase C to regulate cell migration (Dorey & Amaya, 2010; 







FGFs 2 and 9 are expressed predominantly in the adrenal capsule, and FGFRs 2 IIIb, 2 
IIIc and 3 IIIc are expressed mainly in the cortex, with FGFR 2 IIIb and IIIc expression in 
subcapsular clusters of cells similar to Shh and β-catenin (Guasti et al., 2013). FGF2 is a 
mitogen for adrenocortical cells in culture and gland regeneration experiments (Lepique 
et al., 2004) and binds specifically to ZG cells, where FGFR2 IIIc is located. Deletion of 
both isoforms of FGFR2 leads to hypoplastic adrenals and male to female sex reversal, 
implying that FGFR2 is required for adrenal growth and development after AGP 
formation. FGFR2 IIIb null mice have thickened capsules with disorganised cells, with 
enhanced cell proliferation and upregulated Gli1 expression, suggesting that FGF 
signalling may actually be a negative regulator of Shh expression (Chida et al., 2007). 
1.6.3 POMC and ACTH 
ACTH is a product of the proteolytic cleavage of the prohormone pro-opiomelanocortin 
(POMC) in the pituitary gland and a variety of extra-pituitary tissues (Dores & Baron, 
2011). Pituitary POMC is expressed in anterior lobe corticotroph cells and intermediate 
lobe melanotroph cells, although the intermediate lobe is not prominent in humans.  
 
POMC gene:  
The POMC gene is 8-kb and located on chromosome 2p23 in the human, and consists of 
three exons and two intervening introns (Fig 1.5a). The first exon encodes a leader 
sequence, the second encodes the signal initiation sequence and the N-terminal portion 
of POMC, and the third encodes most of the mature peptide sequences. Transcription is 
initiated in the pituitary from a promoter which generates an mRNA transcript of 
approximately 1200nt. In extra-pituitary tissues a downstream promoter is capable of 
generating truncated 800nt transcripts arising from the 5’ end of exon 3, and longer 
1380nt transcripts via an upstream promoter. This was demonstrated by Clark et al using 
Northern Blot analysis of tissue from ACTH-secreting pancreatic neuroendocrine tumours 
(Clark et al., 1989). In human placental tissues all three transcripts are present: a 
pituitary-like 1200nt transcript in addition to the 800nt and 1380nt species (Grigorakis 
et al., 2000). Translation of the shorter peptides can potentially be initiated from the 
methionines (ATG) indicated in figure 1.5a, but they lack the signal sequence for 
targeting to the ER, and it is felt unlikely that these peptides would be secreted (Jeannotte 










Figure 1.5 POMC processing 
A: The POMC gene consists of three exons and two introns. A pituitary selective promoter produces 
a transcript of 1200nt, in extra-pituitary tissues a downstream promoter can produce 800nt 
transcripts (downstream promoter) and 1380nt transcripts (upstream promoter). The 800nt 
transcripts can potentially be translated from an ATG site just upstream of ACTH, but these lack 
the signal sequence for targeting to the secretory apparatus. 
B: The POMC proprotein convertase processing enzymes PC1/3 and PC2 are differentially 
expressed in the` anterior and intermediate lobes of the pituitary. PC1/3 expression alone will 
generate ACTH, but high levels of PC2 in the intermediate lobe lead to the production of alpha-
MSH 
C: POMC peptides act mainly through a family of five G-protein coupled receptors known as the 
melanocortin receptors (MCX-R where X is a number from 1–5). β-endorphin acts via the κ  and μ 
opiate receptors and the receptor through which the N-terminal peptides stimulate adrenal 
mitogenesis remains to be identified. ACTH, adrenocorticotrophin; CLIP, corticotrophin-like 
intermediate peptide; LPH, lipotrophin; MSH, melanocyte-stimulating hormone. Adapted from 
(Bicknell, AB, 2008). Anterior lobe processing as shown in the figure occurs in humans as well as 






pars intermedia regresses soon after birth although immunoreactive alpha-MSH is seen in the zona 
intermedia of the human gland, between anterior and posterior pituitary (Coates et al., 1986). 
Both anterior and intermediate lobe-like POMC processing takes place in the central nervous 
system (Bicknell, AB, 2008) and in neuro-endocrine tumours (Beuschlein & Hammer, G. D., 2002). 
 
 
Control of POMC expression: 
In the pituitary gland expression of POMC is under multihormonal control with the main 
stimulatory input from CRH and AVP, and inhibitory regulation from adrenal 
glucocorticoids(Drouin, 2016). The role of neuropeptides and cytokines in stimulating 
steroid production in the adrenal will be described later, but there is a similar level of 
involvement in control of POMC gene expression and production of POMC peptides, with 
factors such as serotonin, oxytocin and leptin, along with pro-inflammatory cytokines, all 
involved (Slominski et al., 2000).   
 
The role of methylation status of the POMC promoter in enabling POMC expression has 
been established by Newell Price et al (Newell-Price et al., 2001). They demonstrated that 
the POMC promoter is embedded within a defined CpG island, much of which is 
methylated in non-expressing tissues, and specifically un-methylated in POMC-expressing 
tissues and tumours. Ye et al  (Ye et al., 2005)defined a region between -417 and -260 bp 
upstream of the POMC transcription initiation site where the levels of POMC expression 
correlated inversely with methylation density.  
 
There are a variety of transcription factors whose restricted pituitary expression leads to 
cell-specific POMC expression. The key attributes are an enhancer region with a site that 
cooperatively binds TF pituitary homeobox 1 (Pitx1) and Tbox TF Tpit (Tbx19), and a 
further binding site which is a target for neurogenic differentiation 1 (NeuroD1) (Poulin 
et al., 2000) – together these two regulatory elements synergistically control transcription 
of the POMC gene in corticotrophs. Melanotroph-specific gene expression is enabled by 
the expression of the transcription factor Pax7 (Budry et al., 2012): in Pax7-/- mice 
expression of melanotroph markers such as PC2 (see below) in the intermediate lobe are 
severely reduced, while corticotroph markers such as the CRH and vasopressin V1b 








POMC processing is shown in figure 1.5b and c. Proprotein convertases are widely 
expressed in endocrine tissues and catalyse the cleavage of prohormones including 
proPTH and proinsulin (Chrétien, 2011). The serine proteases PC1/3 and PC2 are the 
members of this family of enzymes involved in the processing of POMC. PC1/3 is 
predominant in the anterior lobe, while in the intermediate lobe both PC1/3 and PC2 are 
expressed (Zhou et al., 1993). This is the molecular basis for the generation of 
predominantly ACTH from the anterior pituitary, while smaller POMC peptides such as 
α-MSH are produced in the intermediate lobe.  
 
The presence of an intermediate lobe in humans is debated, as the fetal pars intermedia 
regresses soon after birth, and there is no distinct intermediate lobe on histological 
examination (Horvath, E. et al., 1999). There is no pituitary secretion of alpha-MSH in 
normal physiological circumstances, supporting the idea that the intermediate lobe is not 
a significant presence (Iino, K. et al., 2010).  It is reported, however, that immunoreactive 
alpha-MSH is seen in the zona intermedia of the human gland, between anterior and 
posterior pituitary (Coates et al., 1986); and that there is an. increase in circulating levels 
of α-MSH in the serum of Addison’s disease patients  (Donahoo et al., 2009). PC2 
expression is reported in both normal human pituitary (Hook et al., 2009; Lloyd et al., 
1995) and pituitary adenomas (Jin et al., 1999; Iino, K. et al., 2010); and pituitary 
dependent Cushing’s disease is associated with the presence of smaller POMC peptides 
such as α-MSH (Colao et al., 1993; Coates et al., 1986). Levels of PC2 expression in 
tumours associated with ectopic production of ACTH are significantly higher than in 
ACTH-secreting pituitary adenomas (Tani et al., 2011). In conclusion, the literature to 
this point suggests that hormone production from the pituitary intermediate lobe does 
not play a physiological role in humans, although intermediate lobe-like POMC processing 
does occur in endocrine tumours from the pituitary and elsewhere. 
 
ACTH in fetal adrenal development: 
Much of the early evidence for the role of fetal pituitary ACTH in adrenal development 
comes from the study of anencephalic fetuses. In this common congenital abnormality of 
varying severity a major portion of the brain, skull and scalp is absent – generally fetuses 
lack a hypothalamus but often the anterior pituitary is retained (Swaab et al., 1978). Early 
adrenal development proceeds normally, suggesting that hypothalamic input at least is 






conception (Benirschke, 1956; Mazzitelli et al., 2002). Microscopic examination reveals 
a structurally intact DZ and medulla, but a small FZ with diminished DHEA production. 
Pituitary ACTH is detectable at around 50dpc, contemporaneous with adrenal 
steroidogenic enzyme expression, and thought to be responsible for FZ androgen 
production (Goto et al., 2006). Pituitary glands in anencephalic fetuses have decreased 
ACTH production by midgestation, so there is an ongoing requirement for hypothalamic 
stimulation; ACTH administration to anencephalic fetuses in utero is able to restore the 
size of the FZ. 
 
Based on these data it has been proposed that ACTH, or possibly another POMC peptide 
(Estivariz et al., 1988), is the primary regulator of adrenal development. However, Pomc 
null mice (Karpac et al., 2005) and Mc2r null mice (Chida et al., 2007) have normal 
adrenals at birth, indicating that neither ACTH, nor any other POMC peptide, is required 
for fetal adrenal development in this species. It is possible that because the rodent 
placenta, unlike humans, expresses CYP17 and is able to make oestrogen (Arensburg et 
al., 1999; Durkee et al., 1992), whereas in humans this is formed from adrenal androgens 
secreted from the FZ under the control of ACTH, there is no need for ACTH signalling in 
utero in mice. This would indicate that the role of ACTH in humans is to maintain 
pregnancy through its actions on steroidogenesis rather than via its effects on growth. 
ACTH is not mitogenic for adrenocortical cells grown in vitro, and in some systems has 
shown to be anti-mitogenic (Masui & Garren, 1971; Rocha et al., 2003). It has been 
hypothesised that ACTH upregulates the expression of other growth factors locally, such 
as IGF2 (Voutilainen & Miller, 1987) and FGF2 (Mesiano et al., 1991), both of which 
themselves are potent mitogens for adrenocortical cells in vitro (Crickard et al., 1981). 
IGF2 is not expressed in the adult cortex, but is proposed to be a major regulator of fetal 
adrenal growth (Mesiano et al., 1997). 
1.7 Postnatal growth, zonation and remodelling  
The postnatal and adult adrenal cortex is highly dynamic: in addition to the continuous 
centripetal migration of cells described under normal conditions, the relative sizes of the 
cortical zones can be remodelled in response to hormonal requirements, and the 







The mechanism by which the functional zonation of the adrenal cortex is defined has 
been described above, but the manner in which this is established and thereafter altered 
in response to the organism’s hormonal requirement is becoming increasingly understood. 
The centripetal migration theory would predict the ability of ZG cells in the outer cortex 
of the mouse adrenal to transdifferentiate into their adjacent ZF cells, but an intervening 
undifferentiated zone (ZU) in rats presents a conundrum for the maintenance of zonation 
in this species. The ZU is further subdivided into an outer Shh-expressing oZU and smaller 
inner layer that does not express Shh (iZU)(Guasti, Paul, Laufer & King, 2011b). The 
juxtaposition of the proposed capsular or subcapsular stem/progenitor cells with the ZG 
and ZF raises some interesting questions regarding the differentiation processes that occur 
during centripetal migration.  
 
Capsular cells delaminating and entering the cortex would seemingly first become 
CYP11B2-positive ZG cells, not Shh-positive cells. Mitani et al respond to this with the 
idea that the capsular cells instead migrate through the CYP11B2-expressing ZG layer of 
cells to the oZU, and from there can differentiate in either the ZF or ZG direction (Mitani 
et al., 2003). Interestingly, they observed a circadian rhythm to this process, with a peak 
at 4am for differentiation into ZF, and at 8pm for differentiation into ZG cells. This is in 
keeping with Miyamoto et al (Miyamoto et al., 1999), who showed a burst of cell 
proliferation in the outer ZF at 3-4am. Such bidirectional movement from the ZG/ZF 
boundary is also observed in the mouse adrenal by Chang et al (Chang et al., 2013). The 
iZU has very high levels of steroidogenic enzyme expression, and expresses the MC2R and 
its accessory protein MRAP (Gorrigan et al., 2011), perhaps because this zone is a 
transitional one, where Shh expression has been lost again, but the definitive identity of 
CYP11B1 or B2 positivity has not yet been achieved. A pool of such CYP11B1 and B2 
negative cells has been found in the human adrenal cortex, hinting that the rat ZU does 
have a human equivalent.  
 
Similarly in ZF, chronic ACTH administration expands this zone with increased CYP11B1 
expression, but HPA suppression from exogenous dexamethasone contracts the zone 
(Dallman, 1984). The mechanisms by which these expansions and contractions occur may 
involve induced differentiation from stem/progenitor cell populations or trans-






type (McEwan et al., 1996). McEwan et al have observed enhanced ZU proliferation when 
the HPA or RAS axes are chronically activated (McEwan et al., 1996), and Mitani et al 
have reported migration of BrdU labelled cells from ZU to ZG when the RAAS is activated 
(Mitani et al., 2003).  
 
Freedman et	 al performed cell fate mapping in the adrenals of aldosterone synthase 
(AS)/Cre x R26RmT/mG reporter mice, in which Cre-mediated activation of a cell lineage 
marker in differentiated ZG cells is driven by the AS gene promoter (Freedman et al., 
2013).  They reported trans-differentiation of lineage-marked ZG cells into ZF cells in the 
first twelve weeks of life, and also in the recovery period following HPA axis suppression 
with dexamethasone. However, lineage conversion did not occur in mice in which SF-1 
had been deleted specifically in the ZG. It was also reported that under alternative stress 
conditions, i.e. in ZG-specific SF1 knockout mice which retain a functional ZF, 
differentiated fasciculata cells could derive from non-Cyp11b2-expressing cells, 
suggesting that the must be other means of deriving differentiated ZF cells. This is 
supported by the possibility of bidirectional migration of cells into the ZG and ZF cell from 
a putative progenitor population located at the ZG/ZF interface mentioned earlier. 
 
The paradigm of adrenal regeneration following surgical injury seen when the cortex is 
regenerated from just remaining capsule and subcapsular adherent ZG cells, or when the 
contralateral gland undergoes hypertrophy following unilateral adrenalectomy provides 
further insights. In the rat adrenal following enucleation, the remaining ZG cells lose 
CYP11B2 expression before cortical proliferation replaces the lost cells, while there is an 
initial thickening of the capsule, indicating potential involvement of capsule cells in 
regeneration (Reiter & Pizzarello, 1966). Following unilateral adrenalectomy, cell 
proliferation in the outer ZF is seen within 2 days, although there is no increase in ZG 
proliferation. Interestingly, no such compensatory growth is seen in SF-1+/- mice 
(Beuschlein et al., 2002). This latter observation supports the idea from Freedman et al 
on the importance of SF-1 expression in ZG to ZF trans-differentiation. 
 
The expression of MC2R and MRAP in the iZU would suggest a role in causing 
differentiation to the ZF phenotype, possibly via a downregulation of Dax1 expression. 
The role for Dax1 in inhibiting steroidogenesis has been discussed, but it is also a negative 






adrenal stem cell mobilisation. Inhibition of the HPA has not been consistently shown to 
inhibit compensatory growth after unilateral adrenalectomy however: dexamethasone 
inhibits the process in some studies (Engeland et al., 2005; Krueger & Orme-Johnson, 
1983; Phillips et al., 1985) but not others (Grizzle & Dunlap, 1984), while 
hypophysectomy blocks regeneration following enucleation(Estivariz et al., 1988) but 
does not completely block compensatory growth (Dallman, 1984). Hypophysectomy does 
reduce the extent of compensatory growth, however, but the precise identity of the 
pituitary factor involved is unclear. 
1.8 Control of adrenal cortex proliferation and steroidogenesis 
As mentioned, adrenal steroid output adjusts rapidly in response to acute changes in HPA 
or RAS activity, and chronic activation is accompanied by profound changes in the size 
and steroidogenic gene expression of the appropriate zone.  
1.8.1 Zona Glomerulosa and the RAS 
Rodent studies have confirmed how prevailing low sodium or high potassium conditions 
expands the ZG to generate more CYP11B2 expressing cells, and therefore more 
aldosterone, to correct the physiological imbalance (Romero, Yanes et al., 2007). RAS 
suppression with a high sodium diet or administration of angiotensin converting enzyme 
(ACE) inhibitors, causes the ZG to shrink rapidly with a reduction in both CYP11B2 
expression and blood flow (Brennan et al., 2008; Dallman, 1984).  
1.8.2 Zona Fasciculata and the HPA axis 
The effect of ACTH in inducing ZF glucocorticoid production is established, but its role in 
regulating proliferation during remodelling is much more controversial. The circadian 
rhythm of zona fasciculata proliferation is closely matched to that of ACTH (Mitani et al., 
2003), while Cushing’s disease (excess pituitary ACTH) is associated with adrenocortical 
hyperplasia  (Bertagna et al., 2009). Hypophysectomy of experimental animals leads to 
adrenocortical hypoplasia, and the Pomc null mice described previously have glands 
which atrophy soon after birth, in a manner that is correctable by the administration of 
ACTH (Coll et al., 2004). Such ACTH treatment does not restore the adrenals of the 
hypophysectomised animals, however (Payet & Lehoux, 1980). Recently the importance 






macronodular adrenal hyperplasia has been proposed. Lefebvre et al have demonstrated 
expression of POMC and bioactive ACTH (1-39) in adrenal nodules in this condition, but 
without expression of pituitary-specific transcription factors such as Pit1 and Pitx1 
(Lefebvre et al., 2011). The authors did not identify which POMC promoter was 
responsible for transcription in this case – previous observations on extra-pituitary tissues 
such as adrenal and testis suggest that the major mRNA product is the 800nt transcript, 
produced via the downstream promoter (Lacaze-Masmonteil et al., 1987). As described 
previously, the translated product would lack the hydrophilic signal peptide, precluding 
adequate processing and secretion of ACTH. 
 
The role of POMC-derived peptides other than ACTH in the control of adrenal growth is 
becoming increasingly well understood. For instance, the N-terminal fragment of POMC, 
alternatively known as N-POMC or pro-γ-MSH is a 76 residue glycopeptide that is co-
secreted with ACTH from the pituitary into the circulation. While antibodies directed at 
this peptide can block compensatory growth following adrenalectomy, the peptide itself 
has no mitogenic activity to adrenocortical cells in vitro, although N-POMC1-28 and N-
POMC2-54 are potent mitogens in this context (Lowry et al., 1983). The latter are not 
products of normal pituitary processing, but an enzyme expressed in the outer rat ZF has 
been identified that can cleave pro-γ-MSH to produce smaller mitogenic peptides. 
Expression of this adrenal secretory protease (AsP) is increased during compensatory 
growth (Bicknell et al., 2001). Synthetic N-POMC 1-28 has subsequently been shown to 
stimulate proliferation of human H295R cells, and to activate the ERK signalling pathway 
(Fassnacht et al., 2003). Interestingly, N-POMC 1-28 cannot restore adrenal growth in 
Pomc null mice (Coll et al., 2006). 
 
These studies may suggest that ACTH is not involved in adrenal cell proliferation during 
adrenal remodelling, but it has been reported that the elevated ACTH levels that 
accompany enucleation are required for the de-differentiation of the ZG cells that is an 
immediate response in the regenerating adrenal (Engeland & Levay-Young, 1999). 
Whether this works via inhibiting Dax1 expression has not been reported. ACTH does not 
affect proliferation in the ZG; the cell proliferation observed by placing animals on a low 
sodium diet is inhibited by type 1 angiotensin receptor antagonists (McEwan et al., 1996) 
indicating that cell growth in this zone is controlled by the RAS (Chatelain et al., 2003). 






express CYP11B1 or CYP11B2, but which were induced to proliferate following acute 
treatment with ACTH (Chang et al., 2013). This is consistent with the idea that the ZG 
contains a population of slow-cycling stem or progenitor cells which are activated in 
response to physiological stimuli.  
1.8.3 Autonomic nerve supply 
The anatomy of the considerable autonomic nerve supply to the adrenal gland has been 
described previously. Acetylcholine release from preganglionic sympathetic fibres 
stimulates release of catecholamines from the medulla, but there is significant evidence 
for a role in the regulation of glucocorticoid secretion.  
 
Sympathetic innervation of the gland is required to maintain the circadian rhythm of 
glucocorticoid secretion (Ottenweller & Meier, 1982; Dijkstra et al., 1996; Muglia et al., 
1997); and can modulate secretion even in hypophysectomised animals (Engeland & 
Gann, 1989). Such stimulation also increases adrenal blood flow in dogs and calves, likely 
mediated by various neuropeptides, which will be described in more detail below 
(Breslow et al., 1987). There is evidence for a local VIPergic neuron system in the rat 
adrenal(Hokfelt et al., 1981), and increased VIP staining in the medulla when the 
splanchnic nerve is ligated(Holzwarth, 1984) 
 
Engeland et al suggested that the phenomenon of compensatory growth following 
unilateral adrenalectomy was neurally mediated (Engeland et al., 1975). Compensatory 
growth is blocked by interruption of the nerve supply (Kleitman & Holzwarth, 1985), 
while mechanical perturbation of the nerves of one adrenal causes increased proliferation 
in the other (Dallman et al., 1976). This suggests that both afferent and efferent nerves 
are involved in mediating this process via the hypothalamus. Sectioning of the splanchnic 
nerve has also been shown to decrease the adrenal response to ACTH (Edwards & Jones, 
C. T., 1987). Additionally, there is also evidence for electrical coupling between cells of 
the adrenal cortex via gap junctions, enabling signals received in a few cells to spread 
more widely through the gland (Usadel et al., 1993; Murray et al., 2009) 
1.8.4 Adrenal Neuropeptides 
In addition to catecholamine secreting cells, the adrenal medulla also contains multiple 






al., 1980; Dumont et al., 1983). There is also neuropeptide secretion from splanchnic 
nerves and local intra-adrenal nerve endings, leading to autocrine, paracrine and 
endocrine effects. The main steroidogenic effect is on the generation of aldosterone, 
which is stimulated by PACAP, VIP, Substance P, adrenomedullin and Neuropeptide Y 
(NPY)  (Neri et al., 1996; Hinson et al., 1992; Mazzocchi et al., 1995; Mazzocchi et al., 
1996; Bernet et al., 1994) as well as ANP and somatostatin synthesised in chromaffin 
cells. Three of the most well-described neuropeptides are adrenomedullin, PACAP and 
VIP. 
 
Adrenomedullin (ADM) is a 52 amino acid peptide with homology to calcitonin gene-
related peptide that was initially isolated from a human phaeochromocytoma (Bełtowski 
& Jamroz, 2004). In vitro it inhibits basal and CRH-mediated ACTH secretion from the 
pituitary, but activates CRH-producing neurons in vivo.  As well as expected expression 
in the adrenal medulla, both ADM and its receptors are expressed in the ZG (Andreis et 
al., 1997), where it inhibits Ang II-induced aldosterone production, while also increasing 
basal and ACTH-stimulated aldosterone production (Kapas et al., 1998). There are very 
few ADM receptors in the ZF and ZR and no discernible effect on cortisol secretion 
(Ziolkowska et al., 2003). The systemic effects of adrenomedullin are in keeping with a 
role as a negative regulator of aldosterone action, causing vasodilation, diuresis, 
natriuresis and having an inhibitory effect on cardiac remodelling (Kato & Kitamura, 
2015). 
 
PACAP (pituitary adenylate cyclase-activating peptide) is the most conserved member of 
the nine hormone superfamily which also includes glucagon, GLP-1, secretin and VIP 
(Sherwood et al., 2000). There is extensive innervation of the adrenal medulla with 
PACAP-ergic fibres, where it increases catecholamine secretion by up regulating tyrosine 
hydroxylase, PNMT and dopamine β-hydroxylase, but it also stimulates aldosterone 
secretion from the ZG (Bodart et al., 1997; Neri et al., 1996) 
 
Vasoactive intestinal peptide (VIP) content of the rat adrenal is stimulated by a low 
sodium diet, and it has a synergistic effect on aldosterone secretion from the ZG (Hinson 
et al., 1992). This is mediated in part at least by VIP-ergic nerves with their origins in the 
medulla (Holzwarth, 1984) . VIP stimulates catecholamine secretion from the medulla in 







1.8.5 Intra-adrenal immune cells and cytokines 
The importance of the immune system in stimulating the adrenal gland via activation of 
the hypothalamus and pituitary is well established(Jones, T. H. & Kennedy, 1993; 
Chrousos, 1995), but there is evidence for local immune regulation within the gland itself. 
There is a population of macrophages found primarily in the ZR, (Gonzalez-Hernandez 
et al., 1994), but there is also cytokine production from adrenal cells themselves 
(Bornstein et al., 2004). Mast cells are present in the adrenal capsule, and degranulate 
releasing 5-HT and histamine when activated by ACTH. Inhibition of mast cell 
degranulation abolishes the effect of ACTH to increase adrenal blood flow (Stark et al., 
1965; Hinson et al., 1991). Chromaffin cells may also produce cytokines (Bornstein et al., 
1996), but are more notable for their extensive expression of cytokine receptors: receptors 
for TNF-α, IFN-α, IL-1 α/β and IL-6 are all present on chromaffin cells (Bunn et al., 2012) 
 
IL-1 can induce glucocorticoid secretion independent of ACTH (Kapcala et al., 1996) in a 
manner that may be related to local prostaglandin release (Winter et al., 1990). Indeed, 
IL-1 secretion from an inflammatory mass has been responsible for a single reported case 
of ACTH-independent Cushing’s syndrome. IL-6 also increases cortisol levels independent 
of ACTH, but its effect is most marked on the production of adrenal androgens. IL-6 is 
expressed in the ZR and stimulates DHEA secretion (Parker, L. N. & Odell, 1980).(Path 
et al., 1997), and in humans has a role in maintaining upregulation of adrenal 
steroidogenesis during chronic stress, independent of the CRH-ACTH axis (Chrousos, 
1995; Naito et al., 1992). TNF-α on the other hand, while an inducer of pituitary ACTH 
secretion, inhibits the local ACTH-induced cortisol production within the adrenal 
(Voutilainen, 1998). 
1.9 Summary 
There has been a significant increase in our understanding of the mechanisms controlling 
adrenal development and function, but with much remaining to be discovered. Definitive 
identification of the adrenocortical stem/progenitor cells is awaited - do they reside in 
the capsule, the subcapsular cortex or both? They are likely to have extremely important 






the organism. The dogma of ACTH stimulating cortisol release has been shown to be a 
gross oversimplification of a process with multiple different neurohumoral and immune 
inputs, and further characterisation of these is an exciting prospect.  
 
1.10 Aims 
This thesis aims to provide an improved understanding of the mechanisms involved in 
remodelling of the adrenal cortex, and of the role of POMC derived peptides and 
melanocortin receptors in stimulating adrenocortical growth and activity.  
 
1. Dietary and pharmaceutical modification of the renin-angiotensin-aldosterone 
system will be employed to remodel the rat adrenal gland and investigate (i) 
gross histological changes; (ii) changes in proliferation; (iii) changes in 
expression of markers of the cell cycle. 
2. A case of ACTH-independent macronodular adrenal hyperplasia and Cushing’s 
syndrome will be described. Potential mechanisms for the development of the 
disease will be explored, with a potential role for a co-existing gastro-intestinal 
stromal tumour being considered. 
3. A variety of histological and immunohistochemical techniques will be employed 
to (i) Elucidate the mechanism of pigmentation in pigmented adrenal diseases; 










Chapter 2  Materials and Methods 
2.1 Cell culture  
Human adrenocortical carcinoma cell line NCI-H295R 
H295R cells were grown at 37ºC with 5% CO2 in a standard media of 50% 
DMEM(Dulbecco’s Modified Eagles Medium), 50% F12(Nutrient mixture F12 Ham) (1:1) 
supplemented with 100 U/mL penicillin, 100 μg/ml streptomycin (Sigma), 10% fetal 
bovine serum (FBS; Invitrogen) and 1x insulin-transferrin-selenium solution (10 μg/ml 
insulin, 5.5 μg/ml human transferrin, and 5 ng/ml sodium selenite; BD Biosciences) 
(Wang, T. et al., 2012).  
 
It is more common in the published literature to culture H295R cells in a medium that 
contains a serum substitute rather than fetal bovine serum, for example Nu-serum 
(Collaborative Biomedical Products, Bedford, MA) or Ultroser-G (2.5%, Pall Corporation, 
Port Washington, NY) (Tao Wang, 2012). The effects of culture supernatant from another 
cell line on cortisol production were being assessed (GIST primary culture), so H295R 
cells were cultured in the same standard medium to provide a valid negative control. 
 
Mouse Melanoma Cell Line B16F10 
These cells were kindly provided by Professor John Marshall, Barts Cancer Institute. 




Primary cultures of human GIST and adrenal gland and were obtained as follows. Tissue 
samples were collected in ice-cold phosphate buffered saline, and treated with type 1 
collagenase (Sigma) 1mg/ml and DNase A (Sigma) 10μg/ml in serum free standard 
media for 2-4 hours at 37ºC with frequent agitation. Cells were collected by centrifugation 
at 800g, resuspended in 10ml serum free media and strained through a 40 μl cell strainer 
(BD Biosciences). The strainer was washed twice with 5ml serum free media and cells in 
the flow through were pelleted by centrifugation at 500g. After a 3 minute treatment with 
erythrocyte lysis buffer (NH4Cl 150mM, KHCO3 10mM, disodium EDTA 10mM) at room 






centrifugation at 500g and plated in standard media containing 10% fetal bovine serum 
as described for H295R (Mukaisho et al., 2006). All cells were incubated in a humid 
atmosphere of 5% CO2 at 37ºC. 
 
Cultured GIST cells had media changed on reaching 80% confluency, then media 
removed after 48 hours, sterile filtered and stored at -80ºC prior to cell stimulation.  
 
Primary cultures of rat adrenal gland were obtained as follows. Both adrenals were 
harvested from 4 male Wistar rats, 6 weeks old and approximately 380g each. The 
surrounding fat was trimmed and the glands were squeezed between two autoclaved 
microscope slides. The adrenal capsules were removed and the cortex/medulla from all 
rats was combined and digested according to the protocol described above. Primary 
cultures of human adrenal cells were 
 
For stimulation of rat adrenal primary cultures cells were initially plated in 12 well plates 
at a density of 2x105 cells per well and stimulated after 5 days (Ramachandran & Suyama, 
1975). H295R cells were plated at the same density and stimulated the following day. 
2.1.1 Cell passage and long term storage 
For all cell lines, culture media was removed and cells washed with room temperature, 
calcium-free PBS. Trypsin-EDTA (0.5g/l trypsin, 0.2g/l ethylenediaminetetraacetic acid; 
Invitrogen) was added and the cells were returned to the incubator for 2 minutes. The 
reaction was quenched with standard growth media containing 10% FBS. The resulting 
suspension was centrifuged at 500g and the resulting pellet resuspended in growth 
medium for subsequent plating. 
 
Confluent cells were trypsinised and centrifuged as described. The cell pellet was 
resuspended in a freezing solution of standard growth medium containing 10% DMSO 
(Dimethyl Sulfoxide; Sigma), and cooled at a maximum of 1ºC/min to -80ºC in 1ml 
cryotubules. These were transferred to liquid nitrogen for long term storage. 
2.1.2 Cell stimulation 
Cells were stimulated at 80-90% confluence. Media was removed and cells washed twice 






primary culture (GCM or NCM), or standard growth media supplemented with the 
following: Forskolin 10μM (Sigma); ACTH 1-24 100nM (Sigma); α-MSH (Sigma or 
Phoenix Pharmaceuticals); H89 10μM (Sigma). Media was removed after 24 hours and 
flash frozen prior to hormonal assay. Cells were washed twice with ice-cold PBS and 
removed for RNA extraction or melanin assay as described. 
2.2 RNA extraction and RT-PCR  
2.2.1 RNA extraction 
Cells were washed twice with cold PBS, and lysed directly in the wells with the addition 
of 350μl buffer RLT from the RNeasy Mini Kit (QIAGEN). Well contents were scraped off 
and transferred to 1.5ml micro centrifuge tubes. RNA was extracted using the RNeasy kit 
according to the manufacturer’s instructions. Fresh tissue specimens were collected in 
RNA Later (QIAGEN) and RNA extracted according to the RNeasy Mini Kit manufacturer’s 
instructions as above. 
2.2.2 Genomic DNA elimination 
Genomic DNA was eliminated in a 50μl reaction containing 2μg RNA, 5μl 10x DNase 
Turbo buffer (Ambion), 0.5μl RNase inhibitor (40u/μl, Promega) and 1μl 
Deoxyribonuclease I (≥10,000U/mg, Ambion) and RNase free water (Qiagen) added to 
a final volume of 50μl, and incubated at 37ºC for 15 minutes. An equal volume of phenol 
pH 4.7 is added, the sample vortexed for 30 seconds then centrifuged at 14000 rpm for 1 
minute. The upper aqueous layer is subjected to ethanol precipitation of RNA by the 
addition of 1/10 volume of 3M sodium acetate (pH 5.5) and 2.5 volumes of 100% 
ethanol. After a 1-hour incubation at -80ºC samples were centrifuged at 14000rpm at 4ºC 
for 10 minutes, and the resulting pellet washed in ice-cold 70% ethanol. The 
centrifugation was repeated twice more, and the pellet allowed to air-dry.  
2.2.3 First strand cDNA synthesis 
Pellets were dissolved in 12.5μl RNase free water and 0.25μl random primers (500μg/l; 
Promega) added, before vortexing and incubation at 80ºC for 10 minutes, then cooled on 
ice. This was used for first strand cDNA synthesis at 37ºC for 1 hour in a reaction 






(25μM each of ATP, CTP, GTP, TTP; Promega), 0.5μl RNase Inhibitor (40u/μl), 1μl 
MMLV-RT enzyme (200u/μl; Promega) and RNase free water to final volume of 20μl. 
 
2.2.4 Polymerase chain reaction 
PCR was performed in a 20μl reaction containing: 1μl template DNA, 1μl 10μM F+R 
primers, 0.2μl 25mM dNTPs, 2μl 10X Standard Taq reaction buffer, 0.125μl Taq DNA 
Polymerase (all New England Biolabs). Thermocycling conditions were: initial 
denaturation 95ºC for 30s; denaturation 95ºC for 15s, annealling at 55-62ºC for 15s, 
extension 68ºC for 30s (30 cycles); final extension 68ºC for 5 minutes, holding at 4ºC. 
Human adrenal and skeletal muscle RNA was purchased from Clontech Laboratories (Cat 
No. 636528 and 636534) and cDNA synthesised as above. Human pituitary cDNA was 
obtained from Prof Marta Korbonits, human paraganglioma cDNA was obtained from Dr 
Sam O’Toole. THP-1 cDNA was kindly provided by Dr Rebecca Gorrigan. 
2.2.5 Gel electrophoresis 
Following PCR amplification samples were combined with 5μl of loading dye (Promega) 
containing 0.03% bromophenol blue and loaded onto a 1% agarose gel containing 
0.05μl/ml GelRed (Biotium) within and electrophoresis chamber containing TAE buffer 
(Tris-acetate-ethylenediamene-tetraacetic acid buffer; National Diagnostics). An 
electrical current was passed through the tank and the cDNA visualised using a UVP UV 
transilluminator. 
2.2.6 DNA gel extraction 
The DNA fragment was extracted from the agarose gel using a clean scalpel, and DNA 
purified using the QIAquick Gel Extraction kit (QIAGEN) according to the manufacturer’s 
instructions. 
2.2.7 Primer sequences and annealing temperatures  
GAPDH  F TGC ACC ACC AAC TGC TTA G   
  R GGA TGC AGG GAT GAT GTT C, Ta 55-60ºC;  
PC1/3  F TGT TCA CAC ATG GGG AGA GA   
  R ACG AGG CTG CTT CAT ATG CT, Ta 55ºC ;  
PC2   F GAG AAG ACG CAG CCT ACA CC   
  R CCA TCA GCT TGC CCA GTA TT, Ta 55ºC;  






  R CTG ATT ATC TGC CAC GAC CC, Ta 60ºC;  
MC1R  F ACT TCT CAC CAG CAG TCG TG   
  R CAT TGG AGC AGA CGG AGT GT, Ta 64ºC 
StAR   F CAA GGA GAT CAA GGT CCT GC  
  R GAG GTC GAT TGC CTG AGT AGC C, Ta 64ºC 
SCC  F GTC CTG TTG AAG AAG TCG GC  
  R GAT GGA CTC AAA GGC AAA GC, Ta 64ºC    
2.2.8 Real Time Quantitative PCR 
Real time qPCR replicates a DNA template as in traditional, end point PCR, but quantifies 
this in real time by detection of a magnitude of fluorescence proportional to the amount 
of DNA amplified. A DNA binding dye SYBRGREEN is used which fluoresces when bound 
to dsDNA. This allows starting amounts of cDNA (and hence mRNA) to be calculated. For 
each reaction a Ct value is generated - the threshold cycle value at which amplification is 
first detected above background fluorescence. The lower the Ct, the greater the amount 
of amplification target in the starting cDNA. A standard curve of known DNA 
concentrations for each gene of interest (GOI) is used to calculate DNA copy number from 
Ct values. This is corrected for differences in the starting amounts of DNA with reference 
to a housekeeping gene, in this case GAPDH. A no template control without any starting 
DNA is used for quality control. Results were included if they met the following criteria: 
standard curve gradient = -3.3 (±0.3); efficiency 100% (±10%); R2 = 0.97-1.00. 
 
Quantitative PCR was carried out in a 10μl reaction containing 2μl cDNA template, 5μl 
2x SYBRGREEN I (KapBiosystems), 0.2μl low Rox (KapaBiosystems), 0.5μl primers (10μM 
F+R) and 2.3μl RNase free water. The master mix contains the SYBRGREEN dye, MgCl2, 
dNTPS, stabilisers and the DNA polymerase. Rox is a reference dye to control for 
evaporation during cycling. 
 
Thermocycling was performed in a Stratagene MX4000 real-time thermocycler using 
conditions as follows: initial denaturation 95ºC for 3minutes; denaturation 95ºC for 3s, 







2.3 Hormonal assays 
2.3.1 Cortisol  
Cortisol was assayed in serum and in cell culture supernatant using the Roche 
electrochemiluminescence immunoassay on the Elecsys 2010 analyser. 
Electrochemiluminescence is a kind of luminescence produced by electrochemical 
reactions in solutions. In this case the luminescence is produced by the application of an 
electrical current to a complex containing the element Ruthenium, which releases a 
photon at 620nm. The cortisol assay makes use of a competition test principle using a 
polyclonal antibody which is specifically directed against cortisol. Endogenous cortisol in 
the sample competes for binding with this antibody with a ruthenium complex labelled 
cortisol derivative. Depending on the concentration of the analyte in the sample and the 
formation of the respective immune complex, the labelled antibody binding site is 
occupied in part with sample analyse and in part with ruthenylated hapten. Streptavidin-
coated microparticles are added, and the complex becomes bound to the solid phase via 
interaction of biotin and streptavidin. The reaction mixture is aspirated into a measuring 
cell where the microparticles are magnetically captured on to the surface of an electrode. 
Application of a voltage to the electrode induces chemiluminescent emission which is 
measured by a photomultiplier. Results are determined via a calibration curve which is 
generated by 2-point calibration within the analyser (Yaneva et al., n.d.) .  
2.3.2 ACTH 
ACTH was assayed in serum and culture medium using the Elecsys 2010 analyser, but 
this using the sandwich principle. Blood and culture supernatant are flash frozen on 
collection, and thawed for analysis. An aliquot of sample is added to a biotinylated 
monoclonal ACTH-specific antibody, and a monoclonal ACTH-specific antibody labelled 
with a ruthenium complex, and these react to form a sandwich complex. This becomes 
bound to the solid phase after the addition of streptavidin-coated microparticles, through 
the interaction of biotin and streptavidin. The reaction mixture is aspirated into a 
measuring cell and magnetically captured on to the electrode surface. A voltage is applied 








Corticosterone was assayed using the DEMEDITEC Corticosterone rat/mouse ELISA kit 
(Demeditecm DE4164). The microtitre wells are coated with a polyclonal antibody 
directed towards an antigenic site on the corticosterone molecule. Endogenous 
corticosterone in cell culture supernatant competes with a corticosterone-HRP conjugate 
for binding to the coated antibody. After incubation this is washed off. The amount of 
bound peroxidase conjugate is proportional to the concentration of corticosterone in the 
sample - after addition of substrate solution, the intensity of colour developed is inversely 
proportional to the concentration of corticosterone.  
 
20μl of each sample or control (0-240nmol/l) are dispensed into appropriate wells, 
followed by 200μl of enzyme conjugate, and thoroughly mixed for 10 seconds. The 
mixture is incubated for 1 hour at room temperature, before the well contents are briskly 
shaken out. The wells are rinsed with 400μl of wash solution three times, with the plate 
being firmly struck on to absorbent paper each time. 100μl of substrate solution 
(tetramethylbenzidine, TMB) is added to each well and incubated for 15 minutes at room 
temperature, before the reaction is stopped by adding 50μl of “stop solution” (1 N acidic 
solution) to each well. The optical density was measured at 450nm using the Perkin Elmer 
Wallac Victor2 1420 microplate reader. A standard curve was generated using a 4 
parameter logistic model with myassays.com and corticosterone concentrations in 
unknown samples determined. The dynamic range of the assay is between 1.63 - 
240nmol/l and shows cross-reactivity with the following substances: progesterone 7.4%, 
deoxycorticosterone 3.4%, 11-dehydrocorticosterone 1.6%, cortisol 0.3%, pregnenolone 
0.3%. 
2.3.4 Alpha-MSH 
Alpha MSH concentrations in cell culture supernatant was determined using two separate 
systems, the first an enzyme immunoassay (EIA) purchased from Phoenix 
Pharmaceuticals, the second a sandwich ELISA developed in collaboration with Dr 
Andrew Bicknell, University of Reading. 
 
Alpha-MSH EIA: Microtitre wells are coated with a secondary antibody which can bind to 
the Fc fragment of a primary antibody, which in turn will be competitively bound by α-






complex interacts with streptavidin-HRP, and this catalyses a reaction in the substrate 
solution (TMB) and a resulting colour change which is inversely proportional to the 
amount of α-MSH in the original sample. Peptide standard solutions are prepared with 
concentrations 0.01ng/ml - 1000ng/ml using a standard peptide supplied. Into each well 
is added 50μl of sample, standard or positive/negative control, 25μl of primary antibody 
and 25μl of biotinylated peptide, before a 2-hour incubation at room temperature (RT), 
with orbital shaking of 300-400rpm. Each well is then washed 4 times with 350μl of wash 
buffer, and emptied before adding 100μl of SA-HRP solution to each well for a 1-hour 
incubation at RT. Following this the wells are washed 4 further times as before. 100μl of 
TMB substrate is added and incubated in the dark for 1 hour at RT. The reaction is stopped 
with the addition of 100μl 2N HCL, changing the colour from blue to yellow. Optical 
density was read at 450nm and unknowns calculated as for corticosterone, outlined 
above. 
 
Alpha-MSH Sandwich ELISA: Antibodies and ELISA plates were generated by Dr Andrew 
Bicknell, University of Reading as follows. Antibodies to alpha MSH were raised in sheep 
by cross-linking either the C-terminal (CRWGKPV-amide) or the N-terminal (Ac-SYSMEC-
amide) of alpha MSH to purified protein derivative (PPD) using NHS-maleimide (Pierce). 
Animals were immunized on a monthly basis as described previously (Page, N. M. et al., 
2003) and were titered using the same peptides linked to Maxisorb plates (NUNC). High 
affinity antibodies were subsequently purified using the same peptides linked to Ezlink 
Iodacetyl gel (Pierce) and the C-terminal antibody was labelled with biotin as described 
previously (Page, N. M. et al., 2003; Bicknell et al., 2001). 96 well Maxisorb plates 
(NUNC) were coated with 100ng/well of N-terminal antibody diluted in 0.1M sodium 
bicarbonate. The plates were subsequently blocked with blocking buffer (PBS containing 
0.1% w/v bovine serum albumin (BSA)) and stored in the same buffer at 4ºC before use. 
 
Plates were washed 3x with 300μl wash buffer (PBS containing 0.1% v/v Tween-20) 
before the addition of either standard or sample and left to incubate overnight at room 
temperature. The plates were subsequently washed 3X with wash buffer before the 
addition of 100ng/well of biotinylated C-terminal antibody diluted in blocking buffer. 
After incubation for 2hrs the plates were washed 3X with wash buffer before the addition 
of streptavidin-HRP conjugate (Sigma) diluted 1:2000 in blocking buffer. After a further 






with TMB, the reaction stopped by the addition 1N HCL and the absorbance read at 
450nm. Unknowns were interpreted from a four parameter logistic curve assay using 
myassays.com. 
2.4 Melanin assay 
The biological activity of synthetic α-MSH was tested on the basis of its ability to stimulate 
melanin production from B16F10 mouse melanoma cells. Cells were cultured as described 
in 6 well plates until confluent. Media was removed and cells were washed twice in PBS. 
Cells were stimulated overnight with 1μM ACTH 1-39 or 1μM α-MSH in standard media 
(DMEM plus 10% FBS), or supernatant from GIST primary culture. Culture media was 
removed and cells washed twice in PBS. Cells were detached with 200μl TE per well and 
the reaction quenched with 800μl of standard media. The cell suspension was pelleted by 
centrifugation at 500g, and resuspended in 1ml 1N NaOH. 200μl aliquots were added in 
duplicate to a 96 well microassay plate and absorbance measured at 420nm. Melanin 
concentration was determined with reference to a standard curve of synthetic melanin 
(Sigma) in the range 1-100μg/l, and corrected for the protein content of the cell lysate.  
 
Protein content of the cell lysate was measured using a modified Bradford assay. 
Following a neutralization step using an equivalent volume of 1M HCl, 160μl aliquots of 
cell lysate were added in triplicate to a 96 well micro assay plate. 40μl of protein assay 
dye reagent (Bio Rad) was added to each well and incubated for 5 minutes at room 
temperature. Absorbance was measured at 595nm using a spectrophotometer. Protein 
concentration was determined with reference to a standard curve of bovine serum 
albumin (Sigma) in the range 0.1 - 1.0 mg/ml. Standard curves were plotted using 
Microsoft Excel. 
2.5 General Histology 
2.5.1 Paraffin embedding 
Rat adrenals 
After harvesting, rat adrenals were fixed immediately in neutral buffered formalin 
(Sigma) and incubated overnight at 4ºC. They were washed in H2O for 1 hour then 






70%, 90% and 100% ethanol) then cleared with 2 consecutive one hour incubations in 
xylene. Adrenals were then soaked in liquid paraffin for 24 hours at 56ºC with gentle 
agitation. The samples were poured into plastic moulds and left to set at room 
temperature. 
 
Human tissue embedding 
Human tissue specimens were processed using the Leica ASP300 S Fully Enclosed Tissue 
Processor prior to paraffin embedding using the Leica Histocore Arcadia Embedding 
system. FFPE processing of human paraffin sections was carried out by the pathology 
department of the Royal London Hospital. 
2.5.2 Sectioning and Mounting 
3μm sections were cut from paraffin embedded sections using the Thermo Shandon 
Finesse E+ microtome and mounted on TESPA treated slides (3-
triethoxysilylpropylamine; VWR) using the floating out technique (Sack, 1963) on a water 
bath maintained at 45ºC. Sections were dried overnight at 37ºC to increase adherence.  
2.5.3 Deparaffinisation 
All staining techniques used required sections to be deparaffinised. Sections were 
deparaffinised in xylene for 2 changes of 2 minutes each, then the xylene was removed 
with 2 changes of 70% alcohol for 2 minutes each, before sections were placed under 
running tap water for 5 minutes. 
2.5.4 Haematoxylin and Eosin Staining 
Sections were deparaffinised as described, then stained in Gill’s Haematoxylin (Sigma) 
for 15 minutes and washed in tap water for 5 minutes. Following a 1-minute incubation 
in 1% acid alcohol (70% alcohol; 1% conc.HCL) slides were washed in running tap water 
for 5 minutes, then stained with 1% Eosin (in distilled water) for 3 minutes. This was 
followed by a brief differentiation step in tap water, then rapid dehydration through an 
alcohol series (2 changes of 1 minute in 95% ethanol, 2 changes of 1 minute in 100% 
ethanol) then sections cleared with xylene (2 changes of 10 minutes). Sections were 
mounted with DPX mounting media (Lamb Laboratories) and covered with glass 
coverslips. Nuclei stain blue, other elements stain various shades of red. An optional 5 






staining to bleach endogenous melanin - this process does not bleach lipofuscin (Hongwu 
Shen, 2015). 
2.5.5 Periodic Acid Schiff Staining 
Sections were deparaffinised as described, washed in tap water for 2 minutes then 
oxidised in 1% aqueous periodic acid solution for 5 minutes before a further 2-minute tap 
water wash. Staining was achieved with a 10-minute incubation in Schiff’s reagent 
(Sigma), a ten-minute wash in tap water, a 2-minute incubation in Gill’s haematoxylin 
for nuclear staining, a further 5-minute wash in running tap water. Staining was 
differentiated with a 1-minute incubation in acid alcohol, before a further 5-minute 
washing step in running tap water. Sections were dehydrated, cleared and mounted as 
described. Substances containing vicinal glycol groups of their amino or alkyl amino 
derivatives are oxidised by periodic acid to form aldehydes, which combine with Schiff’s 
reagent to form an insoluble magenta compounds (Scott & Dorling, 1969). Nuclei stain 
blue.  
2.5.6 Ziehl-Neelson Staining 
Deparaffinised and rehydrated sections were placed on a staining rack and filter on carbol 
fuschin, and heated gently until steam started to rise. Sections were differentiated with 
1% acid alcohol with alternate blotting until the sections were colourless, then washed in 
tap water for 10 minutes. Nuclei were counterstained in diluted methylene blue for 20 
seconds, and sections dehydrated, cleared and mounted as before. Lipofuscin stains a 
strong purple pink by this method (Dayan et al., 1979). 
2.5.7 Masson Fontana 
Deparaffinised and rehydrated sections were impregnated in pre-heated silver solution at 
60ºC checking every 5 minutes until the required intensity is obtained, before washing in 
distilled water for 1 minute, then incubating in gold chloride for 10 minutes, and washing 
in distilled water for a further minute. Staining was fixed by incubating in 5% sodium 
thiosulphate for 1 minute. Following a 10-minute wash in tap water sections were 
counterstained lightly in 1% neutral red, then dehydrated, cleared and mounted as 
before. For a working silver solution, concentrated ammonia is added drop by drop to 






until a faint opalescence persists. By this method melanin stains black, some forms of 
lipofuscin may also stain a brown/black colour (Bancroft & M, 2008). 
2.5.8 Tissue Microarray 
A tissue microarray was constructed using paraffin embedded adrenalectomy specimens 
from patients with primary aldosteronism - Conn’s syndrome. For each patient, a H&E 
slide was used to identify the nodule and marked by a consultant histopathologist with a 
black marker. 0.6mm cores were extracted using the manual Beecher Instruments tissue 
arrayer. Three cores were taken from within the nodule, and three cores of “normal” 
adrenal cortex from outside the nodule were taken. Cores were added to open slots within 
a recipient TMA paraffin block that had been softened in an incubator for 10 mins at 
37ºC. After this incubation the block was removed and the cores pressed inside with a 
glass slide to leave a smooth surface for sectioning. Sections were cut at 0.3μm as 
previously described and stained as for standard sections. 
2.6 Immunohistochemistry  
Immunohistochemistry (IHC) was performed using three methods.  Using the Envision 
Flex Peroxidase Kit (Dako) the secondary antibody is bound directly to the enzyme horse-
radish peroxidase. In the presence of HRP, 3,3’diaminobenzidine (DAB) is converted to 
an insoluble brown pigment which can be visualised under bright field light microscopy. 
For certain antibodies, particularly those not raised in mouse or rabbit, it was more 
appropriate to use the Vectastain Elite Avidin-Biotin complex (ABC) method (Vector Labs) 
of antigen detection. Avidin is a tetrameric protein that binds with high affinity and 
specificity to biotin. In the ABC method the secondary antibody is conjugated to biotin to 
amplify the signal from the primary antibody. HRP is conjugated to a large avidin-biotin 
complex, and this is added to the sample to enzymatically label the primary - secondary 
antibody complex. This enzyme will change the colour of the DAB chromogen as before. 
Adding a conjugating streptavidin to alkaline phosphatase rather than HRP allows for the 
use of alternative chromogens. 
 
All washing steps involved sections being covered in wash buffer (Envision Flex wash 
buffer; Dako) for 3 minutes, then rinsed briefly and covered similarly for two further 






antigen retrieval conditions was performed for all antibodies according to the protocol 
described below. All antibody incubations were 30 minutes at room temperature. 
Counterstaining was performed by incubating for 30 seconds with Mayer’s haematoxylin 
(Sigma) prior to a final dehydration, clearing and mounting with DPX. 
2.6.1 IHC Methods 
Envision Flex HRP IHC 
Following antigen retrieval sections were washed as described, then incubated in Envision 
Flex peroxidase blocking reagent (Dako DM821) for 10 minutes at room temperature. 
After a second washing step, sections were incubated with primary antibody. Following a 
third washing step, bound primary antibody was visualised by incubating the slides for 
30 minutes with Envision Flex/HRP (Dako DM822), washing and then developing using 
the 3,3’diaminobenzidine (DAB) chromogen. One drop of DAB chromogen per ml of 
ready-to-use stable substrate buffer (Biogenex) was mixed to prepare a working solution. 
This was applied to sections for 5 minutes, before washing in running tap water for 5 
minutes. Sections were counterstained, dehydrated and mounted as described. 
 
Linker 
Staining using antibodies against CYP11B1 and CD117 also included a 10-minute 
incubation with Envision Flex+ LINKER following primary antibody incubation to amplify 
the signal. 
 
Vectastain Elite ABC IHC 
Sections were washed as above, then endogenous peroxidase activity was blocked with a 
15-minute incubation in 3% hydrogen peroxide. A further wash step was followed by a 
30-minute incubation in 2.5% horse serum, then application of primary antibody as 
above. Sections were washed, then incubated with a biotinylated secondary antibody 
(Table 2.1) for 30 minutes at room temperature. Following a further washing step 
sections were incubated in Vectastain ELITE ABC Reagent for 30 minutes at room 
temperature. After washing, the reaction product was developed using the DAB 








Staining performed as for ABC. Following biotinylated antibody incubation and washes, 
sections were incubated in streptavidin-AP (Vector Labs) for 30 minutes at room 
temperature. After washing the reaction product was developed using the Ultraview 
Universal Alkaline Phosphatase Red detection kit. Counterstaining with haematoxylin and 
mounting as before. This was used to provide a red staining for MITF on pigmented tissues 
when DAB might be non-specific (Jiang et al., 2014). 
 
Avidin-biotin block 
High levels of endogenous biotin in the adrenal gland may sometimes lead to significant 
levels of background staining using the ABC method. Where noted in table X, adrenal 
sections were consecutively incubated for 10 minutes with avidin and d-biotin solutions 
(Invitrogen 004303) prior to incubation with horse serum. 
 
2.6.2 Antibody optimisation 
For each new antibody used the specific conditions for antigen retrieval were optimised 
as follows. 12 sections of an appropriate control tissue were obtained from the histology 
library of the Core Pathology dept, Queen Mary, University of London. An appropriate 
staining technique (Flex HRP or Vectastain ABC) was selected.  
 
Three different antigen retrieval solutions of varying pH were used: 
• Vector antigen unmasking solution pH 6 (Vector Labs) 
• Tris-EDTA Citrate Unmasking Solution pH 8.1 (EDTA 0.5g/l, Tris-Base 
0.25g/l, sodium citrate  0.32g/l; adjusted to pH 8.1 with NaOH) 
• Tris-EDTA unmasking solution pH 9.0 (EDTA 0.37g/l, Tris-Base 1.21g/l) 
 
Sections were incubated in each of these antigen retrieval solutions in a waterbath at 
95ºC for 10 or 40 minutes, or in a microwave set to full power for 10 minutes or 35 
minutes. A starting primary antibody concentration was chosen based on the 
manufacturer’s recommendations, or if these were not available, a starting concentration 
of 1/100 dilution was used. The antigen retrieval technique which provided the best 
balance between specificity and sensitivity of staining was chosen and the primary 
antibody concentration adjusted in turn. Additional steps were added as necessary (e.g. 







Table 2-1 Antibodies used in immunohistochemistry 
 
2.6.3 Immunocytochemistry 
For immunocytochemistry, adherent cells were trypsinised and resuspended at 5 x 105 
cells/ml. 200μl of cell suspension was added to a Shandon EX single cytofunnel and 
centrifuged at 800rpm for 5 minutes in a Shandon 3 cytospin centrifuge to deposit cells 
Antibody Manufacturer Clonality Antigen Retrieval Primary Ab Concentration Staining method
N-POC 1-28 AB Bicknell Rabbit polyclonal pH 9.0, 40 min water bath 1:2000 Flex
N-POC 1-49 AB Bicknell Rabbit polyclonal pH 9.0, 40 min water bath 1:2000 Flex
γ1-MSH AB Bicknell Sheep polyclonal pH 9.0, 40 min water bath 1:2000 ABC
γ3-MSH AB Bicknell Sheep polyclonal pH 9.0, 40 min water bath 1:1250 ABC
C-term ACTH AB Bicknell Rabbit polyclonal pH 9.0, 40 min water bath 1:2000 Flex
Mid ACTH AB Bicknell Sheep polyclonal pH 9.0, 40 min water bath 1:1250 ABC
N-term ACTH AB Bicknell Sheep polyclonal pH 9.0, 40 min water bath 1:2000 ABC
N-term αMSH 
(acetylated) AB Bicknell Sheep polyclonal
pH 9.0, 40 min 
water bath 1:1250 ABC
C-term αMSH 
(amidated) AB Bicknell Sheep polyclonal
pH 9.0, 40 min 
water bath 1:2000 ABC
HMB45 Dako Mouse monoclonal pH 9.0 , 40 min water bath Ready to use Flex
MC1R Abcam ab125031 Rabbit monoclonal pH 9.0 , 35 mins microwave 1:100 ABC
CYP11B1 Santa Cruz sc374096 Mouse monoclonal
pH 9.0, 40 min 
water bath 1:200 + linker Flex
CD117 Dako 4502 Rabbit polyclonal pH 9.0, 40 min water bath 1:1000 + linker Flex
DOG-1 Leica NCL-L-DOG1 Mouse monoclonal
Sodium citrate 
buffer pH 6.0, 45 
mins water bath
1:300 ABC
MITF Ventana Mouse monoclonal pH 9.0 , 40 min water bath Ready to use Flex
S100 Abcam ab868 Rabbit polyclonal pH 8.1 30 min microwave 1:200 ABC
Beta-catenin Dako M3539 Mouse monoclonal pH 9.0 , 40 min water bath 1:200 ABC
p27kip1 abcam ab3928 Rabbit monoclonal pH 8.1, 40 min water bath 1:100 Flex
p57kip2 abcam ab4058 Rabbit polyclonal pH 8.1, 40 min water bath 1:100 Flex
Ki67 Dako Mouse monoclonal pH 6.0, 40 min water bath 1:150 Flex
SDHB Thermofisher 29843 Mouse polyclonal
pH 8.1, 40 min 
water bath 1:500 ABC







on to a standard glass slide. Cells were fixed for 10mins in ice cold acetone, then staining 
proceeded as above, without any antigen retrieval step. 
2.6.4 Slide Scanning and quantification of positive immunostaining 
Slides were scanned using a NanoZoomer 2.0-HT Digital slide scanner and images 
analysed using NDP.View2 viewing software (Hamamatsu).  
 
The Ki67 positivity index for zona glomerulosa and zona fasciculata was calculated as 
follows. ZG and ZF were identified histologically by H+E staining. Images from Ki67 
stained sections were annotated to define these zones using the drawing facility of 
NDP.View2 viewing software. The total number of cells in each zone was counted 
manually. Cells exhibiting nuclear staining of Ki67, or those with mitotic figures were 
counted as positive by a single observer blinded to the treatments given. Mean percentage 
of Ki67 positive cells (+/- SEM) was recorded for each zone from each experimental 
condition in the rat adrenal remodelling experiment (see section 2.9). For other 
immunohistochemistry, interpretations of staining made by the author were confirmed 
by Professor Dan Berney, Consultant Histopathologist, Royal London Hospital. 
2.6.5 Electron Microscopy 
Paraffin embedded tissue was dewaxed in xylene and rehydrated through an alcohol 
series, incubated overnight in 0.2 M sodium phosphate buffer and fixed in 2.5% 
glutaraldehyde in 100mM phosphate buffer at pH 7.0 for three hours. Fresh surgical 
specimens were collected and fixed immediately in 2.5% glutaraldehyde. Specimens were 
postfixed in 1% osmium tetroxide in 100mM phosphate buffer for 2 hours at 4ºC, 
dehydrated through a series of alcohols and propylene oxide using the Leica EM TP tissue 
processor and embedded in epoxy resin. 90nm sections were cut on the Reichert Ultracut 
E ultramicrotome. Samples were visualised using a J.E.O.L JEM1230 transmission 
electron microscope and images captured with an Olympus “Morada” digital camera. 
2.7 Sanger sequencing 
Genomic DNA (gDNA) extraction was performed from flash frozen tissue (DNeasy mini 
kit; QIAGEN) and whole blood lymphocytes (Illustra DNA Extraction kit; GE Healthcare) 






using the QIAmp DNA FFPE Tissue Extraction kit (QIAGEN) according to the 
manufacturer’s instructions. PCR was performed in a 20μl reaction containing: 1μl 
template gDNA (50ng/μl), 1μl 10μM F+R primers, 0.2μl 25mM dNTPs, 2μl 10X 
Standard Taq reaction buffer, 0.125μl Taq DNA Polymerase (all New England Biolabs). 
Thermocycling conditions were: initial denaturation 95ºC for 30s; denaturation 
95ºC for 15s, annealling at 55-62ºC for 15s, extension 68ºC for 30s (30 cycles); final 
extension 68ºC for 5 minutes, holding at 4ºC. 
 
Sequences corresponding to all exons from armadillo repeat containing 5 (ARMC5; 
NG_034258.1) were amplified by PCR following the protocol of Assié et al (Assie et al., 
2013) and subjected to Sanger sequencing. The exon of the MC1R gene (NM_002386.3) 
and exons 1 and 2 of the SDHB gene (NM_003000.2) were amplified by PCR and similarly 
sequenced.  
 
Sanger sequencing for the following genes was carried out within our own laboratory 
using primers as outlined in table X, then sequenced again by the genetics department at 
Royal Devon and Exeter NHS Foundation trust using gDNA extracted from tissues as 
described above.  
 
1. Human adrenal and leucocyte DNA: Analysis of all coding regions and exon/intron 
boundaries of the PRKAR1A gene (NM_002734.3) and all coding regions and exon/intron 
boundaries of the PDE11A gene (NM_016953.3). Preliminary PDE11A sequencing was 
not carried out within our own laboratory. 
2. GIST and leucocyte DNA: Sequence analysis of exons 9, 11, 13 and 17 of the KIT gene 
(NM_000222.2), exons 12, 14 and 18 of the PDGFRA gene (NM_006206.4) and codon 
600 of the BRAF gene (reference sequence NM_004333.4). This assay can only detect a 
mutation present at a level of greater than 10% in a background of genomic DNA. 
 






Table 2-2 Details of primers used for Sanger Sequencing 
 
Forward Primer Reverse Primer Ta ºC
c-Kit exon 9 TCCTAGAGTAAGCCAGGGCTT TGGTAGACAGAGCCTAAACATCC 58
c-Kit exon 11 GTGCTCTAATGACTGAGAC GTGCTCTAATGACTGAGAC 58
c-Kit exon 13 GACATCAGTTTGCCAGTTGT TGTTTTGATAACCTGACAGAC 58
c-Kit exon 17 TGTGAACATCATTCAAGGCG GACTGTCAAGCAGAGAATGGG 58
PDGFRA exon 12 TCCAGTCACTGTGCTGCTTC GCAAGGGAAAAGGGAGTCTT 60
PDGFRA exon 14 TCTGAGAACAGGAAGTTGGTAGC CCAGTCAAAATCCTCACTCCA 60
PDGFRA exon 18 ACCATGGATCAGCCAGTCTT TGAAGGAGGATGAGCCTGACC 60
BRAF exon 15 ATCTCTTACCTAAACTCTTCATAATGC AACTCAGCAGCATCTCAGGG 58
hSDHB exon 1 TTGGATATTGAATGCCTGCC TTGGTCTTGAACTCCCAACC 60
hSDHB exon 2 TCCGAAGGTGACCTGAGAAG CTCTATCAGCTTTGGCCAGC 60
PRKAR1A exon 1 CCACCTGTCATCTGAGACGC CCGGTTCTCTCCTCCTTCC 62
PRKAR1A exon 2 AATGCCAGATTGACATTTTGC AATCACCTCATCATCTCCCC 62
PRKAR1A exon 3 GAGTGCCAGCTTTACATGCC ATGACCACCAAGTGGGTCC 62
PRKAR1A exon 4 TAATTGAAGCGCAGGTTGC AACAATTTGGGATCACACCC 62
PRKAR1A exon 5 GCTTAATGTTTGAAATTCACGG ATATTGCATGCTCCAGAGGC 62
PRKAR1A exon 6 TTGCTTGATTTTCTTTCCCC ATTCTTATTGCTCGGAAGCG 62
PRKAR1A exon 7 TTTTTGATGTCACTTGCACTTT TTCTAAATCACACTCTCAAACACCA 62
PRKAR1A exon 8 TGATAATTACACGTCTTGGGG GCTTTTCCCAAGTCCATCC 62
PRKAR1A exon 9 AGAATGTTGAATGGGCATGG GAATTAGCCCACTCTTTCCC 62
PRKAR1A exon 10 GTTTAAGGTGCCACCCTGG GAAACCATGTATTTATTGTGAGGG 62
PRKAR1A exon 11 AGCCTGTTACCCATCTTTGC GCAGTTTGCATGAGTGAAGC 62
MC1R ATCCTTCCTGGACAGGAC CAT TTA GTC CAT CCT CTT TG 62
ARMC5 exon 1 (a) GATTCTCCCTCGCCTCTTCT GAGCTTCTCACGCCTACCTC 60
ARMC5 exon 1 (b) GTCGGACTTCTGGGCTGTTC CTCAGGGGTGTCTCGTTGGT 60
ARMC5 exon 1 (c) TTTCCCTGTCTTCCAGTTCC ACGTTATTCCGGGATAGGAC 56
ARMC5 exon 2 AGGGGTAGAACCCTCACAAG CACTCAAGCCTTTCTTCTGC 60
ARMC5 exon 3 (a) GTAAGAGGCTGTGAGGTTGG TCATCTACCAGCACCTCCAC 64
ARMC5 exon 3 (b) GATCCTCGCCAACCTGTGT CACTGCTCACCCTCCCAAG 60
ARMC5 exon 4 (a) TTGGCTCTGGGTTCAGTCTC GAGTGGGAAGGTGAGGTTCT 60
ARMC5 exon 4 (b) GGCCTGCTGACCTATGTGAC CAGAAGGGCTCCTTGGTCTA 60
ARMC5 exon 5 GTCTCACTCACCCCACCTG ACAGTGGGAGACACCAGGTC 60
ARMC5 exon 6 (a) ACACCCGCTCTTCCTCTTCT CTCTTCCAGCTCCTCCTCCA 60








The role of methylation status of the POMC promoter in enabling POMC expression has 
been established by Newell Price et al (Newell-Price et al., 2001). They demonstrated that 
the POMC promoter is embedded within a defined CpG island, much of which is 
methylated in unexpressing tissues, and specifically unmethylated in POMC-expressing 
tissues and tumours. Ye et al  (Ye et al., 2005) defined a region between -417 and -260 
bp upstream of the POMC transcription initiation site where the levels of POMC 
expression correlated inversely with methylation density. Methylation levels at this site 
were assessed using bisulphite modification of genomic DNA and pyrosequencing. 
2.8.1 Principle of methylation analysis 
Methylation of any of the four nucleotides making up DNA can occur in various nucleotide 
pairs, with the most common being methylation of the cytosine residue in the context of 
a CpG dinucleotide. Conversion of this epigenetic change into a genetic change allows it 
to be measured by DNA sequencing. Incubation of the DNA sample with sodium bisulphite 
converts unmethylated C into U (Uracil) while leaving methylated C unmodified. PCR 
primers may be designed that are specific to the modified DNA strand. Any C which is not 
followed by a G is now treated as a T, since uracil will be converted to thymine during 
PCR; one of the primers is tagged at the 5’ end with a biotin label. Primers should ideally 
be designed which generate a PCR product that is 150-250 base pairs, without primer 
overlap onto CpG sites.  
 
Streptavidin beads are combined with the PCR product to select out the biotin labelled 
product, then the DNA is denatured so that single stranded molecules may be sequenced. 
Pyrosequencing uses a chemical light reaction to detect the incorporation of dNTPs into 
the synthesising strand. A sequencing primer is hybridised to the amplified DNA template 
and incubated with DNA polymerase, ATP sulfurylase, luciferase and appears, along with 
the substrates, adenosine 5’ phosphosulphate (APS) and luciferin. The first of four dNTPs 
is added to the reaction, and if complementary it is incorporated into the growing strand, 
accompanied by the release of pyrophosphate (PPi) in a quantity equimolar to the amount 
of incorporated nucleotide. PPi is converted to ATP by ATP sulfurylase in the presence of 
APS, and this ATP drives luciferase-mediated conversion of luciferin to oxyluciferin, 






and recorded as a peak in a program which is proportional to the number of nucleotides 
incorporated. 
 
Apyrase degrades unincorporated nucleotides and ATP, and the next nucleotide is added 
when degradation is complete. dNTPs are added one at a time and the process continues, 
with the sequence being determined by the light generated with each dNTP addition. The 
degree of methylation at CpG sites is determined according to the ratio of T and C at that 
point. 
2.8.2 Pyrosequencing method 
Primers were designed using the PyroMark Assay Design Software 2.0 to include a region 
-417 to -260 upstream of the POMC transcription initiation site. 
 
Amplification primers.  







Genomic DNA was extracted from GIST tumours and lung carcinoid tumours associated 
with and without Cushing’s syndrome, and pituitary corticotroph adenoma as described 
previously. gDNA was initially quality controlled using Nanodrop 8000 UV-Vis 
Spectrometer and Tapestation 2200. 500ng of each Genomic DNA sample were bisulphite 
converted using the EZ-96 DNA Methylation Kit (Zymo Research) as described by the 
manufacturer’s protocol alongside a control DNA sample (CEPH). Samples were then 
quality controlled using the Nanodrop 8000 UV-Vis Spectrometer to check concentrations 
of resulting bisulphite converted DNA. Converted DNA was diluted to 5ng/µl ready for 
PCR reaction. Primers POMC_Meth_Forward and POMC_Meth_Reverse were then used 
initially to test the Control sample (annealing temperature gradient) and then 
subsequently on the samples themselves. The reverse primer was biotinylated for this PCR 
reaction and subsequent PCR products were run on a 1.5% agarose gel to access the 







The MyTaq PCR (Bioline) kit was used in a 50µl reaction: 10µl Reaction Buffer, 1µl 
POMC_Meth_Forward, 1µl POMC_Meth_Reverse, 0.5µl Taq Polymerase, 35.5µl Water, 
2µl of diluted bisulphite converted DNA (5ng/µl). Thermocycling conditions for PCR 
were: 95°C for 1 minute; 95 for 15 seconds, 50°C for 15 seconds, 72 for 10 seconds (25 
cycles).  
 
20µl of the PCR products were added to 37µl of Binding Buffer and 3µl of Streptavadin 
beads, then shaken for 20 minutes at 1600rpm. Using a vacuum preparation workstation 
samples were washed with 70% ethanol, 0.2M NaOH and wash buffer. Samples were 
then transferred into 43.5µl of annealing buffer and 1.5µl of sequencing primer 
(POMC_Sequencing_Primer1 or POMC_Sequencing Primer2). Samples were heated for 2 
minutes at 80°C and then placed onto the PyroMark Q96 ID for analysis. Control DNA 
was obtained from Thermofisher Scientific (CEPH Individual 1347-02). 
2.9 Rat adrenal remodelling 
Adult male Wistar rats of 8 weeks’ old weighing 100 - 120g were obtained from Charles 
River Laboratories. They were housed in rooms with controlled light and temperature and 
treated under the Home Office Animals (Scientific Procedures) Act 1986 - project licence 
70/6841 “Mechanisms underlying adrenocortical growth”. Animals were kept under 
conditions expected to stimulate or inhibit remodelling of the zona glomerulosa as 
described by Brennan et al (Brennan et al., 2008). Control animals were maintained on 
a standard diet consisting of dry pellets made from wholemeal flour (Sainsburys Ltd, 
London, UK) supplemented with 1% CaCO3 (Sigma) and 1% NaCl (Sigma) with access 
to distilled water for two weeks. In addition, one group of animals received the standard 
diet with supplementation of their drinking water with Captopril (0.5mg/ml; Sigma) and 
one group received a low sodium diet which omitted the 1% NaCl.  
 
Animals were anaesthetised in a CO2 chamber, then killed by cervical dislocation. 3 
animals from each group were sacrificed at days 2, 4 and 7. At this point the groups were 
crossed over: captopril treated animals were converted to a low sodium diet; low sodium 
diet animals were given a standard diet with captopril supplementation. 3 animals per 






was fixed overnight in neutral buffered formalin (Sigma) and processed as described 
previously. The right adrenal was embedded in Tissue-Tek OCT Compound (Sakura) and 
flash frozen on dry ice, then stored at -80ºC. 
2.10 Dynamic clinical investigations 
Low dose dexamethasone suppression test. 
A baseline serum cortisol level is taken at 9am, then 0.5mg oral dexamethasone is 
administered immediately and every 6 hours for 8 doses (i.e. 0900h, 1500h, 2100h and 
0300h). Bloods are taken for cortisol assay at 24 and 48 hours. Serum cortisol should be 
suppressed to <50nmol/l. Failure to suppress is seen in the autonomous production of 
cortisol in Cushing’s syndrome, but also in certain other conditions associated with altered 
cortisol dynamics (e.g. depression, obesity). The test should therefore be interpreted in 
conjunction with the clinical suspicion for Cushing’s syndrome. 
 
Mixed Meal Test 
Following a baseline 9am assessment of fasting serum cortisol, a meal comprising 30g 
cornflakes, 250ml semi-skimmed milk, 4.5g sachet sugar, 170ml unsweetened orange 
juice, 40g (medium) slice white bread, 10g portion butter, 50g piece cheddar cheese and 
100g low fat fruit yoghurt (composition 31.1g Protein / 124.4 kcal / 16%, 31.1g Fat / 
297.9 kcal / 38% and 95.6g CHO / 358.5kcal / 46%). Blood samples were then obtained 
post prandially at +15, 30, 45, 60, 90 and 120 minutes. The test is performed to assist in 
the diagnosis of food-dependent Cushing’s syndrome, a rare condition due to the ectopic 
expression of receptors for gastric-inhibitory polypeptide on the surface of adrenocortical 
cells (Christopoulos et al., 2005). A rise in cortisol levels following the meal is suggestive 
of the syndrome. 
 
Octreotide Test. 
Following a baseline 9am assessment of fasting serum cortisol, a 100mcg subcutaneous 
dose of octreotide is administered, and repeat measurements of serum cortisol taken 
hourly for the next 8 hours. Octreotide is a somatostatin analogue, and is used to inhibit 
the function of various neuroendocrine cell types expressing somatostatin receptors. The 
intention with this octreotide test dose is to transiently reduce the production of a 










Three basal fasting samples of cortisol are taken at 15 minute intervals. Immediately 
following the third sample 100mcg of corticotropin releasing hormone is administered 
intravenously. Further serum samples are taken for cortisol assay at intervals up to 120 
minutes’ post-injection. A rise in cortisol from basal to peak of >20% suggests a pituitary 
source. A rise in ACTH from basal to peak of > 50% suggests a pituitary source (Kaye & 
Crapo, 1990). 
2.11 Data Analysis 
All data were analysed using Microsoft Office Excel for Mac 2011 and SPSS version 22. 
One-way ANOVAs (analysis of variance) were implemented, and the appropriate pre-
planned and post-hoc comparisons including the bonferroni correction for multiple 
comparisons(Brace et al., 2006). Pre-planned tests are those between factors that are 
expected to differ, and are already decided upon before carrying out an experiment. Post-
hoc comparison tests are comparisons not foreseen, that may reveal interesting 
connections between data sets. Graphs were produced using SPSS version 22 and 
Autodesk Graphic for Mac. 
2.12 Ethics and consent 
Ethical approval for studies involving human tissue was granted as follows. 
Consent was taken for experiments involving GISTs, human adrenal primary culture, 
human adrenal from ACTH-dependent Cushing’s disease, PPNAD adrenal specimens, lung 
carcinoid tumours: 
 
Genetics of Endocrine Tumours 
Reference: 06/Q0104/133 







Experiments involving human adrenal tissue taken at the time of adrenalectomy for 
Conn’s syndrome: 
 
Analysis of bone morphogenetic protein and sonic hedgehog signal transduction pathway 
components in adrenal tumours and adjacent normal tissue 
Reference: O8/H0701/59 






Chapter 3 The role of p27kip1 and p57kip2 
in rat adrenal remodelling 
3.1 Aims 
This chapter aims to understand mechanisms controlling remodelling of the rat adrenal 
gland. Using dietary and pharmaceutical modification of the renin-angiotensin-
aldosterone system the adrenal response will be assessed in terms of histological changes, 
and immunohistochemical expression of markers of proliferation and the cell cycle.  
 
Rats will be placed on a low sodium diet to activate the renin-angiotensin-aldosterone 
system (RAS), or treated with an ace-inhibitor in their water supply to inhibit the RAS. 
The adrenal response to these experimental conditions will be assessed in terms of the 
gross histological changes within the ZG, and by expression of the Ki67 marker of cell 
proliferation by immunohistochemistry. The expression of the cyclin-dependent kinase 
inhibitors p27kip1 and p57kip2 will also be assessed by immunohistochemistry. There is 
a literature to suggest that these may mark populations of progenitor cells (Bilodeau et 
al., 2009; Besson et al., 2007), and changes in their expression during rapid ZG 
remodelling may indicate the locations of these cells. 
3.2 Introduction 
3.2.1 Adrenal remodelling 
The response to changes in activity of the HPA axis or RAA system in terms of steroid 
production are rapid. In rodent models RAAS activation in low sodium conditions rapidly 
expands the ZG, with an increase in the number of CYP11B2 expressing cells and 
therefore more aldosterone secretion (Romero, Yanes et al., 2007). Similar changes have 
been demonstrated in patients with primary aldosteronism (Boulkroun et al., 2010). On 
the other hand, suppression of the RAAS by administration of angiotensin-converting 
enzyme (ACE) inhibitors causes rapid shrinking of the ZG, a reduction in CYP11B2 
expression(Romero, Rilli et al., 2007). Likewise, excessive ACTH stimulation leads to 
expansion of the ZF and increased CYP11B1 expression, and the converse in response to 







There are several possible mechanisms by which such remodelling could occur. 
Potentially this could involve increasing rates of differentiation of stem or progenitor cell 
populations, or it could arise from proliferation within existing cell populations - 
enhanced proliferation has been shown within the ZU and the ZF or ZG depending on 
which is being remodelled(McEwan et al., 1996). There may be transdifferentiation from 
one steroidogenic population to another, for example ZF cells converting to ZG cells when 
the RAAS is activated, or dedifferentiation of ZG cells when the RAAS is inhibited. 
Changes in the rate of apoptotic cell death may also be altered – there is evidence that 
ACTH forestalls apoptosis of terminally differentiated ZR cells in the hypophysectomised 
rat (Carsia et al., 1996) How these processes are controlled is unclear. 
3.2.2 Control of cell cycle progression 
Regulation of cell cycle progression is an important determinant of cell proliferation and 
differentiation. Progression though the cell cycle is controlled by cyclins and cyclin-
dependent kinases (CDKs). CDK activity is regulated by a variety of mechanisms, 
including intracellular levels of cyclin, the presence of CDK inhibitors, or phosphorylation 
of the CDKs themselves.  
 
The cyclin-dependent kinase (CDK) inhibitors can be divided into two main families: INK4 
and Cip/Kip. The INK4 gene family encodes p16INK4a, p15INK4b, p18INK4c and 
p19INK4d. All of these bind to CDK 4 and CDK6 and interfere with their binding to D-
type cyclins, thereby inhibiting their kinase activities (Sherr & Roberts, 1995). The 
Cip/Kip family members p21Cip1, p27kip1 and p57kip2 have an identical N-terminal 
domain which binds and inhibits a variety of cyclin-CDK complexes, with their primary 
target being the cyclin E-cdk2 complex (Gomez Lahoz et al., 1999; Musgrove, 2006) This 
complex is of particular importance in regulating the G1/S transition of the cell cycle. 
 
The roles of p57 and p27 in the development of the adrenal gland have been shown in 
knockout models. In the mouse adrenal gland, p27 expression was demonstrated in the 
medulla but not the cortex, and p57 in the cortex but not the medulla (Nagahama et al., 
2001). Mice lacking p27 had a phenotype suggesting impaired control of cellular 
proliferation, with an increase in size of the adrenal medulla, as well as the thymus, testis 
and pituitary, although without gross developmental defects (Nakayama et al., 1996) 






cleft palate, but these animals are noted to have adrenocortical hyperplasia (Zhang et al., 
1997). 
 
The effect of ACTH on the expression of p27 and p57 in the rat adrenal was investigated 
by Kobayashi et al (Kobayashi et al., 2006). They showed low expression of p27 in the rat 
cortex, in keeping with the earlier descriptions in the mouse. This was present mainly in 
the ZG, and was diminished by suppression of ACTH stimulation of the gland using high 
dose dexamethasone. Expression of p57 expression was not altered by dexamethasone, 
but was increased by treatment with ACTH, and again this was recognised mainly within 
the zona glomerulosa. 
 
3.2.3 Quantification of proliferation using Ki67 
Ki67 is a nucleolar non-histone protein identified in the 1980s, which is universally 
expressed in proliferating cells but absent in quiescent cells. It is therefore used widely as 
a marker of tumour proliferation, where it has been shown to have both prognostic and 
predictive value. It functions as a cell-cycle regulated protein phosphatase 1 binding 
protein, and is involved in the assembly of the perichromosomal compartment during 
mitosis (Booth et al., 2014) It also has a role in spatially organizing heterochromatin to 
enable specific expression of genes required for proliferation (Sobecki et al., 2016). 
 
Its exact function is not known, but it is thought to be involved in the synthesis of 
ribosomal RNA (Scholzen & Gerdes, 2000). The fraction of Ki67 positive cells in a tumour 
sample correlates well for many cancers with the course of the disease, and it is now well 
established as a factor in scoring systems to determine the prognosis of adrenocortical 
cancer (Terzolo et al., 2001) 
 
It has also been used widely in experiments investigating adrenal remodelling to identify 
dividing cells. In response to chronic stress increased Ki67 density has been demonstrated 
in the outer zona fasciculata  of the rat adrenal (Ulrich-Lai et al., 2006), during 
compensatory growth following unilateral adrenalectomy (Engeland et al., 2005), or 








It was hypothesised that as controllers of cell cycle progression p27 and p57 would mark 
transiently amplifying populations of progenitor cells during differentiation of stem cells, 
and thus might indicate the location of these populations. By forcing the gland to undergo 
rapid differentiation during remodelling these changes would be more obvious. 
3.3 Results 
3.3.1 Experiment design 
8-week old adult male Wistar rats were maintained under conditions expected to 
stimulate or inhibit the RAS. Control rats received a diet of wholemeal flour supplemented 
with 1% CaCO3 or 1% NaCl. RAS activation was achieved by omitting the NaCl from their 
diet, while captopril was added to drinking water to inhibit the RAS. 
 
Three rats from each experimental group were sacrificed at 7 days and 14 days. At 7 days 
3 rats on low sodium diet switched over to RAS inhibition with captopril and a normal 
diet, and 3 rats receiving captopril had this stopped, and were placed on to a low sodium 
diet (Figure 3.1). This was performed to equalise the basal level of RAS activation 
(maximally activated or inhibited) across each group. Additionally, the stimulus each 
experimental group achieved would be of a greater magnitude, thereby amplifying any 
effects in terms of changes in expression of cell cycle markers. The left adrenal of each 
animal was harvested and stained as described for H&E, Ki67, p27kip1 and p57kip2. (Full 







Figure 3.1. Experimental design. Rats were fed a normal diet, a low sodium diet, or a normal diet 
supplemented with captopril in their drinking water. Rats were sacrificed at 7 days and 14 days. 
At 7 days 3 rats from each experimental groups were crossed over to receive the reverse treatment. 
3.3.2 Activation of the renin-angiotensin aldosterone axis causes expansion 
of the zona glomerulosa 
The histological identity of the ZG was determined using standard H&E staining. Rats fed 
a low sodium diet demonstrated expansion of the ZG from a thickness of 8-10 cells below 
the capsule to 14-17 cells (Fig 3.5 panel C). Captopril treatment led to a slight contraction 
of the ZG to 6-8 cells below the capsule (Fig 3.5 Panel G). Crossing over from low sodium 
to captopril resulted in ZG contraction (Fig 3.5 Panel H), and crossing over from captopril 
to low sodium caused ZG expansion as above (Fig 3.5 Panel D). 
 
An attempt at functional identification of the ZG using immunohistochemical labelling for 
CYP11B2 was initially successful (Figure 3.2), demonstrating that RAS activation 
increased CYP11B2 expression and captopril inhibited it. However, this same antibody 
failed to successfully stain positive controls reliably, and we were unable to use it for all 
sections. Alternative markers for this zone include the angiotensin II receptor, but no 
antibody was available. The use of β-catenin to label ZG (Drelon et al., 2015) was 






increased β-catenin staining in the same region as CYP11B2 in initial controls, the staining 
in general is difficult to interpret, and therefore was not used in the formal analysis. 
 
 
Figure 3.2 CYP11B2 and β-catenin staining in the rat adrenal gland following 7 days of low sodium 
diet or captopril treatment, followed by 7 days of the opposite treatment. Sections were stained 
for CYP11B2 (1:100) and beta-catenin (1:200). Maximal inhibition of the renin-aldosterone 
system (RAS) using captopril, followed by 7 days of RAS stimulation on a low sodium diet results 
in CYP11B2 expression in the zona glomerulosa. There is increased beta-catenin expression but 
overstaining with this antibody in basal conditions makes this impossible to reliably interpret. 
Images were taken using the NanoZoomer 2.0-HT Digital slide scanner. Scale = 100µm. See 
Section 2.6.3 for full method. Panel A shows the same positive control adrenal stained for CYP11B2 









3.3.3 RAS activation causes an increased in proliferation within the ZG 
Sections were immunostained for Ki67, a marker of proliferation. ZF and ZG were 
identified using H+E sections, and identified on Ki67–stained slides using drawing 
software on the NDP.View2 viewing programme. All cells were counted within each zone 
across the entirety of the section, and mean percentage (+/- SEM) of Ki67 positive cells 
for each condition is shown in Figure 3.3 (See Section 2.6.4).  Proliferation as assessed 
by Ki67 positivity was low in all zones of the adrenal cortex in control animals. Rats fed 
a low sodium diet to stimulate the RAS demonstrated increased proliferation in the ZG at 
7 days, and greater still at 14 days (Figure 3.5 Panel C). At 7 days most of the Ki67 positive 
cells were just below the capsule (Figure 3.5 Panel B), but at 14 days and in the animals 
crossing over to low sodium diet, Ki67 positive cells were spread throughout the ZG 
(Figure 3.5 Panel D). Captopril treatment significantly reduced the number of Ki67 
positive cells in the ZG (Figure 3.3), but in animals treated with captopril for 14 days, or 
treated initially with low sodium diet and then switched to captopril, there were Ki67 
positive cells at the border of ZG/ZF (Figure 3.5 Panels G and H). There was no significant 




Figure 3.3. Ki67 proliferative index in ZG and ZF cells under RAS remodelling conditions 
Rats were fed a normal diet, a low sodium diet, or a normal diet supplemented with captopril in 
their drinking water. Rats were sacrificed at 7 days and 14 days. At 7 days 3 rats from each 
experimental groups were crossed over to receive the reverse treatment. Sections were 
immunostained for Ki67, a marker of proliferation. ZF and ZG were identified using H+E sections, 
and identified on Ki67 –stained slides using drawing software on NDP.View2 viewing programme. 
All cells were counted within each zone across the entirety of the section, and mean percentage 
(+/- SEM) of Ki67 positive cells) for each condition is shown.  A significant increase in expression 
was found in the adrenal from rats who were treated with a low sodium diet to activate the RAS 
for 14 days, or in rats that were initially treated with captopril to inhibit the RAS. * = p<0.05 







3.3.4 Staining pattern of p27 and p57 in control animals. 
Nuclear p27 staining was detected in the medulla, and the subcapsular cortex in control 
animals (Figure 3.4 Panel A). In addition, there were p27 positive cells in the adrenal 
capsule. Nuclear staining for p57 was detected throughout the cortex, with the greatest 









Figure 3.4 p27kip1 and p57kip2 staining in control adrenals 
Control sections of rat adrenal gland were provided by the tissue library of the Core Pathology 
Dept, Blizard Institute, QMUL. Immunohistochemical staining was carried out for p27kip1 and 
p57kip2 (Ab concentrations 1:100; see section 2.6.2). No antibody controls shown in B and D. 
Positive nuclear immunostaining for p27 is seen in the adrenal medulla and the outer cortex (A). 
Staining for p57 is not present in the medulla, but is found throughout the cortex and is particularly 










Figure 3.5 Immunostaining of p27, p57 and Ki67 under remodelling conditions 
Rats were fed a normal diet (A and E), a low sodium diet (B-D), or a normal diet supplemented 
with captopril in their drinking water (F-H). Animals were sacrificed at 7 days and 14 days. At 7 
days 3 rats from each experimental groups were crossed over to receive the reverse treatment (D 
and H). Representative images are shown. Sections were stained with H&E, and adjacent sections 
immunostained for p27kip1 (1:100), p57kip2 (1:100) and Ki67 (1:150). The number of Ki67 
positive cells increases in the outer ZG after 7 days of low sodium diet (B), and is present 
throughout the ZG after 14 days (C), and in animals crossing over to low sodium diet from initial 
captopril treatment (D). Numbers of Ki67 positive cells are low in captopril treated animals (F-H). 
Nuclear expression of p27 and p57 is reduced in captopril treated animals (F-H) compared with 
those on low sodium diet (B-D), but p27 expression in the cytoplasm is apparent. Scale bars 
200µm. 
A B C D 






3.3.5 Activation of the RAS is associated with reduced ZG expression of p57, 
and cytoplasmic staining for p27. 
Immunohistochemical staining for p27 and p57 is shown in figures 3.4 and 3.5 Nuclear 
p57 staining in the ZG was restricted to sub capsular cortex cells by placing rats on a low 
sodium diet for 7 days, with a further reduction in staining after 14 days. Inhibition of 
the RAS with captopril treatment increased the degree of nuclear p57 staining, with mild 
cytoplasmic staining in addition. Rats which were initially treated with captopril then 
switched to low sodium diet after 7 days also demonstrated reduced p57 staining. Animals 
initially on a low sodium diet who then received captopril demonstrated the strongest ZG 
p57 staining of all animals studied.  
 
Activation of the RAS led to a reduction in nuclear p27 staining in the ZG, but the 
development of mild to moderate cytoplasmic staining. Cytoplasmic staining was mild 
and restricted to the immediate sub capsular cells after 7 days of low sodium diet, slightly 
expanded at 14 days, but most pronounced in the animals which had been converted to 
a low sodium diet after initial RAS inhibition with captopril. Captopril treated animals 
demonstrated an increase in nuclear p27 staining in the ZG that was present by 14 days, 
but was most prominent in animals initially on a low sodium diet. 
 
 
Figure 3.6 Higher magnification images of p27 and p57 staining in crossover arm. 
3 animals from each experimental group (Low sodium diet; captopril) were switched to the 
opposite treatment after 7 days, and sacrificed at 14 days. Sections were immunostained for 










adrenals switched from low sodium diet to captopril treatment (B and D). Cytoplasmic staining of 
p27kip1 is present in the outer ZG from animals switched from captopril to low sodium diet (A) 
3.4 Discussion 
3.4.1 Lack of functional zona glomerulosa staining 
CYP11B2, or p450 aldosterone synthase is the most appropriate functional marker of the 
zona glomerulosa. The lack of a commercially available antibody has hindered 
experimental investigation of this zone in the past. Antibodies to CYP11B2 in the rat have 
been available for some years, manufactured by the lab of Gomez-Sanchez et al (Engeland 
et al., 1996) and an aliquot was kindly provided. This gave successful staining on a few 
occasions, but unfortunately there was inconsistent staining of positive control sections. 
Colleagues within our own laboratory are attempting to establish a local supply of the 
antibody using the same method as Gomez Sanchez et al but this is not yet available. An 
alternative marker of the ZG was therefore sought. 
 
In the rat adrenal cortex β-catenin is accumulated in a discrete peripheral domain which 
encompasses cells expressing CYP11B2 (ZG) but is distinct from cells that express Shh 
(ZU) (Drelon et al., 2015). Experimentally induced constitutive expression of β-catenin 
in the adrenal cortex of transgenic mice led to ectopic differentiation of ZG at the expense 
of ZF cells (Berthon et al., 2010), and it has been demonstrated that β-catenin controls 
the expression of the angiotensin receptor and CYP11B2 in both mouse and human 
adrenocortical cells (Berthon et al., 2014). Furthermore, WNT/β-catenin signalling has 
also been shown to specifically inhibit ZF differentiation (Walczak et al., 2014). 
Unfortunately, we failed to optimise staining with β-catenin, with significant positive 
staining even in negative controls. The angiotensin II receptor would be an additional 
marker that it would be informative to use to label the ZG. 
 
Using functional markers to establish the location of the ZG is useful given the existence 
of the ZU between ZG and ZF in the rat which expresses neither CYP11B1 or CYP11B2, 
and is thought to be the location of Shh positive cells which signal to the stem cells in the 








3.4.2 Increased proliferation within the ZG 
RAS activation led to ZG expansion, and RAS inhibition led to its contraction. ZG cell 
hypertrophy, hyperplasia and increased expression of steroidogenic enzymes are expected 
when the RAS is stimulated (McEwan et al., 1996; McEwan et al., 1999). On H&E staining 
we were able to demonstrate that RAS activation led to ZG expansion, and RAS inhibition 
led to ZG contraction (Figure 3.5). In addition, there was hypertrophy within the cells of 
the outer ZG in rats on the RAS activating low sodium diet. 
 
Activation of the RAS caused increased Ki67 immunopositivity in subcapsular cells at 7 
days and throughout the ZG at 14 days. Animals switched from captopril to low sodium 
had the highest levels of Ki67 positivity in the ZG (Figure 3.3), but this was most 
prominent in the inner ZG at the boundary with the ZF (Figure 3.5 Panel D). There were 
scattered Ki67 positive cells within the ZF, particularly towards the inner ZF boundary in 
the captopril to low sodium cross over group (Figure 3.5 Panel H). This appearance was 
also apparent during the compensatory adrenal response to unilateral adrenalectomy in 
the rat (Engeland et al., 2005) but the authors do not comment on its significance. In the 
low-sodium to captopril cross over image shown (Fig 3.4), there is also a distinct pattern 
of staining for Ki67 at the ZF/ZR boundary. However, this is not consistent over the whole 
adrenal in that animal, nor is it present in adrenals from the other biological replicates. 
Furthermore, there was no statistical difference in ZF Ki67 positivity between any of the 
experimental groups (Fig 3.4), and this would be in keeping with previous reports of the 
effect of captopril treatment on rat adrenal ZF and ZR proliferation (McEwan et al., 
1996). 
 
It would be interesting to use additional markers of proliferation such as PCNA or 
phosphohistone H3 to establish whether this was a consistent finding. One possible 
explanation for this maybe that the Ki67 is labelling proliferating cells of the adrenal 
vasculature – aldosterone secreted from the ZG will be carried centrally through venous 
sinusoids, and could potentially stimulate proliferation and remodelling of the inner 
vascular plexus. Co-labelling of adrenal sections with Ki67 and CD31 to identify adrenal 
microvascular endothelial cells would clarify this possibility (Karaca et al., 2015). 
 
It has been shown in the mouse that capsular cells delaminate and become steroidogenic 






ZG in rats fed a low sodium diet has also been demonstrated (Mitani et al., 2003). Our 
data showing subcapsular Ki67 positivity after 7 days of RAS activation, spreading to the 
whole ZG at 14 days, along with cytoplasmic p27kip1 staining throughout the ZG would 
be consistent with centripetal migration. To determine if bidirectional migration was 
taking place it would be instructive to carry out lineage tracing experiments to follow the 
cells with cytoplasmic p27 localisation under conditions of RAS activation and ACTH 
stimulation. 
 
3.4.3 p57 staining 
Activation of the RAS reduced the expression of p57 in the ZG, while inhibition of the 
RAS increased expression.  Kobayashi et al found that p57 expression was increased by 
ACTH treatment (Kobayashi et al., 2006) and therefore one may have expected the same 
pattern with activation of the RAS by low sodium diet. However, the level of p57 
expression in control animals in their study was reported as zero, whereas previous 
studies had demonstrated significant cortical staining (Nagahama et al., 2001). Control 
animals in our study showed p57 staining throughout the cortex, with strongest staining 
in the subcapsular ZG (Figure 3.4 Panel C). This would be consistent with this as a 
location containing a stem or progenitor cell population. 
 
Bilodeau et al suggested that the expression of p57 in the pituitary gland marked a cell 
population that was intermediate between progenitors and differentiated cells, and that 
p57 was itself a signal for differentiation. (Bilodeau et al., 2009). Differentiation in those 
cells was accompanied by loss of p57 expression and the appearance of p27. The high 
levels of p57 expression seen in the subcapsular cortex when the RAS system is inhibited, 
with loss of p57 when progenitor cells in the subcapsular adrenal cortex are stimulated 
to proliferate and differentiate would be predicted by this model. Downregulation of 
p27kip1 and p57kip2 would be predicted to release their inhibition of the Cyclin E-cdk2 
complex, thereby facilitating the G1/S transition in the cell cycle, and allow these 
quiescent progenitor cells to proliferate (Musgrove, 2006). It will be necessary to perform 
dual immunostaining with p57 and Ki67 to confirm that cells which are p57-positive are 







The role of p57 in adrenal pathology is also instructive here. In addition to adrenocortical 
hyperplasia in p57-/- mice (Zhang et al., 1997) there are two syndromes in human disease 
where changes in p57 affect adrenal development. Beckwith-Wiedemann syndrome 
(BWS) is the most common overgrowth syndrome: clinical findings include macrosomia, 
macroglossia, enlarged organs and hemihyperplasia. The syndrome is associated with a 
variety of adrenal tumours, and adrenocortical hyperplasia in the neonate (Mazzuco et 
al., 2012). The syndrome is associated with a number of genetic and epigenetic alterations 
related to the chromosome region 11p15.5, where the p57 gene CDKN1C is located. 
Mutations in CDKN1C are found in 10% of sporadic cases, and up to 40% of familial cases 
(Miozzo et al., 2014). Some of the mutations in BWS abrogate the CDK2-inhibitory ability 
of p57, while some affect sub cellular localisation and exclude it from the nucleus. There 
was a mild amount of cytoplasmic p57 staining in the ZG of low sodium treated rats in 
our study, suggesting that the sub cellular location of the protein may be important in 
normal physiology. As discussed below, it is clear that this is the case for p27. 
 
In contrast, gain of function mutations in CDKN1C have been identified in patients with 
the IMAGe syndrome: intrauterine growth restriction, metaphyseal dysplasia, adrenal 
hypoplasia and genital anomalies (Vilain et al., 1999). Six missense mutations in the 
PCNA-binding domain in the C-terminal of CDKN1C have been reported, with evidence 
that this leads to increased stability and gain of function (Hamajima et al., 2013). 
 
There is also frequent down-regulation of p57 in human cancers and this is correlated 
with aggressiveness in several of these (Guo et al., 2010). Down-regulation has been seen 
in adrenal tumours, although no CDKN1C mutations have yet been detected (Barzon et 
al., 2001). 
 
3.4.4 p27 staining 
Activation of the RAS in our study led to a reduction in p27 nuclear staining but an 
increase in cytoplasmic staining. There are reports in the literature of downregulation of 
p27 in rat adrenals treated with ACTH or other N-terminal POMC derived peptides 
(Kobayashi et al., 2006; de Mendonca et al., 2013). Kobayashi et al showed a transient 
inhibition of p27 expression within the whole adrenal by western blot assay of the protein, 






but representative figures of p27 immunohistochemistry in their paper clearly 
demonstrate increased cytoplasmic staining in the ZG of rats treated with ACTH and N-
POC 1-29. Interestingly, chronic ACTH treatment led first to a reduction in p27 and later 
an increase in the Kobayashi et al study, measured at time points up to 8 days. 
 
The p27 -/- mouse has medullary hyperplasia, consistent with the high expression of p27 
in this region, but no reported cortical defects (Nakayama et al., 1996). These mice 
develop adenomas of the intermediate lobe of the pituitary gland, and a novel human 
multiple endocrine neoplasia syndrome - MEN4 - has been described in which there are 
heterozygous mutations in p27  (Marinoni & Pellegata, 2011). The tumour suppressor 
role of p27 suggested by this phenotype is supported by the low amounts of p27 found in 
a number of human malignancies, including breast, colon, prostate and lung cancer. It is 
associated - like p57 - with an increase in tumour aggressiveness (Besson et al., 2008)  
 
Other malignancies show mislocalisation of p27 to the cytoplasm: this occurs in up to 
40% of breast cancer (Viglietto et al., 2002); it is also a negative prognostic factor in these 
cancers (Tanaka, T. & Iino, M., 2014). Additionally, whereas the p27-/- mouse develops 
only pituitary tumours, the p27CK- mouse which contains a mutant protein that lacks the 
ability to interact with CDKs and cyclins,  develops hyperplasia and tumours of multiple 
organs (Besson et al., 2007). Lung tumours in this model arise from a population of 
bronchoalveolar stem cells, supporting the hypothesis that p27 is a stem cell marker. This 
is supported by the observation that both p27 and p57 have a role in maintaining 
quiescence in haematopoietic stem cells (Zou et al., 2011). Interestingly, in this tissue a 
deficiency of p57 leads to up regulation of p27, suggesting a degree of redundancy in the 
system which was also proposed by Bilodeau et al in the mouse pituitary (Bilodeau et al., 
2009). 
3.4.5 Cell migration 
The effect of cytoplasmic p27 in malignancy, and behaviour of the p27CK- mouse suggests 
an oncogenic effect of p27 in addition to its tumour suppressor role. This may lie in its 
role in modulation of cell migration. p27 promotes the migration of metastatic 
hepatocellular carcinoma cells in vitro, via a reduction in the activity of the RhoA GTPase 
(Nagahara et al., 1998; Wang, X. Q. et al., 2008). The Rho GTPases are a group of 






proteins(Ridley, 2013). They are well known for their roles in cell migration, though 
effects on actin and microtubule dynamics, adhesion between individual cells and 
between cells and the extracellular matrix (ECM) (Parsons et al., 2010). RhoA-GTP 
activates Rho-kinases ROCK1 and ROCK2; inhibition of this pathway by p27 leads to a 
decrease in focal adhesions, leading to an increase in cell motility (Larrea et al., 2009).  
 
Regulation of RhoA by p27 is critical for proper migration of neural progenitor 
cells(Nguyen et al., 2006), while cytoplasmic p27 is required for in vivo infiltration of 
macrophages into tumours in mice(Gui et al., 2014). Although most of the p27 effects on 
cell migration are to encourage it, this seems to be dependent on the precise cellular 
context. Progesterone inhibits the migration of rat aorta smooth muscle cells by 
upregulating p27, while estradiol reduces p27 and enhances proliferation and migration 
of vascular endothelial cells (Wang, H.-C. & Lee, 2014; Oviedo et al., 2011). This may 
reflect the particular mode of migration - cells lacking in p27 have been shown to migrate 
in an amoeboid fashion rather than a mesenchymal one (Belletti et al., 2010). The effect 
of p27 on cellular migration is modulated by protein phosphorylation at various sites. For 
instance, phosphorylation at Ser10 target it for export to the cytoplasm, while binding to 
RhoA is facilitated by phosphorylation at Thr198 (Larrea et al., 2009). 
3.4.6 Stem cells and migration 
We observed that RAS activation reduced nuclear immunostaining for p27 in the ZG, but 
increased cytoplasmic staining. On the basis of these results, a model can be proposed 
that under conditions of RAS activation there is down regulation of nuclear p27 and p57 
in the ZG, allowing progenitor cells to proliferate and differentiate into steroidogenic 
cells. Downregulation of p27 and p57 allows the cyclin E-cdk2 complex to phosphorylate 
p27, enabling its translocation to the cytoplasm (Sheaff et al., 1997). An accumulation of 
cytoplasmic p27 provides a mechanism whereby cell migration may be induced, mediated 
by the inhibition of the RhoA GTPase.  
3.4.7 Further Experiments 
Optimisation of immunostaining for CYP11B2 is essential to further elucidate the 
mechanisms by which alterations in p27 and p57 are involved in mediating the effects of 
RAS activation. The change in nuclear staining of p27 and p57 is grossly similar, but 






cortex, whereas p57 is expressed throughout the ZG. Characterising these cells in more 
detail will require double immunostaining with B2. Double immunostaining is more 
straightforward using immunofluorescence, although this technique can be less successful 
in FFPE sections due to background fluorescence induced by the fixation process. For each 
rat the contralateral adrenal gland was harvested in liquid nitrogen and can therefore be 
used for immunofluorescent staining. The assertion that downregulation of p57 is 
enabling proliferation must also be tested with dual immuno-staining of p57 and Ki67 – 
if cells are both p57 and Ki67 positive then this would have to be rejected or at least 
substantially modified. Similar dual staining for p27 and Ki67 is also necessary for the 
same reasons. 
 
Determining the specific time points and locations at which p27 and p57 are expressed 
during differentiation could be effectively studied using a lineage tracing approach. King 
et al defined the Shh lineage (ZU) and Gli1 lineage (inner capsule) using the cre driver 
alleles Shh-creT2 and Gli-creT2, showing that the Gli1 expressing cells are the progenitors 
of steroidogenic cells (King, P. et al., 2009). Following the expression of p27 and p57 in 
both of these models following tamoxifen treatment would help to identify if they have 
separate roles in this process. Performing the immunostaining at multiple shorter intervals 
would also be informative however, although activation of the RAS system using a low 
sodium diet would be unsuitable. Infusion of rats with angiotensin II subcutaneously via 
osmotic minipump (Ruiz-Ortega et al., 2001) and performing the same immunostaining 
over a period of 24-48 hours may be a more appropriate method. 
 
The mechanism by which cytoplasmic p27 is proposed to enable cell migration of newly 
differentiating cells can be further investigated by immunostaining for the phosphorylated 
forms of p27 which localise it to the cytoplasm, and immunostaining for RhoA-GTPase, 
which would be expected to be downregulated in RAS activation. Expression of p27 and 
p57 in dispersed rat adrenal cells treated with ACTH or AngII could be performed by 
quantitative PCR or western blot for the protein. Cell migration assays in such an in vitro 
system are unlikely to be particularly informative, although cells lacking p27 tend to have 
a more amoeboid mode of migration, which is the most straightforward to investigate in 
vitro. It would also be instructive to observe the response of the p27-/- mouse adrenal to 






in p57, and to see whether p57 behaves more like p27 in this model, given suggestions 
that there is some degree of redundancy between them. 
 
3.4.8 Conclusion 
These experiments have demonstrated RAS activation leading to the histological 
appearance of ZG expansion in the rat adrenal as defined by H+E staining, with Ki67 
immunostaining showing early subcapsular proliferation, and later proliferation at the 
ZG/ZF interface. Nuclear expression of the cyclin-dependent kinase inhibitors p27kip1 
and p57kip2 is suppressed when the RAS system is activated, and upregulated in slightly 
different locations when it is inhibited, suggesting that there may be some overlap in their 
functions. Cytoplasmic p27 expression is increased by RAS activation, and this is known 
to have a role in enabling cell migration in other systems, and so may be involved in 








Chapter 4 A case of ACTH-independent 
Cushing’s syndrome 
4.1 Aims 
This chapter describes the case of a patient with ACTH-independent Cushing’s syndrome 
and a gastro-intestinal stromal tumour (GIST). It aims to demonstrate that the GIST is 
directly responsible for stimulation of cortisol production from the adrenals. 
4.2 Introduction 
Cushing’s syndrome is the result of chronic overexposure to glucocorticoid, either from 
oral, topical or inhaled corticosteroid, or endogenous overproduction of cortisol from the 
adrenal gland. Endogenous Cushing’s syndrome is most commonly ACTH-dependent. 
When it is the result of dysregulated secretion of ACTH from a corticotroph tumour of the 
pituitary gland it is termed Cushing’s disease. 
 
The ectopic ACTH syndrome (EAS) represents 20% of ACTH dependent Cushing’s 
syndrome(Newell-Price et al., 2006). Neuroendocrine tumours secreting ACTH are most 
commonly found in the lung (bronchial carcinoids, small cell lung cancer) or the GI tract 
and pancreas. Phaeochromocytomas and medullary cell thyroid cancers also make a 
significant contribution, but in up to 38% of cases no tumour is identified (Alexandraki & 
Grossman, 2010). Ectopic secretion of CRH from  neuroendocrine tumours is well 
recognised but extremely rare, and may occur with co-secretion of ACTH (Carey et al., 
1984). A host of non-neuroendocrine tumours including breast cancer and melanoma 
have been identified in isolated case-reports as the source of ectopic ACTH secretion, 
leading Alexandraki et al to conclude that almost any tumour may be associated with EAS 
(Alexandraki & Grossman, 2010). 
 
Around 20-30% of Cushing’s syndrome is ACTH-independent (Lacroix et al., 2015). This 
is usually the result of a single cortisol-producing adrenal adenoma, but may be due to 
bilateral adrenal hyperplasia. ACTH-independent macronodular adrenal hyperplasia 
(AIMAH) may be caused by ectopic expression of G-protein linked receptors for ligands 






mutation in the armadillo containing repeat 5 gene (Assie et al., 2013). Primary 
pigmented nodular adrenal disease (PPNAD) is a form of ACTH-independent Cushing’s 
usually diagnosed in childhood, and most often as part of the Carney complex. It is the 
result of inactivating mutations of the regulatory subunit type 1a of PKA (PRKAR1A) 
(Kirschner et al., 2000), or in the phosphodiesterase enzymes PDE11A or PDE8B 
(Horvath, A. et al., 2006), leading to up regulation of PKA mediated signalling pathways 
downstream of the MC2R. 
 
Gastrointestinal stromal tumours are mesenchymal tumours of the GI tract which are 
believed to arise from the gut’s pacemaker cells - the interstitial cells of Cajal (Corless et 
al., 2004). Sporadically occurring GISTs are characterised by activating mutations in KIT, 
PDGFRA or BRAF (Yang et al., 2008), while there are a host of multiple tumour 
syndromes which have GISTs as a major feature (Burgoyne et al., 2014). Of these 
syndromes, a number include synchronous or metachronous endocrine tumours, but the 
capacity for endocrine function in GISTs themselves is restricted to case reports of 
paraneoplastic hypoglycemia from IGF-II production (Beckers et al., 2003) and in vitro 
studies which identified some molecular characteristics which GISTs share with endocrine 
tissues (Ekeblad et al., 2006; Bumming et al., 2007).  
 
4.3 Case History 
4.3.1 Clinical Assessment 
A 51-year-old lady with severe hypertension developed proximal myopathy with atrophic 
and hyperpigmented skin, and weight gain of 15kg over a 9-month period. She had 
suffered from a low impact fracture of the third metatarsal in the previous year which 
was managed conservatively, but prompted an assessment of bone density, and a 
subsequent diagnosis of osteoporosis. Her past medical history was remarkable for a 
bilateral oophorectomy 2 years previously. There was no family history of any endocrine 
disease. She had smoked 20 cigarettes daily for 30 years, but had stopped a year before. 
 
She had achieved reasonable control of her blood pressure with spironolactone 25mg 






preparation to prevent vasomotor symptoms of the menopause, and once weekly 
alendronic acid for osteoporosis. 
 
On clinical examination she was profoundly cushingoid (Figure 4.1), with a body mass 
index of 37kg/m2. Blood pressure was 120/75 mmHg with no postural drop. She had 
developed a tanned appearance over her face and the sun-exposed areas of her upper 
chest; she was red-haired and had never previously tanned in this way. A diagnosis of 
Cushing’s syndrome was suspected based on these clinical findings.  
 
Figure 4.1 Clinical Photography 
Typical appearances of Cushing’s syndrome are apparent with centripetal obesity, midscapular fat 
pad and muscle wasting of the arms and legs. The patient is profoundly pigmented in her face and 
upper chest. 
 
Routine haematological tests revealed evidence of an iron deficiency anaemia: Hb 11.1 
g/dl (10.9-14.5), MCV 79.9fl (83-98), serum iron 5μmol/l (9-30). Screening endocrine 
biochemistry results are demonstrated in tables 4.1-4.2. Further biochemical assessment 
demonstrated complete loss of circadian rhythm of cortisol secretion and failure of 
suppression of cortisol during a standard low dose dexamethasone suppression test 
(LDDST) (2mg/day for 48 hours; cortisol levels 761nmol at baseline, 771 nmol/l at 48h. 
(Table 4.3, 4.4)). Levels of adrenocorticotrophic hormone (ACTH) were consistently 






or a mixed meal tolerance test (Tables 4.5, 4.6). A CRH test demonstrated no change in 
serum cortisol or ACTH (Table 4.7). Fasting gut peptide levels were within normal limits 
(Table 4.8) 
 
Table 4.2 - Endocrine Biochemistry
Reference Range
Cortisol 770 200-600 nmol/l
Androstenedione 9.9 2.0-5.4 nmol/l
DHEA 8.5 1.6-7.8 nmol/l
Testosterone 1.4 < 3.0 nmol/l
ACTH < 5 <50 ng/
free T4 13.4 10.5-24.5 pmol/l
TSH 0.44 0.3-4.0 mU/l
LH < 0.3 4-14 U/l
FSH 2.8 1.5-8 U/l
Oestradiol 244 250-1000 pmol/l
Prolactin 423 < 496 mU/l
Table 4.3 - Cortisol Day Curve
Time ACTH ng/l Cortisol nmol/l
900 < 5 681










Table 4.7 - CRH test










Table 4.5 - Octreotide Test










Table 4.8 - Fasting gut peptides
Time 0h Time 4h Reference Range
Chromogranin A 50 44 < 60 pmol/l
Chromogranin B 77 79 < 150 pmol/l
Gastrin 150 125 < 40 pmol/l
Glucagon 17 6 < 50 pmol/l
Pancreatic 
polypeptide
42 15 < 300 pmol/l
Somatostatin 32 50 < 150 pmol/l
VIP 5 6 < 30 pmol/l
Table 4.6 - Mixed Meal Test








Table 4.1 - Biochemistry
Sodium 141 135-145 mmol/l
Potassium 4.3 3.5-5.1 mmol/l
Chloride 104 98-106 mmol/l
Bicarbonate 31 22-29 mmol/l
Urea 6.8 2.5-6.4 mmol/l
Creatinine 64 44-80 μmol/l
Bilirubin 4 1-17 μmol/l
ALT 34 7-35 IU/l
ALP 63 35-104 IU/l
Protein 62 60-83 g/l
Albumin 37 35-50 g/l
Corr Calcium 2.39 2.15-2.65 mmol/l
Phosphate 1.14 0.8-1.5 mmol/l
Magnesium 0.86 0.7-1.0 mmol/l
Table 4.9 - Hydrocortisone Day Curve          
(2 years post op)


















Dual emission X-ray absorptiometry (DEXA) confirmed reduced bone mineral density 
(BMD) at the lumbar spine and femoral neck (T scores -2.2 and -1.4 respectively; 
measured in SD from the mean BMD in a healthy population) 
 
Cross-sectional imaging revealed bilateral nodular enlargement of the adrenal glands 
(right 5.5 x 4.9cm; left 1.7 x 3cm plus smaller nodules). The right gland contained areas 
of high and low density, with contrast washout of 73%. The nodules on the left all 
measured less than 10HU pre-contrast, in keeping with lipid-rich adenomata. In addition 
to these, there was a 4.1cm mass lesion consistent with a gastrointestinal stromal tumour 
(GIST), arising exophytically from the greater curvature of the stomach (Figure 4.2).   
 
 
Figure 4.2 Non-contrast CT scan of the abdomen 
Coronal unenhanced CT scans of the abdomen show an exophytic lesion (G) arising from the 
stomach in the upper panel, consistent with a GIST. Bilateral macronodular adrenal hyperplasia is 
seen in the lower panel (arrows), larger on the right than the left. 
 
A hypothesis was formed that the GIST was secreting some factor with the capacity for 
stimulating adrenal growth and cortisol secretion. For this reason, and although there 
was no previous evidence in the literature for GIST hormone secretion leading to 
Cushing’s syndrome, consideration was given to performing a surgical procedure to 






concern at the possibility of malignancy, so a final surgical decision was taken to remove 
the GIST and the right adrenal in a combined procedure. Surgery was carried out after 
several weeks of treatment with oral metyrapone. The pathological specimens are shown 
in figure 4.3.   
 
Figure 4.3 Surgical specimens of right adrenal gland and GIST 
4.3.2 Histological Examination 
The right adrenal gland weighed 36.5g and measured 48 x 43 x 25mm, with multiple 
pigmented nodules, the largest of which of 21 x 15 x 34mm. On microscopy the glad 
contained poorly defined nodules of densely packed large cells with eosinophilic 
cytoplasm and markedly pleomorphic nuclei with prominent nucleoli (Fig 4.4). Most of 
the large cells contained pigment. No mitotic figures were seen in 50 high power fields 
which were examined. The nodules themselves were unencapsulated, and contained 
adipose tissue and scattered lymphoid aggregates. The degree of pigmentation led to a 
concern from the examining pathologist that primary pigmented nodular adrenal disease 
(PPNAD) ought to be excluded, with the caveat that it would be rare in this age group. 
As described in more detail in Chapter 5, PPNAD is characterised by a pigmented and 
micro-nodular adrenal, with Cushing's syndrome usually developing in childhood 
(Horvath, A. & Stratakis, 2007)  - neither the histological appearance of the adrenal, nor 
the clinical history would be in keeping with this disease. 
 
The gastric tumour measured 45 x 49 x 30mm with a thin fibrous stalk of 5mm in length. 
Extensive sampling demonstrated the lesion to be moderately cellular and composes of 
sheets of epithelioid cells with round vesicular nuclei, inconspicuous basophilic nucleoli 
and moderate amounts of eosinophilic cytoplasm. The lesion was fairly vascular with 
some areas of haemorrhagic infarction. There was a mild, patchy lymphocytic infiltrate 
and mitotic figures at 2 per 50 high power fields. Immunohistochemistry demonstrated 






and membrane positivity for CD-117 (c-kit) (Figure 4.4). Tumour cells were negative for 
CD34, desmin, smooth-muscle actin (SMA), S100 and AE1/3. The Ki67 proliferative 
index was 15%. The overall morphological and immunohistochemical profile of the 
tumour confirmed its identity as a GIST. Of particular note, immunostaining for ACTH 
was negative. The GIST was classified as “Low Risk” according to the National Institute 
for Health (NIH) classification. 
 
 
Figure 4.4. Histological specimens of adrenal gland and GIST. 
The adrenal gland contained multiple large nodules with a pleomorphic appearance, and heavy 






the gastric tumour was a GIST. The Ki67 proliferation index was 15% but the GIST was classed as 
low risk according to NIH criteria. Staining was carried out according to methods (Section 2.5) 
4.3.3 Clinical outcome 
Post-operatively, 9am serum cortisol was 49 nmol/l and she commenced oral 
hydrocortisone replacement. She remains in remission from Cushing’s syndrome three 
years on from surgery, still dependent on supplementary hydrocortisone. Surveillance 
imaging of the abdomen has demonstrated a slight reduction in the size of the remaining 
left adrenal gland (Figure 4.5). There has been no recurrence of the GIST and no use of 
chemotherapy or radiotherapy.  
 
Interestingly, the patient developed a seronegative arthropathy in the first year following 
her surgery, and required high dose glucocorticoid treatment. When stabilised on 
methotrexate, her prednisolone dose was weaned down and she was switched to oral 
hydrocortisone, 10mg on waking and 5 mg early afternoon. A hydrocortisone day curve 
was performed 2 years after surgery (Table 4.9) and demonstrates low baseline ACTH 
levels, and a low pre-dose cortisol level of 95nmol/l. She remains on oral hydrocortisone 
at the time of writing, although this has been reduced to 5mg twice daily.  
 







Figure 4.5. Pre and post-op portal venous phase CT images of the abdomen 
Re-imaging of the left adrenal gland 3 years post-operatively demonstrated a reduction in size. 
Upper and lower panels show equivalent slices. Left adrenal size: Upper images 1.397 x 1.687cm 
to 1.020 x 1.559 cm; lower images: 1.384 x 2.017cm to 1.278 x 1.835cm. 
4.3.4 Negative control GIST 
A GIST was acquired from a 72-year-old man with no significant past medical history, 
and no clinical or biochemical evidence of Cushing’s syndrome. The tumour in this case 
was also taken from the stomach wall, and measured 35 x 12 x 25mm. It had a more 
variable appearance on microscopy, with some areas composed of spindle cells arranged 
in fascicles, and more epithelioid cells in others. Immunohistochemistry showed positive 
staining for CD117, DOG-1 and CD34, with negative staining for S100 and desmin (Figure 









Figure 4.6. Immunohistochemical images of negative control GIST 
A GIST from a patient with no clinical or biochemical evidence of Cushing’s syndrome was used as 
a negative control. H+E staining demonstrates spindle cells arranged in fascicles. Immunostaining 
was carried out with antibodies against CD117 (1:1000) and DOG-1 (1:300) according to methods 
laid out in Section 2.5, Table 2.1. Immunostaining was positive for both antibodies, confirming 
that this tumour was a GIST 
4.4 Experimental Results 
4.4.1 GIST expresses a somatic mutation in PDGFRA 
Sanger sequencing of genomic DNA from the GIST tumour revealed a previously reported 
heterozygous PDGFRA mutation c.2525A>T (pAsp842Val) that was not present in 
leucocyte DNA (Figure 4.7).  No mutations were detected in KIT, BRAF or SDHB. The 
majority of GIST mutations are heterozygous, and pAsp842Val is the most common 
mutation in GISTs which do not have a KIT mutation (Xu, C.-W. et al., 2015). Further 
confirmation of the lack of SDHB mutation was provided by a normal pattern of SHDB 
immunohistochemical staining (Figure 4.7). 
 
Sequencing of genomic DNA from the patient’s leucocytes and the excised right adrenal 








Figure 4.7 GIST carries PDGFRA mutation pAsp842Val 
Sanger sequencing electropherogram on the left shows a heterozygous PDGFRA mutation 
c.2525A>T (pAsp842Val) that was not present in leucocyte DNA. On the left normal SDH-B 
staining is demonstrated, effectively ruling out a mutation in any of the SDH chain enzymes A-D. 
4.4.2 Supernatant from GIST primary culture stimulates cortisol release in 
vitro 
Primary cultures were successfully established from the GIST tumour of the patient with 
Cushing’s syndrome (GC) and patient without Cushing’s syndrome (NC). Both cultures 
demonstrated positive immunocytochemical staining with the GIST markers CD117 and 







Figure 4.8 Immunocytochemistry of cultured GIST cells 
Cultured GIST cells were trypsinised and resuspended, then centrifuged at 800rpm for 5 minutes 
to deposit them on to standard glass slides for immunostaining. Immunochemistry was carried out 
according to methods laid out in section 2.6.3. Cells from both GIST primary cultures stained 
positively for the GIST markers CD117 and DOG-1. 
 
Supernatant from each primary culture was assayed and found to contain no significant 
trace of cortisol or ACTH. Supernatant from the GIST culture (GCM) induced a significant 
elevation in cortisol production from H295R cells (Figure 4.9 panel A). There was no 
significant elevation in cortisol when cells were incubated with supernatant from the 
negative control GIST culture (NCM). This rise was prevented by co-incubation with the 
PKA pathway inhibitor H89, and by pre-heating the media to 65ºC to denature protein 
(Figure 4.9 A). Culture supernatant from the first GIST passages led to cortisol production 
in excess of that produced by the adenylyl cyclase activator forskolin. This effect fell with 
later passages as can be seen in figure 4.19 (Panel A): supernatant from the third passage 
of GIST primary culture causes less H295R cortisol production than forskolin, whereas 
supernatant from the first passage (Figure 4.9 Panel A) causes more cortisol production 
than forskolin. 
 
In addition to H295R cells, dispersed rat adrenal cells were also incubated with 
supernatants from both GIST cultures. These cells are not capable of producing cortisol, 









Figure 4.9 GIST-supernatant induced cortisol and corticosterone secretion 
(A) H295R cells were incubated overnight with GIST culture medium (GCM), then media 
removed and assayed for cortisol. GCM induced a rise in cortisol secretion that was 
significantly greater than the positive control treatment with the cAMP signalling activator 
forskolin. This rise was abolished by co-incubation with the PKA pathway inhibitor H89, 
or by pre-heating the media to denature protein. Conditioned media from the negative 
control GIST (NCM) did not stimulate cortisol secretion.  
(B) Dispersed rat adrenal cells were incubated overnight with GCM and NCM as above, and 
media analysed for corticosterone production by ELISA. GCM induced a statistically 
significant rise in corticosterone secretion above control. All experiments performed in 
triplicate. ** p< 0.01; *p< 0.05 
 
Quantitative-PCR analysis of RNA extracted from H295R cells incubated with GIST 
culture supernatant demonstrated increased expression of the steroidogenic pathway 
components SF-1 and StAR. (Figure 4.10). 
 
 
Figure 4.10 GCM upregulates the steroidogenic enzymes StAR and SCC 
cDNA was harvested from H295R cells following an overnight incubation with GIST-conditioned 
medium (GCM), and demonstrated increased expression of steroidogenic acute regulatory protein 
(StAR) and side chain cleavage enzyme (SCC) by quantitative RT-PCR. There was no such increase 






4.4.3 GIST culture supernatant does not interfere with the ACTH assay. 
The absence of ACTH on electro-chemiluminescent assay of GIST culture supernatant, 
and from patient GC’s serum, was considered to be the possible consequence of a factor 
which was interfering with the assay. A serum sample of ACTH taken from a patient with 
Addison’s disease prior to their morning dose of oral hydrocortisone was used as a 
possible control. The addition of GC supernatant in various proportions made no 
significant difference to the reported ACTH content of this serum sample (Figure 4.11) 
 
 
Figure 4.11 Gist culture supernatant does not interfere with the ACTH assay 
Serum from a patient with Addison’s disease was used as a positive control for the ACTH assay, 
and diluted with various proportions of Gist culture supernatant (GCM, NCM), standard culture 
media or PBS. There was no difference in ACTH levels between these samples. GCM pass 1 and 5 
refer to supernatant taken from the first and fifth passages of this primary culture. STM – standard 
GIST culture medium (see methods section 2.1.1 for constituents). 
4.4.4 GIST expresses POMC and enzymes required for POMC processing 
The possibility that a peptide other than ACTH derived from POMC was responsible for 
the stimulation of cortisol production in vivo and in vitro was considered. RT-PCR 
confirmed expression of POMC, along with the enzymes PC1/3 and PC2 which catalyse 
the processing of POMC into smaller peptides (Figure 4.12). POMC primers were 
designed to exon 3 of POMC, which limits the significance of this PCR result however as 
this would be positive whether transcription was being initiated at the pituitary promoter 
or the downstream “peripheral” promotor. As described in section 1.6.3, initiation of 






800nt, which lacks the signal sequence for targeting to the endoplasmic reticulum and 
therefore secretion of the translated peptide. Primers were designed to span intron B 
(Figure 4.12 C) and were used to demonstrate expression in pituitary tissue and GIST, 
but this was an inconsistent result and could not be repeated even in the positive control.  
 
 
Figure 4.12 GIST expresses POMC and the processing enzymes PC1/3 and PC2 
RT-PCR demonstrated POMC expression (A), along with the proteolytic enzymes PC1/3 and PC2 
(B) required for processing it to constituent peptides. Panel C shows the primer binding sites on 
POMC 
4.4.5 The presence of alpha-MSH in the GIST tumour is demonstrated by 
immunohistochemistry 
Immunostaining was carried out with antibodies directed against a series of POMC-
derived peptides (N-POC 1-29, N-POC 1-49, γ1-MSH, γ-3 MSH, N-terminal ACTH, Mid 
ACTH, C-terminal ACTH, N-terminal α-MSH, C-terminal α-MSH) (Figure 4.13). Positive 
control tissues were human pituitary corticotroph adenoma (supplied by the Core 
Pathology Department, Blizard Institure, QMUL) and an ACTH-secreting lung carcinoid 






control normal bronchial tissue from the same patient was used. All 9 antibodies exhibited 
positive immunostaining against the positive controls and negative immunostaining to 
normal bronchiole (Figures 4.14 and 4.15). 
 
There was no immunostaining of the GC GIST for the N-terminal peptides (Figure 4.16), 
or for unprocessed ACTH (Figure 4.17). However, almost all cells of the GC GIST 
immunostained positively using antibodies directed against the acetylated N-terminus 
and the amidated C-terminus of alpha-MSH (Figure 4.17). There was no immunostaining 
of the control GIST using any of the POMC antibodies. 
 
Figure 4.13 Antibody binding sites for POMC peptide immunostaining.  
Anti-N-term α-MSH binds only to the acetylated N-terminus of the peptide and not to the N-
terminus of ACTH, while Anti-C-term α-MSH binds to the amidated C-terminus, and not to the 








Figure 4.14 N-terminal POMC peptide antibody immunostaining – positive and negative controls. 
Immunostaining of 3μm sections of human pituitary adenoma and an ACTH-secreting lung 
carcinoid were carried out according to methods in section 2.6.1. Antibodies were directed at 
peptides produced from the N-terminal end of POMC (see figure 4.13 for antibody binding sites). 
Positive immunostaining is demonstrated for all 4 antibodies. A section of bronchiole from normal 









Figure 4.15 ACTH and alpha-MSH immunostaining – positive and negative controls. 
Immunostaining of 3μm sections of human pituitary adenoma and an ACTH-secreting lung 
carcinoid were carried out according to methods in section 2.6.1. Three antibodies directed against 
unprocessed ACTH and 2 antibodies directed against alpha-MSH (see figure 4.13) all showed 
positive immunostaining for human pituitary adenoma and ACTH-secreting lung carcinoid. There 








Figures 4.14 and 4.15 
3μm sections of GIST were immunostained according to the method described in section 2.6, table 
2.1. Antibody concentrations were as follows: N-POC 1-28 1:2000; N-POC 1-49 1:2000;  γ1-MSH 
1:2000; γ3-MSH 1:1250; C-term ACTH 1:2000; mid-ACTH 1:1250; N-term ACTH 1:2000; 
acetylated N-terminus of α-MSH 1:1250; amidated C-terminus α-MSH 1:2000. Positive control for 
all POMC-peptide immunostaining was a section of human pituitary adenoma (tissue provided by 
Core Pathology Dept, Blizard Institute, Queen Mary, University of London). Negative control tissue 
was a GIST from a patient with no evidence of clinical or biochemical Cushing’s syndrome. Figure 
4.14 demonstrates negative GIST immunostaining for N-terminal POMC peptides. Figure 4.15 
demonstrates positive immunostaining for acetylated N-term α-MSH and amidated C-term α-MSH, 
but negative immunostaining for the three antibodies directed against unprocessed ACTH (N-term 























4.4.6 POMC expression in GIST is not the result of altered methylation status 
of the POMC promoter 
Bisulphite modification of genomic DNA following by pyrosequencing was performed to 
assess the degree of CpG methylation of a portion of the pituitary POMC promoter -417 
to -260 upstream of the transcription initiation site of exon 1. Three CpG sites reported 
to be hypomethylated in ACTH-secreting tissues were analysed (Figure 4.15, upper 
panels) (Ye et al., 2005). Genomic DNA extracted from a corticotroph pituitary adenoma 
and ACTH-secreting carcinoid tumour demonstrated low levels of methylation at these 
sites, compared with a non-ACTH secreting carcinoid tumour and both GIST tumours 
(Figure 4.15, lower panel). 
 
 
Figure 4.18 The pituitary POMC promoter in GIST tissue is not hypomethylated 
The methylation status of the POMC pituitary promotor was assessed by a pyrosequencing method. 
This region is hypomethylated in pituitary corticotroph cells and in ACTH-secreting 
neuroendocrine tumours. Genomic DNA was extracted from tissue which was known to secrete 
ACTH (a pituitary corticotroph adenoma and an ACTH-secreting lung carcinoid tumour), as well 
as a non-ACTH secreting carcinoid tumour, the Cushing’s associated GIST, and a GIST tumour 
taken from a patient with no clinical or biochemical evidence of Cushing’s syndrome. Bisulphite 
modification and pyrosequencing of a 157bp region which contains three hypomethylated CpG 
sites in ACTH-secreting tissues (Position 1-3). The percentage of methylation in the GIST tumour 






4.4.7 Alpha-MSH is present in GIST culture supernatant 
GIST primary culture supernatant was assayed for alpha-MSH using enzyme-linked 
immunoassay and two-site sandwich ELISA.  Both methods confirmed the presence of 
alpha-MSH in GIST culture supernatant, but not in standard media or control GIST 
supernatant (Figure 4.16). 
 
 
Figure 4.19 GIST culture supernatant contains α-MSH 
GIST culture supernatant was assayed for α-MSH using two methods: an enzyme linked 
immunoassay and a sandwich ELISA (see methods section 2.3.4). α-MSH was detected by both 
methods. Later passages of GIST (p5, p9) demonstrated lower levels of α-MSH, which would be 
in keeping with their diminishing in vitro effect on cortisol secretion. (p<0.05). “Standard media” 
is fresh, unused GIST culture media (See methods section 2.1 for full constituents)  
 
4.4.8 Alpha-MSH stimulates the release of cortisol from human adrenal cells 
in vitro. 
The ability of alpha-MSH to stimulate cortisol production from H295R cells and dispersed 
human adrenal cells was assessed. Initial experiments using alpha-MSH (Sigma) failed to 
demonstrate any increase in cortisol production. A positive control for the biological 
activity of alpha-MSH was sought, namely the up-regulation of melanin production in the 
mouse melanoma cell line B16-F10. A melanin assay was performed as previously 
described. Alpha-MSH (Sigma) failed to generate an increase in melanin production, 








Figure 4.20. Alpha-MSH from one supplier failed to stimulate melanin production from mouse 
melanoma cells 
B16F10 mouse melanoma cells were stimulated overnight 1μM ACTH 1-39 or 1μM α-MSH in a 
DMEM plus 10% FBS. Cells were trypsinised, resuspended and pelleted, before resuspension in 
1ml 1N NaOH. Absorbance was measured at 420nm and melanin concentration was determined 
with reference to a standard curve of synthetic melanin in the range 1-100μg/l, and corrected for 
the protein content of the cell lysate. Panel A shows that α-MSH purchased from Sigma did not 
stimulate melanin production, but α-MSH purchased from Phoenic Pharmaceuticals did result in 
melanin production equivalent to ACTH stimulation. Experiments in triplicate, p<0.05. 
 
A second supplier of synthetic alpha-MSH was sourced - Phoenix Pharmaceuticals. 
Contrary to the Sigma-supplied peptide, the specification sheet for the Phoenix peptide 
instructed that it should be used immediately on first making up a working solution, and 
not frozen. On following these instructions, the biological activity of the peptide was 
assessed using the melanin assay, and an increase in melanin production was 
demonstrated (Figure 4.17 B). Applying this second alpha-MSH peptide to dispersed 
human adrenal cells and H295R cells confirmed the ability of alpha-MSH to stimulate 








Figure 4.21 Alpha-MSH can stimulate cortisol production from H295R and human adrenal cells in 
primary culture 
H295R cells (A) and human adrenal cells in primary culture (B) were stimulated overnight with 
incubated with various concentrations of alpha-MSH and ACTH 1-39, and GIST culture 
supernatant from the third passage of the primary culture (GCM p3). Forskolin was used as a 
positive control for cAMP-mediated signalling. H295R cells (A) demonstrated a significant increase 
in cortisol production in response to forskolin, GCM, ACTH and α-MSH 10-4M. Primary culture of 
human adrenal cells also exhibited statistically significant increases in cortisol production when 
incubated with these Forskolin, ACTH, GCM and α-MSH 10-4M. There was a trend towards 
increasing cortisol production with increasing concentrations of α-MSH which did not become 
statistically significant until the highest 10-4M dose was reached. 
4.5 Discussion 
4.5.1 Clinical Assessment 
The patient described was clinically very severely Cushingoid, with hypertension, 
osteopenia and weight gain in a typical centripetal distribution, and her clinical 
photographs show a typical appearance. The osteopenia may have contributed to her low 
impact metatarsal fracture. The pigmented appearance had not gone unnoticed by the 
patient, who reported that friends had remarked on her tanned appearance, and that this 
was unusual for her as she had never previously had a suntan, rather she developed 
freckles.  
 
The a priori likelihood that any patient with Cushing’s syndrome has ACTH-dependent 
disease is high, with the majority of cases the result of a corticotroph adenoma of the 
pituitary. Skin pigmentation in the context of Cushing’s syndrome increases the clinical 
suspicion for the ectopic ACTH syndrome, where serum levels of ACTH can reach much 






secreting neuroendocrine tumours are secreting a wider variety of peptides with the 
ability to upregulate the tanning process may also contribute to this (Lowry, 2016). 
 
It was unexpected therefore that biochemical assessment demonstrated low levels of 
ACTH in the serum. Assessment of her cortisol axis confirmed the loss of circadian 
variation in cortisol secretion, with failure to suppress with LDDST. It is important to note 
that initial assessment of cortisol axis was performed while the patient continued to apply 
her transdermal oestrogen patch. Oral oestrogen therapy must be stopped 8 weeks in 
advance of cortisol assessment due to its effect of increasing the levels of cortisol binding 
globulin (CBG) - transdermal oestrogen is not subject to first pass metabolism in the liver 
and therefore does not have the same effect on CBG 
 
Radiological investigation demonstrated bilateral macronodular adrenal hyperplasia. A 
comprehensive biochemical assessment for ACTH-independent macronodular adrenal 
hyperplasia (AIMAH) has been recommended by Lacroix et al (Lacroix et al., 1999) on 
the basis that expression of a diverse range of non-mutated membrane bound receptors 
within the adrenal cortex is implicated in the regulation of steroidogenesis. Gastric 
inhibitory polypeptide (GIP) expression is one of the best recognised causes of AIMAH, 
and can be assessed by the response of cortisol to a mixed meal test. Treatment with 
somatostatin analogues has been used to treat this food-dependent Cushings. For these 
reasons both a mixed meal test and an octreotide test dose were given, but without any 
change in cortisol secretion. LH-receptor expression can be assessed by the response to 
GnRH administration, but our patient’s LH and FSH had been suppressed by exogenous 
oestrogen, so this test was not performed. Moving from a supine to upright posture can 
stimulate cortisol secretion when it is being controlled by expression of vasopressin 
receptors, the β-adrenergic receptor or the angiotensin receptor. Expression of the 5-HT4 
receptor causing Cushing’s can be assessed by the response to the 5HT-4 agonist 
metoclopramide. These tests were not performed in this case. A CRH test was performed, 
but there were no changes in ACTH or cortisol in response to its administration. 
 
A failure to fully investigate for all possible mechanisms of AIMAH can be at least partly 
explained by the radiological appearance of the adrenal glands in this case. The large size 
of the right adrenal gland, and the slight heterogeneity noted on CT raised the possibility 






uncommon for the adrenal enlargement in AIMAH to be asymmetrical, as in this case 
(Swain et al., 1998). This can sometimes lead to an erroneous diagnosis of unilateral 
adrenal pathology. On the other hand, unilateral adrenalectomy has been recommended 
in selected patients as a treatment for both AIMAH and PPNAD (Xu, Y. et al., 2013). 
 
The possibility that the GIST could be secreting some agent which was stimulating the 
adrenal gland was considered. There are isolated reports of GISTs secreting IGF-II and 
leading to clinical hypoglycemia, and in vitro studies demonstrating expression of 
receptors for somatostatin, bombesin, cholecystokinin and vasoactive intestinal peptide 
(Reubi et al., 2004). In addition there is evidence of a neuroendocrine phenotype in the 
expression of synaptic vesicle proteins including synaptobrevin, synapsin 1 and 
amphiphysin (Bumming et al., 2007), while a large proportion of GISTs have been shown 
to express ghrelin (Ekeblad et al., 2006). There have been no reports in the literature of 
GISTs causing Cushing’s syndrome, or any other endocrine disease. However, the absence 
of an obvious genetic syndrome to link GIST and AIMAH either in the literature, or from 
clinical examination, suggested a possible link at some level, and it was hypothesised that 
this could be related to hormone secretion from the GIST. From a theoretical perspective, 
removal of the GIST alone would have been correct operation to test this hypothesis, but 
as described, concerns about the size of the right adrenal led to a compromised decision. 
 
As described, GIST tumours are characterised by mutations in the KIT oncogene (75-80%) 
or in the platelet derived growth factor A (PDGFRA; app 10%)(Lasota & Miettinen, 2008). 
Mutations of KIT and PDGFRA promote oncogenic signalling through the mitogen-
activated protein kinase (MAPK) and phosphoinositide (PI3K) pathways (Joensuu et al., 
2013). CD117 is an alternative name for KIT, and used as an immunohistochemical 
marker for GISTs. Staining for CD117 and DOG-1 confirmed that the gastric tumour was 
a GIST. DOG-1 is a chloride channel with a sensitivity of 94.7% in the identification of 
GISTs, and is now widely used alongside CD117 (Miettinen et al., 2009). 
 
The histopathology of the excised adrenal gland will be considered in detail in Chapter 5. 
It is worth noting here that a diagnosis of PPNAD was raised, although the patient was 
not in the typical age range for new onset of PPNAD, and the adrenals are usually small 
with micro nodules in this condition(Travis et al., 1989). However, this possibility was 







She was treated for a short period of approximately 4 weeks with metyrapone, with a 
marginal improvement in her cortisol burden, but immediately following the surgery to 
remove the GIST and the right adrenal gland, her cortisol levels dropped significantly. 
Her 9am cortisol 3 days’ post-surgery was not undetectable however, but this is likely to 
reflect replacement hydrocortisone from the previous day, rather than endogenous 
cortisol production. On the basis of this result, the possible mechanisms for her Cushing’s 
are as follows. 
 
• Secretion of some agent from the GIST which is stimulating cortisol secretion from 
the adrenal glands. Elevated cortisol secretion has suppressed pituitary ACTH 
secretion, so after removal of the GIST there is insufficient ACTH to stimulate 
cortisol secretion from the remaining left adrenal gland. 
 
• Cortisol secretion was due entirely to autonomous secretion from the larger right 
adrenal. Elevated serum cortisol would suppress pituitary ACTH, and therefore on 
removal of the right adrenal, there would again be insufficient ACTH to stimulate 
cortisol production from the left adrenal. One might expect the left adrenal to be 
atrophied rather than hyper plastic and nodular in this situation, however. 
Furthermore, the shrinkage in the size of the left adrenal in the three years 
following removal of the GIST suggests that it has lost some stimulus to its growth. 
 
• AIMAH with asymmetrical enlargement of the right adrenal gland, due to ectopic 
expression of one of the receptors described above. It may be expected that the 
left gland would continue to secrete cortisol following the removal of the right 
this instance, as the stimulus for cortisol production would still be present. 
However, chronic stimulus to the right adrenal could lead to it developing 
autonomous secretion as described above. 
 
The resolution of her pigmentation following surgery is difficult to explain on the basis of 
removal of the adrenal gland alone, without invoking some additional stimulus to 
pigmentation. However, it is worth noting that in cases of ACTH driven 
hyperpigmentation such as Nelson’s syndrome or Addison’s disease, the skin pigmentation 






areas. One might explain this by invoking the stimulus for skin pigmentation as being the 
sum total of melanocortin 1 receptor activation by ACTH or alpha-MSH plus the degree 
of UV exposure. UV light stimulates local MSH production, but also numerous 
keratinocyte derived factors such as NGF, endothelin-1 and bFGF, which are involved in 
the tanning response and synergise with the results of MC1R activation (Gilchrest et al., 
1996). This will be described in more detail in Chapter 5. As described, she had an MC1R 
polymorphism that is associated with reduced activity on ligand binding, but not zero 
activity. The proposed high serum levels of alpha-MSH, along with direct UV exposure 
can therefore be hypothesised to result in hyperpigmentation only in sun-exposed areas. 
 
This patient developed a seronegative arthritis following the resolution of her Cushing’s 
syndrome. The development of overt immune dysfunction is well described in the 
literature following treatment for both ACTH-dependent and ACTH-independent disease, 
with reports of patients developing conditions including sarcoidosis, psoriasis, and 
systemic lupus erythematosus (da Mota et al., 2011). This is generally defined as a 
rebound phenomenon in the absence of previously high cortisol levels. However, the 
direct anti-inflammatory actions of melanocortins is now a well-recognised phenomenon 
(Giuliani et al., 2010), and the consequences of removing a long term stimulus from 
ACTH, or perhaps alpha-MSH, may also be involved, and an interesting area for future 
work. The suppression of ACTH post-operatively as a result of prednisolone treatment 
makes it difficult to attribute the reduction in size of the left adrenal entirely to the 
removal of a putative adrenal growth stimulus from the GIST. 
4.5.2 Negative controls 
A comprehensive examination of the endocrine capabilities of GISTs would require much 
larger numbers of samples. The lack of previous reports of GISTs causing Cushing’s 
syndrome, and the relative rarity of these tumours locally led to the decision to use a GIST 
from one patient with no evidence of Cushing’s clinically or biochemically. A more 
suitable negative control GIST would have been one which shared an identical 







4.5.3 Sequencing and genetic syndromes 
The presence of a previously reported PDGFRA mutation (D842V) in tumour but not 
leucocyte DNA identifies this as a sporadic GIST, in common with most of these tumours. 
This mutation is by far the most common PDGFRA mutation, and is associated with a 
slight reduction in CD117 immunohistochemistry, and a more epithelioid morphology in 
the tumour, as was demonstrated in this case(Lasota et al., 2004). 
 
We also assessed for loss of function in the succinate dehydrogenase (SDH) complex, 
which is present in approximately 75% of gastric GISTs, especially in children and young 
adults (Janeway et al., 2011). Loss of any of the subunits is immunohistochemically 
observed through loss of SDHB expression, but mutations in all of the subunits has been 
described(Dubova et al., 2015). There was normal SDHB expression in this case. The 
familial syndromes of Carney’s triad (GIST, paraganglioma and pulmonary chondroma) 
and Carney-Stratakis syndrome (GIST and paraganglioma) are among the SDH-deficient 
GISTs. Neurofibromatosis type 1 is associated with GISTs but there was no clinical 
suspicion of this syndrome in this case (Andersson et al., 2005). A small set subset of 
GISTs harbour a BRAF mutation (V600E), but was not present in this case (Miettinen & 
Lasota, 2013). 
 
Sequencing was also carried out to look for common mutations associated with PPNAD. 
This condition is characterised by small to normal sized adrenals containing multiple 
black/brown nodules within atrophic surrounding cortex (Horvath, A. & Stratakis, 2007). 
It may occur independently, but 90% of cases are part of the Carney complex (CNC). This 
multiple tumour syndrome is associated with a variety of pigmented lesions, including a 
characteristic spotty skin pigmentation, melanotic schwannomas, and epithelioid blue 
nevus, in addition to cardiac myxomas and adrenocortical and pituitary adenomas 
(Carney et al., 1985).   
 
CNC and PPNAD are characterised by up-regulation of intracellular cAMP mediated 
protein kinase A signalling pathways. As previously discussed, this is the pathway that 
mediates the effects of melanocortin receptor binding. It is therefore apparent that excess 
cortisol production from the adrenal gland may be a consequence; a link to the possible 
mechanism for pigmentation will be discussed in Chapter 5. Mutations in the PKA 






signalling(Kirschner et al., 2000). Phosphodiesterase enzymes including PDE11A and 
PDE8B catalyse the hydrolysis of cAMP and cGTP and down-regulate the PKA pathway, 
and mutations in both of these have been demonstrated in CNC and PPNAD (Horvath, A. 
et al., 2006). 
 
PRKAR1A and PDE11A were sequenced in the adrenal and leucocyte DNA in this case and 
found to contain no mutations. PDE8B was not sequenced, but on the basis of clinical and 
histopathological behaviour a decision was taken that further sequencing was not 
indicated. 
 
A recent study identified mutations in the tumour suppressor gene ARMC5 in a substantial 
proportion of patients with AIMAH, with most having both a germline and somatic 
mutation (Assie et al., 2013). The function of ARMC5 is unknown at this point, but cases 
with mutations included those with ectopic expression of receptors as described 
previously. Sanger sequencing for mutations in ARMC5 detected no mutations in adrenal 
or leucocyte DNA. 
4.5.4 Primary culture experiments 
Primary cultures of both GISTs were established. To ensure that the cells in culture were 
GIST rather than fibroblasts they were successfully stained for CD117 and DOG-1. The 
supernatant from these cultures was used to incubate NCI-H295R cells. The NCI-H295 
cell line was established from an adrenocortical cancer, but is an imperfect in vitro model 
for adrenocortical steroidogenesis in that although it expresses the enzymes necessary for 
steroidogenesis, it expresses the MC2R only weakly, and therefore does not respond 
significantly to ACTH (Rainey et al., 2004). It is widely available however, and was used 
in the preliminary cell culture experiments. 
 
Cortisol production in H295R cells remains driven by the PKA signalling pathway, and 
therefore the adenylyl cyclase activator forskolin is used as a positive control.  Incubation 
with GIST culture supernatant resulted in a significant increase in cortisol production 
from H295R cells, greater than that induced by forskolin, although with supernatant from 
later passages this effect diminished. H89 abolished the effect of GIST supernatant, 
suggesting that its effect is mediated by the PKA signalling pathway. Pre-heating the 






Upregulation of SF-1 and StAR by GIST supernatant was demonstrated by quantitative 
PCR, in keeping with the increase in cortisol secretion. A lack of CYP17A1 expression in 
rats and mice means that DOC is the substrate for both p450c11β as well as p450c11AS 
and therefore the main glucocorticoid produced in these species is corticosterone (Miller 
& Auchus, 2011). An increase in corticosterone secretion from these cells was further 
evidence that GIST supernatant contained some agent, most likely a peptide, with the 
ability to stimulate cortisol production in vitro. The hypothesis that the agent responsible 
for cortisol secretion is alpha-MSH could be further tested by including one or both of the 
anti-alpha MSH antibodies in the cell culture medium when GIST culture supernatant is 
applied to H295R, rat adrenal cells or human adrenal cells. This would be expected to 
bind the alpha-MSH and result in a diminished cortisol response. As discussed however, 
the cortisol response diminished with each GIST culture passage, so there was insufficient 
active media to perform this experiment effectively. Additional negative control GIST 
cultures and cultures from other non-GIST tumours would also be valuable to ensure that 
the active agent was not some non-specific feature of conditioned media. For instance, 
the early passages of any cell culture might be expected to include more fat-containing 
cells from the original tumour. Cholesterol released directly from the cultured cells into 
the media could therefore serve as a substrate for cortisol production within the adrenal 
cells. Other agents that might stimulate cortisol production include cAMP released 
directly into culture supernatant. There are a number of methods for assaying cAMP, 
including ELISA, and these could be performed on aliquots of various culture 
supernatants prior to their use in stimulating H295R cells.  
4.5.5 Assay interference 
Notwithstanding the absence of ACTH in the patient’s serum and in GIST conditioned 
media, the possibility of ACTH being the stimulus for cortisol production in both patient 
and tissue culture remained. The possibility that the GIST was producing ACTH, but that 
for some reason this was not being detected by the two site ACTH 
electrochemiluminescence immunoassay, was considered. This can occur with ectopic 
ACTH secreting tumours in a number of circumstances.  If they are secreting ACTH which 
is substantially phosphorylated at the Ser31 residue this can interfere with the binding of 
the C-terminal antibody, and underestimate the total amount of ACTH present. This form 
of ACTH is biologically active, but whereas only 20-30% is phosphorylated in the 






more like the intermediate lobe of the pituitary (Massias et al., 1994). Such tumours may 
also process ACTH further, producing large amounts of CLIP. This, too, can bind the C-
terminal antibody in the sandwich assay and lead to inaccurate readings of the intact 
ACTH 1-39 peptide (Lowry, 2016). 
 
A positive control ACTH sample taken from a patient with Addison’s disease prior to their 
morning dose of hydrocortisone was used, and various proportions of GIST culture 
supernatant was added, but this failed to alter the assay result compared with PBS or 
standard culture media. An additional means to assess for ACTH in the patient’s serum 
would have been to send it to another laboratory to be run on a different platform. 
Unfortunately, stored serum samples were inadvertently disposed of.  
4.5.6 Strategies for identifying active component of GIST culture 
supernatant 
At this point a number of strategies were considered to enable identification of the 
component of the culture supernatant responsible for stimulation of cortisol secretion. 
The likelihood that this was a peptide led to an initial plan to fractionate the conditioned 
media using a combination of standard protein purification techniques, including 
sequential ion-exchange, reverse phase and size exclusion chromatography. The various 
fractions would be assayed for their ability to stimulate cortisol production from H295R 
cells in vitro. Active fractions would be pooled and further purified, before SDS-Page gel 
electrophoresis to separate out peptide components. The aim would be to have fewer than 
10 bands on Coomassie staining. The bands would be excised and subjected to mass 
spectrometric analysis to identify them. Those proteins which were present in the media 
from the GC supernatant but not the negative control NC supernatant would be 
purchased, and applied to H295R cells to test their activity. Any potential factors which 
were not commercially available would be generated by expression of cloned DNA in a 
bacterial vector. 
 
For a number of reasons, it was decided not to pursue this strategy. As noted previously, 
the supernatant from the primary culture was stimulating cortisol to a lesser extent with 
successive passages. A change in phenotype of primary cells in culture is well recognised, 
so this is not surprising (Wolffe & Tata, 1984). The volumes of most active supernatant 






experiments described. Furthermore, the expertise to carry out the protein purification 
was not immediately available within the laboratory. Therefore, an alternative hypothesis 
was developed. 
4.5.7 POMC 
The steroidogenic effects of POMC-derived peptides other than ACTH 1-39 was briefly 
discussed previously. The γ-MSH peptides have been demonstrated to potentiate the 
adrenal response to ACTH by increasing the activity of hormone sensitive lipase (HSL). 
This breaks down cholesterol esters to free cholesterol that can be used in the 
steroidogenic pathway when ACTH has bound the MC2R. The N-terminal fragment N-
POMC is co-secreted with ACTH from the anterior pituitary, and it has been shown that 
antibodies directed at it can block compensatory growth following adrenalectomy in the 
rat. The smaller peptides N-POC 1-28 and N-POC 2-54 have also been shown to be potent 
mitogens to adrenocortical cells in vitro (Lowry et al., 1983). The latter are generated 
from the action of a serine protease that is expressed in the outer adrenal cortex of the 
rat (Bicknell et al., 2001). Additionally, proliferation of H295R cells has been induced by 
synthetic N-POC 1-28, via an activation of the ERK signalling pathway (Fassnacht et al., 
2003) We therefore sought to establish the presence of POMC-derived peptides in the 
GIST.  
 
POMC processing is demonstrated in figure 4.19B. Proprotein convertases are widely 
expressed in endocrine tissues and catalyse the cleavage of prohormones including 
proPTH and proinsulin. The serine proteases PC1/3 and PC2 are the family members 
involved in the processing of POMC. PC1/3 is the predominant enzyme in the anterior 
lobe, while in the intermediate lobe both PC1/3 and PC2 are expressed (Zhou et al., 
1993). This is the molecular basis for the generation of predominantly ACTH from 
anterior pituitary, while smaller POMC peptides such as α-MSH are produced in the 
intermediate lobe. Expression of both proprotein convertases in the GIST tumour is 
necessary for complete POMC processing to alpha-MSH, and it is interesting to note that 
the PCR band for PC2 is more intense than the PC1 band, suggesting that there is higher 
PC2 expression within the GIST. This would be expected if we are proposing that it is 
behaving more like a melanotroph cell than a corticotroph cell, but a quantitative RT-PCR 






of POMC was demonstrated using RT-PCR, although this alone does not establish that the 
GIST is capable of secreting a processed alpha-MSH peptide, as will be outlined below.  
 
The nine antibodies used to stain for unprocessed and processed POMC were obtained 
from Dr Andrew Bicknell (University of Reading) but had not been used for 
immunohistochemistry previously. Positive control tissues used were human corticotroph 
pituitary adenoma, and a lung carcinoid tumour from a patient with ACTH-dependent 
Cushing’s syndrome. Although it is recognised that ectopic-ACTH secreting tumours may 
process and secrete alpha-MSH peptides (Roth et al., 2008), the validity of using human 
pituitary adenoma tissue as a positive control is not immediately apparent. The lack of a 
distinct intermediate lobe in the human pituitary (Horvath, E. et al., 1999), and an 
absence of circulating alpha-MSH in normal circumstances points to an absence of PC2 
expression in the anterior pituitary (Iino, K. et al., 2010), although there are some reports 
of PC2 expression in the normal human pituitary (Hook et al., 2009; Lloyd et al., 1995).  
 
The presence of PC2 expression and consequent alpha-MSH secretion in pathological 
pituitary conditions is more widely accepted, with PC2 expression reported in pituitary 
adenomas (Jin et al., 1999; Iino, K. et al., 2010), and the presence of smaller POMC-
derived peptides  (including alpha-MSH) detected in the serum of patients with pituitary 
dependent Cushing’s disease (Colao et al., 1993; Coates et al., 1986). Increased levels of 
plasma alpha-MSH have been reported in patients with Addison’s disease, hinting at the 
capacity for pituitary production of this peptide (Donahoo et al., 2009), while infusion of 
corticotrophin-releasing hormone has been shown to increase alpha-MSH levels in the 
inferior petrosal sinuses in a subset of patients with Cushing’s disease (Colao et al., 1996). 
It was felt, therefore, that pituitary adenoma was a reasonable choice as a positive control 
for alpha-MSH. However, the use of malignant melanoma tissue as an additional positive 
control would be valuable. 
 
Immunohistochemical analysis of the GIST tumour using antibodies directed against 
specific short peptide sequences within POMC demonstrated the expression of alpha-
MSH, with positive staining for its acetylated N-terminus and amidated C-terminus, but 
negative staining for ACTH. These antibodies specifically targeted the post-translationally 






terminal ACTH and mid-ACTH. The mid-ACTH antibody targets the same amino acid 
sequence as C-terminal alpha-MSH without the amide group. The absence of C-terminal  
 
Figure 4.22 POMC processing 
A: The POMC gene consists of three exons and two introns. A pituitary selective promoter produces 
a transcript of 1200nt, in extrapituitary tissues a downstream promoter can produce 800nt 
transcripts which can potentially be translated from an ATG site just upstream of ACTH.  
B: The POMC proprotein convertase processing enzymes PC1/3 and PC2 are differentially 
expressed in the anterior and intermediate lobes of the pituitary. PC1/3 expression alone will 
generate ACTH, but high levels of PC2 in the intermediate lobe lead to the production of alpha-
MSH 
C: The production of alpha-MSH proceeds through a number of additional steps, producing an 
active 13 amino-acid peptide which is post-translationally modified by the addition of an acetyl 
group at the N-terminus and an amide group at the C-terminus. Desacetyl-α-MSH is thought to be 
more active within the adrenal, but less active in the skin than alpha-MSH. CPE –carboxypeptidase 
E; PAM peptidyl glycine alpha-amidating mono-oxygenase; NAT n-acetyl transferase; PRCP. 
Phosphorylation at Ser31 on ACTH does not interfere with its biological activity but does interfere 










ACTH staining is more difficult to explain, as the CLIP peptide should be present as a 
result of ACTH processing to alpha-MSH. This could relate to phosphorylation at the 
Ser31 residue mentioned previously, which interferes with the C-terminal antibody 
binding in the ACTH sandwich assay. Immunohistochemical staining for the 
phosphorylated peptide would be informative here. 
 
The lack of N-POMC staining using antibodies directed at the N-terminal POMC peptides 
(N-POC 1-49, N-POC 1-28, γ3-MSH and γ1-MSH) is surprising given the positive staining 
for alpha-MSH. Further post-translational modification of these peptides such that the 
antibody binding sites are obscured or destroyed, or degradation of the peptides entirely 
within the cells of the GIST could be one mechanism for this. A further, and perhaps more 
plausible mechanism relates to alternative splicing of POMC RNA.  
 
The POMC gene is 8-kb and located on chromosome 2p23 in the human, and consists of 
three exons and two intervening introns. The first exon encodes a leader sequence, the 
second encodes the signal initiation sequence and the N-terminal portion of POMC, and 
the third encodes most of the mature peptide sequences. A pituitary selective promoter 
generates an mRNA transcript of approximately 1200nt. In extra pituitary tissues a 
downstream pituitary promoter is capable of generating truncated 800nt transcripts 
arising from the 5’ end of exon 3 (Giraldi et al., 2011). An additional upstream promoter 
(not shown in the figure) can generate longer transcripts of approximately 1350nt, 
particularly in the ectopic ACTH syndrome (Clark et al., 1990) 
 
Clark et al demonstrated the expression of a truncated POMC mRNA lacking the first two 
exons by Northern blot analysis of ACTH-secreting pancreatic NETs (Clark et al., 1989). 
Demonstration of three different mRNA transcripts of POMC has been demonstrated in 
human placental tissues, a pituitary like 1200 base transcript, as well as 800 and 1500b 
species (Grigorakis et al., 2000). Smaller POMC-like mRNA transcripts have also been 
shown in the testes and ovaries of rat, mouse and monkey (Chen, C. L. et al., 1986). Both 
truncated POMC mRNA transcripts and immunohistochemical ACTH staining have been 
demonstrated in human leukaemia cell lines (Murao et al., 1998). Translation of these 






figure 4.19A, as demonstrated in human dermal fibroblasts, but they would lack the signal 
sequence for targeting to the endoplasmic reticulum, and it is therefore unlikely that they 
would be processed and secreted (Jeannotte et al., 1987). The primers used in this case 
were designed to exon 3 of POMC. For the reasons outlined above, it does not follow from 
the positive PCR result that a POMC peptide would be processed and secreted from GIST 
tissue on this basis alone. As noted, an intron-spanning approach to primer design would 
have been preferable, but appropriate primers could not be optimised reliably even on 
positive control pituitary cDNA. 
 
It will be necessary to sequence the POMC gene in full using a 5’ RACE approach to answer 
these questions(Yeku & Frohman, 2011). This method would allow us to obtain full length 
cDNA of the entire transcript using primers at the 3’ end. 
 
The importance of methylation status of the pituitary POMC promoter in regulating 
POMC gene transcription was demonstrated by Newell-Price et al (Newell-Price et al., 
2001). This promoter is embedded within a CpG island that is methylated in non-
expressing tissues, but unmethylated in the pituitary and in ectopic ACTH secreting 
tumours. We examined the methylation status of the pituitary promoter in the GIST 
tumour by focussing on a specific portion -417 to -260 upstream of the transcription 
initiation site of exon 1. Hypomethylation at 3 CpG sites within this region were shown 
by Ye et al (Ye et al., 2005) to be highly specific for ACTH secretion in human pituitary 
and thymic carcinoids. Methylation analysis was performed as described (Chapter 2. 
Materials and methods) using pyrosequencing. Initial results suggest that the POMC 
pituitary promoter in the GIST is normally methylated. Additional positive and negative 
controls are required to validate this pyrosequencing approach. Even minimal 
methylation of the pituitary promoter at the sites described ought to prevent expression 
of the 1200nt POMC peptide, but would still allow the 800nt transcript to be expressed. 
However, as described above, this would result in a translated peptide lacking the signal 
sequence for ER targeting and subsequent secretion. The promoter responsible for 








4.5.8 The steroidogenic activity of alpha-MSH 
There is a long literature investigating the possible roles of α-MSH within the adrenal 
gland. Branchaud et al demonstrated corticotrophic activity of α-MSH in explants 
prepared from the cortex of the human fetal adrenal in 1978 at but only at concentrations 
of 10–6M (Branchaud et al., 1978). Stimulation of aldosterone and corticosterone 
secretion by alpha-MSH in the rat was demonstrated in the 1980s by Vinson et al (Vinson 
et al., 1983; Vinson et al., 1981) and Baumann et al (Baumann et al., 1986). Robba et al 
described the effects of chronic alpha-MSH administration in causing zona glomerulosa 
hypertrophy and aldosterone secretion in the rat, via an action that required normal levels 
of circulating angiotensin II (Robba et al., 1986).  
 
Our findings of alpha-MSH stimulation of cortisol production in vitro confirm the findings 
of Henville et al who demonstrated cortisol, aldosterone and corticosterone production 
from human adrenocortical cells in response to alpha-MSH and desacetyl-alpha-MSH 
(Henville et al., 1989; Branchaud et al., 1978). They found that the minimum effective 
concentrations of alpha-MSH was 0.1μM, whereas desacetyl-alpha-MSH was much more 
potent - minimum effective concentration 1nM. The concentration of alpha-MSH detected 
in GIST culture supernatant by ELISA was of the order of 1.0nM, which is therefore much 
less than the biological activity of the supernatant would predict. It is possible that 
additional desacetyl-alpha-MSH secretion from the GIST supplying some of this biological 
activity, while degradation of alpha-MSH in the supernatant used for EIA and ELISA assay 
may have led to an underestimate of the actual quantities, depending on the level of 
protease contamination in that system. A vulnerability of alpha-MSH to the thaw and 
refreeze cycle is suggested by the manner in which Sigma synthetic alpha-MSH failed to 
stimulate melanin production from mouse melanoma cells in vitro.  
 
As mentioned previously, it is extremely unfortunate that we were unable to 
retrospectively assay the patient’s serum for alpha-MSH following these experiments. The 
large volume of the GIST and the consistent immunostaining for alpha-MSH throughout 
it would be consistent with the possibility of serum levels several orders of magnitude 
higher than ACTH. The high concentration of alpha-MSH required to stimulate cortisol in 
our experiments as well as those quoted above (Henville et al., 1989; Branchaud et al., 
1978), was several orders of magnitude above the levels of ACTH required to stimulate 






than that required by ACTH to stimulate cortisol production in vivo. This calls into 
question the relevance of this effect in physiological terms, although as noted above, the 
volume of the GIST is two orders of magnitude larger than the volume of the average 
normal human pituitary, so the levels of alpha-MSH in the circulation could potentially 
have been much higher than a normal serum ACTH level. Furthermore, it is not suggested 
that alpha-MSH is binding to the MC2R, as will be discussed in detail in chapter 5. As will 
be discussed, upregulation of melanocortin receptors upon repeated receptor binding 
could also serve to amplify the alpha-MSH signal over time (Xing et al., 2010). 
 
Receptor binding studies using radio-labelled ACTH and alpha-MSH have demonstrated 
that the MC2R is very highly specific for ACTH alone, raising questions as to the identity 
of the adrenal alpha-MSH receptor (Schiöth et al., 1996). Doghman et al (Doghman et 
al., 2004; Doghman et al., 2007; Doghman et al., 2005; Dhillo et al., 2005)have identified 
an MC2R independent pathway for cortisol secretion in bovine adrenal cells stimulated 
by α-MSH in vitro via the melanocortin 4 receptor, and antagonised by agouti-related 
peptide (AGRP). AGRP is an agonist of alpha-MSH at the MC3R and MC4R receptors in 
the arcuate nucleus of the brain, and the same authors detected MC3R and MC4R in the 
rat adrenal gland. AGRP does not have significant antagonist activity at the MC2R, and 
does not antagonise the acute steroidogenic effect of ACTH, but is upregulated in 
Cushing’s syndrome, suggesting an inhibitor paracrine role in the human adrenal (Dhillo 
et al., 2005). 
4.5.9 Conclusion 
We have described a case of ACTH-independent Cushing’s syndrome in which it is 
proposed that alpha-MSH secretion from a GIST tumour provided a stimulus for adrenal 
cortisol production. This is supported by the stimulation of cortisol production in vitro 
from the supernatant from a primary culture of the GIST, and alpha-MSH 
immunostaining. Clinical evidence of skin pigmentation which resolved on removal of the 
GIST, and a reduction in size of the remaining left adrenal proved additional clinical 
evidence. 
 
A steroidogenic effect of alpha-MSH has been extensively reported previously, although 
the precise identity of the adrenal receptor for this hormone is not yet known. This is the 






previous instance of an alpha-MSH secreting tumour causing hypercortisolaemia in the 
absence of elevated ACTH - a melanotroph tumour of the pituitary gland in a cat (Meij et 
al., 2005). 
 
Possible candidates for the adrenal alpha-MSH receptor will be discussed in Chapter 5, 







Chapter 5 The causes of adrenal 
pigmentation 
5.1 Aims 
Having concluded in the previous chapter that alpha-MSH secretion from the GIST was 
the stimulus for cortisol production from the patient’s hyperplastic adrenal glands, this 
chapter seeks to determine what role this hormone had in the pigmentation of the 
patient’s skin, and of the excised right adrenal. It is hypothesised that the pigment 
responsible is melanin in both cases. A mechanism will be proposed to account for this. 
This chapter further aims to extend this enquiry into the mechanism for pigmentation in 
pigmented adrenal diseases, and in normal adrenal physiology. 
5.2 Introduction 
Increased skin pigmentation in the context of adrenal disease is well-recognised. It is an 
important diagnostic sign in patients with adrenal insufficiency, and in patients 
presenting with ectopic ACTH secretion from a neuroendocrine tumour, both of whom 
have high levels of serum ACTH (Isidori et al., 2006; Addison, 1855). Both ACTH and α-
MSH are ligands for the G-protein linked melanocortin-1 receptor (MC1R) on the 
melanocyte plasma membrane (Abdel-Malek et al., 1995; Suzuki, I. et al., 1996). 
Activation of a PKA-mediated signalling pathway up-regulates a number of enzymes 
involved in melanin production within the melanosome organelle (Slominski et al., 
2004)(Figure 5.1). The entire organelle is then transferred directly from the melanocyte 
to the adjacent keratinocytes through numerous dendritic processes on the cell surface 
(Wu & Hammer, J. A., 2014). The process is activated by ultraviolet light, while 
production of ACTH and alpha-MSH within melanocytes and keratinocytes themselves is 
a key part of its local regulation of in normal skin. 
 
Pigmentation within the adrenal gland is less well understood. Within the normal adrenal 
gland the presence of lipofuscin in the zona reticularis has been observed, although it has 
not been clear why the ZR alone should be the location for this pigment(Idelman, 1970). 
Lipofuscin is a highly oxidised cross-linked aggregate consisting of oxidised protein/lipid 






to protein structures within the cytosol, and mitochondrial oxidative stress, and as such 
it is considered a “wear and tear” pigment.  
 
The most well-described adrenal pathology where increased levels of pigmentation have 
been observed is primary pigmented nodular adrenal disease (PPNAD). Most often seen 
as part of the Carney complex, PPNAD is characterised by a pigmented and micro-nodular 
adrenal, with Cushing's syndrome usually developing in childhood (Horvath, A. & 
Stratakis, 2007). As described previously, PPNAD is the result of a constitutively active 
PKA-mediated signalling pathway in adrenal cortex cells as a result of  inactivating 
mutations in the regulatory subunit type 1a of PKA (PRKAR1A) (Kirschner et al., 2000) 
or in the phosphodiesterase enzymes PDE11A or PDE8B (Horvath, A. et al., 2006). 
 
The aetiology of adrenal pigmentation in PPNAD has not been satisfactorily explained, 
but is most commonly attributed to lipofuscin deposition (Stratakis et al., 1999). 
However, this raises the question of why adrenal pigmentation is not a more prominent 
feature of adrenal glands in patients with other forms of ACTH-independent Cushing’s 
syndrome, and indeed in ACTH-dependent disease itself. The parallel mechanisms of PKA-
mediated signalling pathways leading to elevated levels of cortisol in this disease, and the 
same processes leading to pigmentation in the skin suggest the appealing possibility that 
the same mechanism could apply in both locations. 
 
This chapter considers the hypothesis that the major pigment involved in pigmented 
adrenal diseases is not lipofuscin but melanin. 
5.3 Results 
5.3.1 Adrenal pigmentation is due to the presence of melanin 
The excised right adrenal contained multiple large, highly pigmented nodules. A brown 
pigmentation was seen on H&E staining. This pigment was eliminated by a pre-staining 
incubation with potassium permanganate to bleach endogenous melanin but not 
lipofuscin. The pigment stained black by the Masson-Fontana method, and did not stain 
pink with Ziehl-Neelsen or magenta with Periodic Acid Schiff (Figure 5.1). This provided 







Figure 5.1 Adrenal pigmentation is due to the presence of melanin. 
3μm sections of adrenal were subjected to a series of histological stains to ascertain the identity of 
a brown pigment visible within nodules on H&E (a). This is removed by pre-incubation with a 
potassium permanganate bleach that removes endogenous melanin but not lipofuscin. Masson-
Fontana stains black with melanin. Ziehl-Neelsen stains lipofuscin pink, while PAS stains the 
glycolipid content of lipofuscin magenta. A positive PAS stain for bowel mucin is shown for 







Immunohistochemical staining was performed using a series of markers for melanocytic 
tissue - melan-A, S100, HMB-45 and MITF. The cortex of the whole adrenal gland 
exhibited strong staining for melan-A. There was mild staining for S100 within the 
pigmented regions of the adrenal and strong staining of the sustentacular cells of the 
adrenal medulla. HMB-45 and MITF staining was strongly positive within the cytoplasm 







Figure 5.2 The pigmented adrenal gland expresses multiple markers of melanocytic cells 
A series of immunohistochemical stains were performed on 3μm sections of pigmented adrenal 
gland.  The pigmented nodules contain melanin (B – Masson Fontana), and stain positively for the 
melanosome marker HMB-45 (C), the marker of melanocyte signalling MITF (E), and the 
melanoma marker S100 (H). There is strong staining for Melan-A, but this marker is known to be 
widely expressed in adrenal cortex, although it is suggested that this is cross-reaction with an 






Pigmented portions of the original gland were removed from paraffin blocks and 
processed for electron microscopy (EM). Scanning EM images of the pigmented portion 
of adrenal gland demonstrate multiple mature melanosomes throughout the cytoplasm, 
along with paler organelles which have some characteristics of lysosomes (Figure 5.3).  
 
 
Figure 5.3 Pigmented adrenal gland reveals the presence of melanosomes under electron 
microscopy 
Cores of pigmented adrenal from FFPE blocks were deparaffinised and tissues refixed in 
glutaraldehyde for processing ahead of electron microscopy. This leads to loss of intracellular lipid 
and some distortion of ultrastructure, but dark black mature melanosomes can be seen alongside 
paler organelles which may be lysosomes (lys) or may be immature melanosomes. Lipofuscin 
granules usually have a more irregular margin than the organelles seen here. Nuc – nucleus; mit 
– mitochondria; mel – melanosomes; lys – possible lysosome. Samples were visualised using a 
J.E.O.L JEM1230 transmission electron microscope and images captured with an Olympus 
“Morada” digital camera. 
 
5.3.2 Human adrenal gland expresses the melanocortin 1 receptor 
Having shown the presence of melanin within the adrenal gland, we hypothesized that 
alpha-MSH stimulation of the gland was causing this pigmentation. Since alpha-MSH is 






it does in skin (Schiöth et al., 1996; Rouzaud et al., 2005). RT-PCR was carried out on 
RNA extracted from the pigmented human adrenal gland, along with a commercially 
purchased human adrenal control RNA, and RNA from the human cell line THP-1 which 
has been shown to express the melanocortin-1 receptor (Taherzadeh et al., 1999). 




Figure 5.4 MC1R expression is demonstrated in human adrenal gland by RT-PCR 
RNA was extracted from tissues using the RNeasy kit (QIAGEN) and RT-PCR carried out using 
primers designed against human melanocortin 1 receptor (see methods section 2.1). Skeletal 
muscle and control human adrenal cDNA was purchased from Clontech laboratories. THP-1 is a 
human cell line which has been shown to express MC1R. Both control human adrenal and the 
patient’s adrenal in this case expressed MC1R. 
 
The patient’s MC1R gene was sequenced and found to contain the common polymorphism 
c.1831C>T (pArg151Cys) which is associated with red hair and an increased risk of 
melanoma(Raimondi et al., 2008). 
 
The possibility that alpha-MSH binding to the MC1R was stimulating the parallel 
processes of cortisol production and melanin production was considered, and 
immunohistochemistry was performed on the pigmented human adrenal using antibodies 
directed against the MC1R and CYP11B1 - 11β-hydroxylase, the final enzyme in the 
cortisol synthesis pathway. Low levels of staining for both of these enzymes were present 
in the non-pigmented areas of the adrenal gland, with strong staining present in the 







Figure 5.5 Pigmented adrenal demonstrates increased expression of the MC1R and 11β-
hydroxylase 
Sections of the patient’s adrenal gland was immunostained for MC1R and CYP11B1, the final 
enzyme in cortisol synthesis (See methods section 2.6.1). The degree of staining was high for both 
antibodies within the pigmented portions of the gland, and only mild outside these areas. Melanin 
staining with Masson-Fontana and the melanocytic markers HMB45 and MITF stain in the 






5.3.3 Adrenal nodules in primary pigmented nodular adrenal disease 
contain melanin, and immunostain for markers of the melanosome 
organelle. 
 
Consent was taken from 3 patients who had previously undergone bilateral 
adrenalectomy for Cushing’s syndrome as a result of PPNAD. In all three cases PPNAD 
was an isolated finding, and there were no other signs of Carney Complex. Formal genetic 
testing had not yet been performed. All three patients were consented at the time of 
surgery for their pathological specimens to be used for research, and consented again for 
the specific experiments described below. Patient A is a female patient who was 11 years 
old at the time of diagnosis and adrenalectomy. Patients B and C were males who were 
17 and 13 years old respectively. In all three cases H&E staining demonstrated multiple 
non-encapsulated cortical nodules composed of eosinophilic cells, most of which 
contained variable amounts of pigment. Formal pathology reports of the time did not 
describe any attempts to classify the pigment. 
 
Sections from each patient were stained for H&E, Masson-Fontana for melanin, and 
immunostained for the melanocytic markers HMB-45 and (Figure 5.6). Immunostaining 
was also carried out for the presence of CYP11B1 and the MC1R. The nodules were shown 
to contain variable amounts of pigment on H&E staining, but in all cases this was positive 
by Masson-Fontana, identifying it as melanin. Counterstaining with 1% neutral red was 
less intense than on previous Masson-Fontana stains. Staining within the nodules was 
strong for CYP11B1 and MITF and moderate for HMB45 and MC1R, while there was 








Figure 5.6 Adrenal nodules in PPNAD contain melanin and stain for the melanocytic markers 
HMB45 and MITF 
Adrenal glands from three patients with ACTH-independent Cushing’s syndrome as a result of 
PPNAD were immunostained for MC1R, CYP11B1, HMB45 and MITF (For full method see section 
2.6.1). Nodules contained melanin in all three cases, and stained positively for all 4 antibodies. 
Masson-Fontana staining was performed without red counterstaining. 
5.3.4 The zona reticularis of adrenal glands from patients with ACTH-
dependent Cushing’s contains melanin, and immunostains positively 
for markers of the melanosome organelle. 
 
Consent was taken from three patients with ACTH-dependent Cushing’s syndrome for 
histological analysis of their adrenal glands. Patient A was a 34-year-old male at the time 
of left adrenalectomy. He had been unsuccessfully treated for Cushing’s disease with 
transsphenoidal hypophysectomy at 27, and had received external beam radiotherapy to 
the pituitary at 29, but remained biochemically and clinically Cushingoid. He underwent 






old male who had ACTH-dependent Cushing’s syndrome from an occult ectopic source 
who was cured of Cushing’s with bilateral adrenalectomy. Patient C had a metastatic 
ACTH-secreting neuroendocrine tumour who was treated briefly with intravenous 
etomidate before an emergency bilateral adrenalectomy. 
 
Histological and immunohistochemical staining was carried out as before. In all three 
cases the adrenal cortex immunostained positively for MC1R and CYP11B1. The presence 
of melanin was detected in the zona reticularis, along with varying degrees of positivity 









Figure 5.7 Adrenal glands from patients with ACTH-dependent Cushing's syndrome contained 
melanin in the ZR, and immunostained for melanocytic markers 
Adrenal glands from three patients with ACTH-dependent Cushing’s were immunostained for 
MC1R, CYP11B1, HMB45 and MITF. In all three cases melanin was detected in the zona reticularis 
(ZR) by Masson-Fontana staining, along with the melanosome marker HMB-45 and the 







5.3.5 The zona reticularis of normal adrenal cortex from patients with 
primary aldosteronism expresses the melanosome markers HMB45 
and MITF 
 
A tissue microarray (TMA) was constructed from adrenalectomy specimens from patients 
with biochemically confirmed Conn’s syndrome, which had been radiologically confirmed 
with a combination of CT scanning and bilateral adrenal venous sampling were required. 
All samples contained a single adenoma. The TMA was stained for H&E, and 
immunostained for HMB45 and MITF. “Normal” cores from 15 glands were reviewed.  
 
14 glands demonstrated cytoplasmic staining for HMB45 and MITF within tissue that had 
been identified as zona reticularis and outside the nodule by a consultant 
histopathologist. The MITF and HMB45 staining correlated in each case, and in a number 








Figure 5.8 Normal adrenal tissue stains positively for melanocytic markers within the ZR 
A tissue microarray was constructed using adrenal nodules and extra-nodular tissue from patients 
with Conns syndrome (see methods section 2.5.8) TMA cores were analysed from 15 patients 
having adrenalectomy for Conn’s syndrome. Tissue identified as normal by a histopathologist are 







In addition to this cytoplasmic staining, 7 specimens demonstrated nuclear staining for 
HMB45 alone in adrenal cortex that had the morphological appearance of ZG or ZF. 
Functional staining to clarify the identity of these cells using CYP11B2 was not available. 
 
 
Figure 5.9 Nuclear HMB45 staining is seen within ZG and ZG cells of normal human adrenal 
Extra-nodular tissue from human adrenal tissue taken from patients with Conns syndrome was 
immunostained for MITF and HMB45 on sections from the Conns TMA. Moderate nuclear staining 




As outlined previously, the most likely cause of adrenal pigmentation is lipofuscin, on the 






presence of melanin has previously been described within the chromaffin cells of the 
adrenal medulla, and pigmented phaeochromocytomas have been reported in the 
literature (Bellezza et al., 2004; Handa et al., 2005). In the light of skin 
hyperpigmentation, and the presence of alpha-MSH within the GIST tumour, a hypothesis 
was made that the adrenal pigmentation was the result of melanin within the adrenal 
cortex. It is worthwhile considering these two pigments prior to describing their 
histological diagnosis. 
 
Lipofuscin is a highly oxidised cross-linked aggregate consisting of oxidised protein/lipid 
clusters (Jung et al., 2007). The formation of lipofuscin is a complex process which is 
hypothesised to start with oxidative damage to protein structures within the cytosol, or 
with mitochondrial oxidative stress. Failure of the normal intracellular repair mechanism 
results in the proteins or mitochondria becoming cross-linked, then taken up by 
lysosomes. They are processed further and accumulate more damaged material, leading 
to lysosomal rupture, with lipofuscin released into the cytosol to do more damage and 
continue the cycle. The ability of lipofuscin to bind metals is key to this cellular toxicity 
(Jolly et al., 1995). Lipofuscin deposition and its toxic effects are felt more keenly in post 
mitotic cells such as cardiac myocytes and neutrons - the “Lipofuscin Hypothesis of 
Alzheimer’s disease” describes the theory that it has a role in the formation of senile 
plaques in that disease (Giaccone et al., 2011) 
 
The reason for the presence of lipofuscin in the zona reticularis of the adrenal cortex but 
not the zona fasciculata has not been satisfactory explained. One view follows from the 
classical theory of adrenal donation driven by cell migration from a common pool of 
progenitors in the peripheral cortex, suggesting that the ZR should be considered a zone 
of cell senescence, prior to apoptosis removing these cells from the system (Hui et al., 
2009). Interestingly, it has also been suggested that oxidation of melanin can directly lead 
to the accumulation of lipofuscin (Kayatz et al., 2001). Granules of “melano-lipofuscin” 
have been implicated in the pathogenesis of age-related macular degeneration 
(Mazzitello et al., 2009). 
 
Lipofuscin and melanin are indistinguishable on H+E staining, so a number of special 
stains are required. Lipofuscin is an insoluble pigment which is not removed by the 






(Hongwu Shen, 2015). Lipofuscin is a deep magenta red on Ziehl-Neelsen staining and 
magenta on PAS staining (Dayan et al., 1988). By all three of these criteria the adrenal 
pigment was not consistent with lipofuscin.  
 
5.4.2 Melanins 
Melanins are the end products of complex multistep transformations of L-tyrosine, and 
include eumelanin, phaeomelanin and neuromelanin. L-DOPA is a precursor to both 
melanins and catecholamines via separate pathways, but the catecholamines can also be 
converted into melanin pigments. Synthesis of the red/brown phaeomelanins is the 
default pathway, whereas the black eumelanins require higher levels of tyrosine and 
activity of the melanogenic enzymes tyrosinase and tyrosinase-related proteins TRP1 and 
TRP2 (Abdel-Malek et al., 2008). MC1R mutations which reduce the efficacy of MC1R 
signalling are therefore associated with reduced eumelanin production, and therefore the 
typical appearance of red hair and pale skin (Switonski et al., 2013). The patient studied 
had one such mutation, and it would be expected that the effect on MC1R signalling 
would be just as limited in the adrenal gland as in the skin. However, the effect of the 
MC1R polymorphism results in reduced activity, rather than zero activity, so high levels 
of stimulation of adrenal MC1R in this patient from alpha-MSH over a prolonged period 
of time would still be expected to cause activity. Additionally, this would also be 
anticipated to lead to receptor upregulation, and therefore amplify the signal (Xing et al., 
2010). Furthermore, the possibility remains that one or more of the adrenal nodules was 
displaying a degree of autonomy, further elevating the effects of alpha-MSH. 
 
The adrenal nodules demonstrated positive staining by the Masson-Fontana method for 
melanin, and the pigment was removed by bleaching.  
5.4.3 Melanoma immunohistochemistry 
A series of immunohistochemical stains which are more commonly used in the diagnosis 
of melanoma were performed to further characterise the pigment. 
 
Melan-A (also known as MART-1) is a melanoma associated antigen which is present in 
melanosomes and the ER and plays a role in the expression and processing of pmel17 






also expressed in more than 80% of adrenocortical tumours, and in steroidogenic tissue 
in the testis (Sangoi et al., 2011; Renshaw & Granter, 1998; Zhang et al., 2003). It has 
been suggested that in fact positivity for Melan-A in the adrenal cortex is the result of 
cross-reactivity with an unidentified epitope, and that the Melan-A gene is not expressed 
there (Busam et al., 1998) Melan-A positivity was present throughout the cortex of the 
adrenal gland in this case. 
 
S100 was the first marker to prove useful in the diagnosis of melanoma (Gaynor et al., 
1980). It has a sensitivity of 93-100% in this circumstance, but its specificity is low due 
to its expression in a wide variety of normal tissues (adipocytes, chondrocytes, certain 
neuronal populations) and other tumours (breast and salivary gland tumours, some 
sarcomas) (Ordóñez, 2014); this is a consequence of the common neural crest derivations 
of these tissues. As demonstrated in figure 5.2 it is highly expressed in the sustentacular 
cells of the adrenal medulla (Lloyd et al., 1985) and is used as a histological marker for 
phaeochromocytoma for that reason.  The adrenal cortex has not been shown to express 
S100 to this point. S100 staining was strong as expected in the adrenal medulla, with 
mild staining of pigmented regions of the cortex. The protein is structurally similar to 
calmodulin, and has no specific mechanistic link to the presence of melanin or the 
melanosome. 
 
HMB-45 is one of several monoclonal antibodies generated by Gown et al to an extract of 
melanoma (Gown et al., 1986). The HMB designation comes from a description of this 
extract: human melanoma black. The antigen target Pmel17 (gp100 in the mouse) is 
involved in the morphogenesis of immature melanosomes, and is such demonstrates 
cytoplasmic staining (Kikuchi et al., 1996; Berson et al., 2001). HMB-45 is therefore 
regarded as being specific for the melanosome, rather than any particular cell lineage. In 
addition to melanocytes and melanoma, positivity can also be seen in perivascular 
epithelioid cell tumours (PEComa) (Doyle et al., 2013; Patra et al., 2013), and various 
pigmented neuroectodermal tumours, such as the melanotic schwannoma (Utiger & 
Headington, 1993; Leger et al., 1996). Interestingly, the latter is a component of the 
Carney complex, although a less common one than PPNAD. There was moderately 
positive immunostaining for HMB-45 within the pigmented adrenal tissue in this case, 







MITF (micro-ophthalmia associated transcription factor) is the master regulator of 
melanocytes, and plays a key role in their development, differentiation, function and 
survival (Hsiao & Fisher, 2014). The role of the mouse equivalent Mitf was first identified 
in 1979 when mouse with semi-dominant mutations showed a loss of pigmentation, 
reduced eye size, failure of secondary bone resorption and early onset deafness (Silvers, 
1979). The human MITF gene has been mapped to chromosome 3p12.3–14.1 (Udono et 
al., 2000), and mutations have been associated with various combinations of abnormal 
skin pigmentation and sensorineural deafness, for example Waardenburg syndrome and 
Tietz syndrome. 
 
Transcriptional control of MITF is governed by a number of transcription factors, with 
CREB (cAMP response element binding protein) and β-catenin of particular importance. 
Both these factors participate in the upregulation of MITF in response to α-MSH binding 
to the MC1R on the melanocyte cell membrane (Hartman & Czyz, 2015). Targets of MITF 
include regulators of the cell cycle and differentiation such as CDK2 and p21kip1, and 
enzymes necessary for melanin synthesis including tyrosinase (Hsiao & Fisher, 2014) 
 
MITF dependence is retained in melanoma, where expression at high levels favours 
differentiation or proliferation. MITF is recognised as a sensitive and specific marker for 
melanoma diagnosis (King, R. et al., 1999), where a strong nuclear staining pattern is 
apparent with immunohistochemistry (Sheffield et al., 2002). However, cytoplasmic 
staining for MITF has been shown in a small number of breast carcinomas (Granter et al., 
2002; King, R. et al., 1999), and the subcellular localisation of MITF has been shown to 
be dynamic in monocytic cells (Lu et al., 2010). Immunohistochemical staining of the 
adrenal cortex for MITF has not been demonstrated previously, although transfection of 
H295R cells with MITF has been shown to significantly increase their cortisol 
secretion(Romero et al., 2010). There was strong MITF immunostaining in the pigmented 
adrenal cortex of this case. 
5.4.4 Electron microscopy 
The immunohistochemical staining of the adrenal nodules supported the hypothesis that 
the pigmentation was melanin within melanosomes. Electron microscopy (EM) was 
carried out to visualise the melanosomes directly. Processing of tissue for EM is best 






however be extracted from FFPE tissues, although some structural integrity as lost. 
Despite this caveat, substantial numbers of mature, dark round and oval melanosomes 
were visualised in the pigmented tissue from one of the large adrenal nodules. 
Melanosomes can be distinguished from lipofuscin within lysosomal granules on the basis 
of their more regular shape, although some of the less dark oval bodies within the EM 
images shown have the appearance of lysosomal granules. 
5.4.5 Control of melanin synthesis 
Having established the presence of melanin and melanosomes in pigmented adrenal 
cortex, we hypothesised that this had been stimulated by the binding of alpha-MSH to the 
MC1R. Binding of this receptor in the melanocyte by alpha-MSH or ACTH stimulates 
cAMP formation (Abdel-Malek et al., 1995). Activation of the PKA signalling pathway 
results in phosphorylation of CREB, and increased MITF expression (Figure 5.10). This in 
turn regulates the expression of multiple enzymes in the melanin biosynthetic pathways, 
including tyrosinase, and in melanosome maturation (Tsatmali et al., 2002). Sites of 
alpha-MSH production in the skin include epidermal keratinocytes, Langerhans cells, and 
melanocytes themselves. Ultraviolet radiation stimulates the process of pigmentation by 
increasing the expression of POMC, the MC1R itself, and melanogenic enzymes such as 
tyrosinase directly (Abdel-Malek et al., 2008).  
 
Expression of the MC1R in human adrenal was confirmed by RT-PCR, and by 
immunohistochemistry. Unfortunately, we were unable to optimise 
immunohistochemistry for the MC2R in the adrenal. This raises the possibility that the 
staining demonstrated within the adrenal is in fact MC2R, however the peptide sequence 
used to raise the MC1R antibody is not present in MC2R, and a basic local alignment 
search tool (BLAST) search suggested no similarity, so we are confident that we have not 
demonstrated MC2R expression with this antibody. However, further evidence could be 
provided by adding an incubation with MC2R peptide to the MC1R staining protocol. 
MC1R expression was most pronounced within the pigmented regions, and up regulation 
of melanocortin receptors in response to chronically activated cAMP signalling is well 
described (Xing et al., 2010). 
 
Upregulated cAMP signalling would be expected to lead to increased expression of 






CYP11B1 expression which correlated with pigmentation, immunohistochemical staining 
for the melanosome, and MC1R expression. This suggests that pigmentation and cortisol 
production are being activated in parallel by a common signalling pathway. 
5.4.6 Primary pigmented nodular adrenal disease 
Having demonstrated parallel increases in steroidogenic enzyme expression and 
pigmentation, we examined three cases of PPNAD to establish whether a similar 
mechanism could be responsible adrenal pigmentation and Cushing’s syndrome in that 
condition. The rarity of the condition meant that availability of archived samples was 
restricted to three adrenalectomy specimens, and unfortunately we did not have access 
to full sufficient data to correlate pathological appearances with the clinical and 
biochemical phenotype. Melanin was detected within PPNAD micro nodules in all cases, 
along with MC1R, CYP11B1, HMB45 and MITF immunohistochemistry. This suggests that 
there is a common mechanism is contributing to both processes, as in the GIST-associated 
Cushing’s syndrome case. If we suggest that in the GIST case, exogenous stimulation of 
MC1R by alpha-MSH or related peptides activates cAMP signalling with melanosome 
maturation, melanin production and unregulated steroidogenic enzyme expression then 
by extension we might predict that the same outcome could be generated by PRKR1A or 
PDE11A mutations in PPNAD.  
 
The nodular enlargement of both PPNAD and the GIST-associated adrenal, rather than a 
diffuse hyperplasia, is a common feature of endocrine neoplasia. The specific genetic and 
epigenetic differences within the nodules in adrenals such as those described, or in multi 
nodular thyroid goitre, for instance, is not well understood(Derwahl & Studer, 2002). 
 
It is interesting to note that the staining characteristics that we have demonstrated in 
PPNAD have also been shown in extra-adrenal pigmented tumours associated with Carney 
complex. Psammomatous melanotic schwannomas positively immunostain for Melan-A, 
S100 and HMB-45, and demonstrate melanosomes on electron microscopy (Utiger & 
Headington, 1993; Leger et al., 1996; Torres-Mora et al., 2014). 
5.4.7 ACTH-dependent Cushing’s syndrome 
We assessed adrenal glands from three cases of Cushing’s syndrome as a result of ACTH 






diffuse hyperplasia, with two of the three showing an expansion of the zona reticularis. 
In all three cases we were able to identify melanin by Masson-Fontana staining, and 
immunohistochemical staining for HMB-45 and MITF. MC1R and CYP11B1 staining was 
strongest within the ZR, although it is possible that this reflects simply the different 
cellular structures: increased lipid in the clear cells of the ZF compared with the compact, 
dense cells of the ZR. The ZR expansion is consistent with the previously described change 
in morphology of ZF cells under chronic ACTH stimulation (Hornsby, 2002).  
5.4.8 Pigmentation within normal adrenal gland 
It is difficult to obtain entirely normal human adrenal tissue for study, with the most 
common means of doing so adrenal glands which are removed during nephrectomy for 
non-endocrine diseases. Previous studies on the pathophysiology of primary 
aldosteronism led us to construct a tissue microarray from tumour specimens and 
“normal” adrenal tissue taken from within the same gland. Whether this tissue can 
actually be thought of as normal is not entirely clear, as it has been reported that tissue 
outside the nodule can show evidence of hyperplasia. This is consistent with the notion 
that there is a spectrum of abnormality between hyperplasia and adenoma. 
Notwithstanding this, on 14 of 15 adrenal glands reviewed we identified zona reticularis 
with positive immunostaining for HMB45 and MITF. The presence of these markers would 
not therefore seem to depend on the presence of Cushing’s syndrome, either from 
exogenous stimulus of the gland or cortisol secreting adenoma as with PPNAD. None of 
the Conns samples studied had any evidence of hypercortisolaemia clinically or 
biochemically.  
 
In addition to this cytoplasmic staining, we were also able to demonstrate nuclear staining 
for HMB45. It would be useful to identify with more certainty the additional 
characteristics in terms of functional steroidogenic gene expression of these cells. 
Functional staining of CYP11B2 would be extremely valuable to confirm the nature of 
these cells as ZG, but as discussed in chapter 3 immunohistochemistry for this enzyme is 
not straightforward, and it was not available to us at the time of staining. Nuclear staining 
for HMB45 has recently been used to discriminate between benign and malignant 
melanocytic lesions, with a higher ratio of nuclear: cytoplasmic staining in benign lesions. 






represent cells in which pathways for melanosome formation have not yet been fully 
activated.  
 
Melanosome development proceeds through a series of defined stages (Seiji et al., 1963). 
Stage I premelanosomes contain internal membranous vesicles that resemble late 
endosomal multivesicular bodies, and irregular fibrous structures, but they do not contain 
any pigment. They  were originally thought to have emerged from the smooth ER, but are 
now believed to be derived from the late secretory or endosomal pathway (Raposo et al., 
2001). These become arranged in regular parallel rows in type II premelanosomes, with 
a striated appearance on electron microscopy. Melanosomes acquire the tyrosinase 
enzyme and melanin pigments are deposited on these fibres as they mature into darker 
stage III and IV melanosomes (Tsatmali et al., 2002). The glycoprotein Pmel17 (which 
stains with HMB45) is a key mediatory of this fibrillary matrix (Berson et al., 2001). 
 
In melanocytes fully formed melanosomes are transferred into neighbouring 
keratinocytes and leave the cell. In cells where melanosome transfer is not possible, it 
might be predicted that younger cells would have the fewest melanosomes, and older 
cells the most. In the adrenal gland, this would be in keeping with the centripetal 
migration hypothesis described earlier. Immunofluorescent staining for HMB45 would be 
extremely informative in this regard. 
5.4.9 Possible functional role of melanin in adrenal tissue 
These data raise the question of what might be the role of melanin in the adrenal gland. 
It is instructive here to consider what its role is in tissues outside of the skin. 
Neuromelanins are a group of melanin pigments found in the central nervous system. 
They include substantia nigra melanin and locus coeruleus melanin which are formed by 
the oxidation of catecholamines(Wakamatsu et al., 2015). The role of these 
neuromelanins is believed to be in protecting neurons against oxidative stress. For 
instance, melanin in the inner ear is believed to protect the organ of Corti from noise and 
ototoxins (Ohlemiller et al., 2009). Chromaffin cells have the same neural crest 
embryological origin as melanocytes, and melanin-containing phaeochromocytomas have 
been described (Bellezza et al., 2004; Handa et al., 2005). We found no pigment or 
melanosome staining present in the adrenal medulla, but we are open to the possibility 






chromaffin cell to ZR would be in keeping with the model of melanosome transfer in the 
skin, with ZR cells equivalent to keratinocytes. However, this would not explain the 
degree of MITF expression in those cells. 
 
The retinal pigmented epithelium (RPE) is a monolayer of pigmented cells forming part 
of the blood/retina barrier, interposed between the neural retina and the choroid 
(Fuhrmann et al., 2014). It plays a key role in the absorption of scattered light energy, 
and protecting the retina from photo-oxidative damage: light absorption via melanin in 
melanosomes is one of the major mechanisms for this (Strauss, 2005).  
 
The anti-oxidative properties of melanin pigments are not only manifest in the nervous 
system. Randhawa et al demonstrated the expression of several melanogenesis related 
genes in human adipose tissues, and subsequently confirmed the presence of melanin 
itself. They proposed that ectopic synthesis of melanin served as a compensatory 
mechanism utilising its anti-inflammatory and oxidative damage-absorbing properties. 
(Randhawa et al., 2009). In addition to this, significantly elevated levels of α-MSH have 
been found in the sera of obese human subjects, perhaps as a homeostatic anti-
inflammatory mechanism (Page, S. et al., 2011).  
 
It may be hypothesised that the anti-oxidant properties of melanin may be valuable within 
the adrenal gland. Electron leakage by the cytochrome p450 enzymes may render the 
adrenal cortex vulnerable to oxidative stress, and this is implicated in adrenal disorders 
including X-linked adrenoleukodystrophy, triple A syndrome and familial glucocorticoid 
deficiency (Prasad et al., 2014). It has been suggested that oxidation of melanin can 
directly lead to the accumulation of lipofuscin (Kayatz et al., 2001). The presence of the 
melanolipofuscin granule which exhibits properties of both pigments, and is implicated 
in the pathogenesis of age-related macular degeneration would support this hypothesis 
(Mazzitello et al., 2009).  
5.4.10  Conclusion 
In conclusion we report the finding of a pigmented macronodular adrenal gland in a 
patient with a co-existing GIST which immunostains positively for alpha-MSH. The 
pigmented nodules contain melanin and positively immunostain for markers of the 






pigmented tissue, along with additional markers of increased cAMP signalling: the 
steroidogenic enzyme CYP11B1 and the melanocyte transcription factor MITF. We 
suggest that upregulation of the cAMP dependent PKA signalling pathway in PPNAD is 
directly responsible for stimulating the parallel processes of steroidogenesis and 
melanogenesis within adrenal nodules. The process of melanogenesis is proposed to be a 
feature of normal adrenal tissue, particularly in the zona reticularis, and a function as an 







Chapter 6  General Discussion 
 
The panoply of physiological roles held by melanocortin peptides signalling in multiple 
different physiological systems has become increasingly apparent over recent years. The 
importance of interdisciplinary communication and collaborations to expand and build 
on this knowledge is vitally important, otherwise a dermatologist may simply focus on 
the role of the MC1R in melanoma, a rheumatologist on melanocortin signalling in 
inflammation, and an endocrinologist may restrict their focus to the MC2R in the adrenal 
cortex. The initial focus in beginning this work was on the particular role of the MC2R in 
adrenal development, building on observations that adrenal-specific knockout of the 
MC2R in the mouse led to embryonic lethality in 75%, and that surviving animals had an 
atrophied ZF and a thickened capsule (Chida et al., 2007). A failure to obtain the KO 
mouse model meant that we were unable to study the receptor in that context, but the 
mice who survived without an adrenal MC2R suggest that alternative signalling 
mechanisms can perform some of the roles that we normally associated with it, in terms 
of steroidogenesis and adrenal growth.  
 
It has been noted already (See Introduction) that the number of inputs to the adrenal 
gland that modulate steroid output is substantial, from cytokine production from immune 
cells within the gland, the effect of autonomic nervous inputs from the hypothalamus and 
contralateral adrenal, to neuropeptides secreted by the adrenal medulla. These additional 
levels of control allow the adrenal gland to respond to changes in the physiological milieu 
in a subtler and more controlled way than a simple ATCH to MC2R on/off switch 
signalling mechanism would allow. It is therefore not surprising that the adrenal gland 
would contain other melanocortin receptors sharing an input into the same downstream 
signalling pathways (Doghman et al., 2004; Doghman et al., 2007; Doghman et al., 
2005). This is the first description of MC1R expression in human adrenal, and it will be 
interesting to determine what its specific physiological roles are in the human adrenal. 
One manner in which it may add value to the control of adrenal steroidogenesis and 
growth is that it differs from MC2R in having a physiological antagonist - agouti related 
peptide (AGRP) - which is itself expressed in the adrenal gland. AGRP is unregulated in 
Cushing’s syndrome, and long term administration has been shown to inhibit 
steroidogenesis in mice, although these effects are not mediated through MC2R or MC4R. 






AGRP influences adrenal steroid production. Improving our knowledge of this signalling 
pathway may open up avenues to new therapies for Cushing’s syndrome - at present 
medical treatment is focussed mainly on the inhibition of steroidogenic enzymes directly. 
 
ACTH and alpha-MSH bind to the MC1R with equal affinity, so it is not necessary to 
invoke alpha-MSH as a physiologically relevant endocrine hormone in humans. The 
absence of a significant intermediate lobe of the pituitary gland in adult humans would 
support this argument, but alpha-MSH immunoreactivity is present in the vast majority 
of human adrenal glands. By immunohistochemistry there is more alpha-MSH in the pars 
anterior than the pars intermedia, and it is also detected in the serum of patients with 
Addison’s disease, mainly as desacetyl-alpha-MSH (Coates et al., 1988; Coates et al., 
1986). The zona intermedia is more prominent in the fetal adrenal gland, and there is 
evidence for production of alpha-MSH and CLIP-like peptides in fetal extract (Silman et 
al., 1976). The pars intermedia is under tonic dopaminergic inhibitory control in rats, and 
the suggestion that this might also be the case in humans was provided indirectly in the 
observation that a dopaminergic antagonist increased alpha-MSH levels in pre-pubertal 
but not post-pubertal children (Facchinetti et al., 1995). A role for alpha-MSH or related 
intermediate lobe peptides in could be extrapolated from the temporal relationship 
between the presence of the FZ in the fetal adrenal, and its adult equivalent the ZR 
developing in pre-pubertal children. Interestingly, a recent Polish study found a 
statistically significant increase in skin pigmentation in 7-10 year old children (Sitek et 
al., 2013), so it would be interesting to measure serum alpha-MSH levels in more detail 
in this population. The physiological role for alpha-MSH in adrenal steroidogenesis has 
by no means been established definitively on the basis of the in vitro experiments 
described, where the applicability of pharmacological concentrations of alpha-MSH to the 
physiological setting is uncertain. However, the expression of adrenal MC1R provides a 
mechanism, and as noted above, one need not even invoke alpha-MSH for it to be 
important.  
 
If one accepts the premise for a physiological alpha-MSH role in humans, it would be 
interesting to examine the stimuli for its release. Premature adrenarche in girls is 
associated with obesity and insulin resistance, and it has previously been hypothesised 
that the mechanism for this is the direct effect of insulin and insulin like growth factors 






patients, and leptin is a strong stimulator of alpha-MSH release (Keen-Rhinehart et al., 
2013). It would be interesting to test the hypothesis that this unregulated alpha-MSH 
signalling is the mechanism by which insulin resistance leads to premature adrenarche. 
Furthermore, an improved mechanistic understanding of the dark skin pigmentation of 
acanthosis nigricans in insulin resistance would be welcome. Conversely, the long term 
effects of alpha-MSH agonists as tanning agents on the adrenal gland is yet to be 
elucidated (Langan et al., 2010).  It would be interesting to see the effects of these 
biological agents on serum cortisol production, meanwhile the previously published case 
reports of Cushing’s from a pure alpha-MSH secreting tumour remain a single case of a 
melanotroph adenoma in a feline patient (Meij et al., 2005) 
 
Melanin was identified in the adrenal glands of patients with ACTH-dependent and 
independent Cushing’s syndrome, along with markers of the melanosome organelle. The 
role for melanin in normal adrenal physiology is not clear, though as discussed it has an 
anti-oxidant and anti-inflammatory role in other tissues. It will be interesting to ascertain 
whether melanocytic markers and melanin are ubiquitous in the human adrenal gland - 
it is difficult to extrapolate from our tissue microarray data, given that although the tissue 
we looked at was not adenoma, the glands themselves were certainly not normal. A 
histopathological study of human adrenals removed at the time of nephrectomy would be 
straightforward. 
 
The endocrine pedigree of gastro-intestinal stromal tumours has been predicted on the 
basis of expression of peptide hormones and synaptic vesicles necessary for their secretion 
(Bumming et al., 2007; Ekeblad et al., 2006). The data presented provide cautious 
support for this, although a full picture of the mechanism for GIST POMC processing and 
alpha-MSH secretion has not been provided. The identity of the POMC promoter used is 
not established, and there are reasons to doubt both the pituitary promoter due to its 
methylation status, and the peripheral promoter since its transcript would lack the signal 
sequence for ER targeting and secretion.  The methylation status at all the CpG sites of 
the pituitary POMC promoter in the GIST tumour needs to be established, and a full 
sequence of the reported POMC transcript is required. As described previously, a 5’ RACE 
approach would allow generation of at full length cDNA of the entire POMC transcript 
using primers at the 3’ end (Yeku & Frohman, 2011), and confirm whether or not the 






POC 1-28 and N-POC 1-49 immunostaining in the GIST, alongside positive alpha-MSH 
staining, and to demonstrate that immunostaining of any of these peptides can be thought 
to correlate with their secretion. There are some reports in the literature that tissues 
expressing almost exclusively the short 800nt POMC transcript are capable of generating 
a secreted peptide when stimulated to do so (Teofoli et al., 1999; Slominski et al., 2000), 
but these do not suggest a robust mechanism which gets around the problems outlined 
above. These papers consider human dermal fibroblasts in culture, so it would be valuable 
and fairly straightforward to attempt to replicate their experimental findings.  
 
It is unlikely that alpha-MSH secretion from occult GIST tumours is responsible for a 
significant burden of disease, but it may be possible that a proportion of patients with the 
ectopic ACTH syndrome, or even subclinical Cushing’s syndrome have a GIST that is not 
visible on routine imaging, and does not take up the radio labels commonly used to locate 
ectopic carcinoid tumours, for instance.  
 
Making conclusions on the basis of initial studies on the roles of the CDK inhibitors in 
controlling rat adrenal remodelling were limited by technical issues related to 
immunostaining. With experience gained from the immunostaining of the adult human 
adrenal as described, it is planned to revisit that work. HMB-45 staining in the nucleus of 
the ZG in the human provided some indirect evidence that the cells are younger than 
those in the ZR, and it will be interesting to immunostain the adrenal tissue microarray 
in both normal and tumour samples for p27 and p57, since that is an extreme example of 
adrenal remodelling. 
 
In conclusion, the data presented in this thesis suggest that POMC-derived peptides other 
than ACTH have a role in adrenal growth and steroid production. There is a potential that 
further elucidation of the mechanisms by which this occurs will improve our 
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